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McKNIGHT, DENNIS L. Treatment Validity of the Dexamethasone Suppression 
Test. (1986) 
Directed by: Dr. Rosemery 0. Nelson. Pp. 228. 
This dissertation examined the value of the dexamethasone 
suppression test in selecting subjects who are responsive to different 
types of treatment for depression, thereby testing the "treatment 
validity" of the dexamethasone suppression test. In addition, the 
effects of a biologically-oriented treatment and a psychologically-
oriented treatment on the dexamethasone suppression test and on 
subjects' dysfuntional thoughts was examined. 
Forty-three outpatient subjects diagnosed with Major Depression 
along with a high level of dysfunctional thoughts participated in this 
project. Subjects were identified as either abnormal or normal 
dexamethasone suppression test responders according to Cortisol blood 
levels, and then randomly assigned to receive either a biologically-
oriented treatment (tricyclic antidepressant medication) or a 
psychologically-oriented treatment (cognitive therapy). Self-report 
depression measures, diagnoses, the questionnaire measuring 
dysfunctional thoughts, and the dexamethasone suppression test were 
administered at pre-intervention and post-intervention and were 
subjected to statistical analyses. 
In short, the results showed that for both treatments, subjects 
overall reported significantly less depressive symptoms according to 
global measures of depression from the Depression Scale of the Minnesota 
Multiphasic Personality Inventory, the Beck Depression Inventory, the 
Lubin Depression Adjective Checklist, and diagnoses based on the 
Diagnostic and Statistical Manual of Mental Disorders, third edition. 
These measures also showed that normal dexamethasone suppression test 
responders reported a significantly greater change (improvement) in 
depressive symptoms at post-intervention than abnormal dexamethasone 
suppression test responders, regardless of type of treatment. 
Furthermore, while normal dexamethasone suppression test responders 
showed no significant change on the dexamethasone suppression test from 
pre-intervention to post-intervention, the abnormal dexamethasone 
suppression test responders did show significant reductions in the 
dexamethasone suppression test (indicating improvement) from 
pre-intervention to post-intervention after receiving either 
antidepressant medication or cognitive therapy, with no difference at 
post-intervention between the two types of treatment. In addition, 
there was a significant reduction overall in depressives' dysfunctional 
thoughts (according to the Personal Beliefs Inventory) after receiving 
either treatment, with subjects receiving cognitive therapy having 
significantly fewer dysfunctional thoughts than subjects receiving 
antidepressant medication. 
These findings are examined in detail and interpretations 
discussed. 
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CHAPTER I 
INTRODUCTION 
Depression, perhaps more than any other psychological disorder, has 
resulted in inordinate amounts of human suffering, loss of productivity, 
and even loss of life. The President's Commission on Mental Health 
(Task Panel reports submitted to the President's Commission on Mental 
Health, Volume IV, Appendix, 1978; cited by Craighead, 1979) estimates 
that approximately twenty percent (20%) of Americans will experience an 
affective disorder during their life, rivaling schizophrenia as the 
nation's number one mental health problem. On an international scale, 
Teuting, Kaslow, and Hirschfeld (1981) estimate that over 127 million of 
the world's people suffer from depression, while approximately 8 to 20 
million Americans currently suffer from depression. In this same 
report, Teuting et al. (1981) estimate that treatment for depression 
costs over $10 billion each year, in addition to the "human cost" of 
depression in terms of discomfort, divorce, suicide, alcohol and drug 
abuse, dysfunctional family life, unemployment, and child abuse. 
Questions such as the following have occupied investigators' interest 
since this clinical syndrome was first identified by Hippocrates in the 
fourth century B.C. (Boyd & Levis, 1980). What is depression? What 
causes this disorder, and what factors are responsible for maintaining 
it over time? 
Researchers have approached the above questions from different 
vantage points. These vantage points, broadly defined, involve the 
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biological, the psychodynamic, and the social approaches (behavioral and 
cognitive) to the etiology and treatment of affective disorders. 
While it is recognized that affective disorders are a serious and 
complicated area of study that can be approached from a variety of 
theoretical viewpoints, this dissertation limited its focus to the 
biological and cognitive assessment and treatment of nonbipolar, 
nonpsychotic depression. Specifically, this study examined the 
"treatment validity" of the dexamethasone suppression test by testing 
whether the treatment of abnormal or normal dexamethasone suppression 
test responders was maximized by using either a biologically-oriented 
treatment (antidepressant medication) or a psychologically-oriented 
treatment (cognitive therapy), respectively. Questions addressed in 
this dissertation were as follows: Does an abnormal dexamethasone 
suppression test, which many believe represents a biologically-based 
depression, respond better to a biologically-oriented treatment 
(antidepressant medication) versus a psychologically-oriented treatment 
(cognitive therapy); and, conversely, does a normal dexamethasone 
suppression test, which many believe represents a psychologically-based 
depression, respond better to a psychologically-oriented treatment 
versus a biologically-oriented treatment? Related to this question, the 
theoretical distinction of endogenous versus exogenous depression was 
explored in terms of its function in predicting behaviors associated 
with the distinction (presence or absence of melancholia) and its 
function in predicting treatment response. Another question posed was 
if a conversion from an abnormal to normal dexamethasone suppression 
test after somatic treatment indicates clinical recovery, what effect 
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does a psychological treatment (cognitive therapy) have on the 
dexamethasone suppression test? Finally, what effect does a 
biologically-oriented treatment and a psychologically-oriented treatment 
have on a subject's dysfunctional thoughts? 
The context in which these questions are posed requires review. 
First, the affective disorder of depression is defined, and theoretical 
distinctions are discussed. Next, a brief review of biological 
approaches and the cognitive approach to depression are examined, 
specifically focusing on effective treatments for depressives: somatic 
treatments (e.g., chemotherapy) and Beck's cognitive therapy. Next, the 
dexamethasone suppression test is discussed as it relates to the 
etiology and treatment of depressive disorders. After this, relevant 
philosophical/conceptual issues are briefly mentioned. Finally, the 
concept and methodology of "treatment validity" is described. 
Depression: Definition and Theoretical Distinctions 
According to the Diagnostic and Statistical Manual of Mental 
Disorders, third edition (American Psychiatric Association, 1980), the 
"affective disorders" are divided into two main groups, Major Affective 
Disorders and Other Specific Affective Disorders. This dissertation was 
concerned with the group Major Affective Disorders, which are subdivided 
into Bipolar Disorder and Major Depression. Theses two subcategories 
are distinguished on the basis of whether or not a manic episode has 
ever occurred in the patient. A client is diagnosed as having bipolar 
disorder if he/she is currently experiencing or has ever experienced a 
manic episode. A manic episode is defined by the Diagnostic and 
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Statistical Manual of Mental Disorders, third edition (American 
Psychiatric Association, 1980) as having a duration of at least one week 
and including at least three of the following symptoms: increased 
activity, pressured speech, flight of ideas, exaggerated self-esteem, 
decreased need for sleep, distractibility, and excessive involvement in 
activities which have the potential for negative consequences (e.g., 
buying sprees, reckless driving). Therefore, a person may be currently 
experiencing a depressive episode, but would be diagnosed as "bipolar 
disorder-depressed" if the person had a history of manic symptoms. 
This dissertation excluded subjects that had a diagnosis of bipolar 
disorder since presently there are no data to suggest that clients with 
bipolar disorder respond to psychotherapy equally well or better than 
they respond to lithium or antidepressant medication (Rush, 1982). 
Therefore, subjects included in this dissertation fit the diagnosis of 
major depression, and included "individuals who have never experienced, 
or are unlikely to experience a manic episode" (Hollon, 1981). 
According to the Diagnostic and Statistical Manual of Mental 
Disorders (American Psychiatric Association, 1980), a major depressive 
episode is characterized by "a dysphoric mood or loss of interest or 
pleasure in all or almost all usual activities and pastimes." The 
dysphoric mood is characterized by symptoms such as the following: "sad, 
depressed, blue, hopeless, low, down in the dumps, irritable." In 
addition, at least four of the following symptoms have to be present 
nearly every day for a period of at least two weeks: poor appetite, 
significant weight loss, insomnia or hypersomnia, psychomotor 
retardation or agitation, loss of interest or pleasure in usual 
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activities, decrease in sexual drive, loss of energy, feelings of 
worthlessness or excessive guilt, inability to concentrate, or thoughts 
of death, suicidal ideation, or suicide attempt. A current episode of 
major depression may also be subclassified as with or without 
melancholia. With melancholia would include the following symptom 
cluster: loss of pleasure in all or almost all activities, lack of 
reactivity to usually pleasurable stimuli, and at least three of the 
following: distinct quality of depressed mood that is different from 
the feeling associated with the loss of a loved one, the depression is 
worst in the morning, early morning awakening, marked psychomotor 
retardation or agitation, significant anorexia or weight loss, or 
excessive or inappropriate guilt. Subjects in this research project 
were subclassified as with or without melancholia. 
In summary, subjects included in this study were diagnosed as major 
depression, with or without melancholia. Subjects who exhibited any 
other psychiatric disorder, including bipolar disorder (manic or 
depressed) or any type of psychosis (impairment in reality testing) were 
excluded from this research project. 
Additional Theoretical Distinctions 
Attempts have been made to classify a major depressive episode in 
addition to the Diagnostic and Statistical Manual (American Psychiatric 
Association, 1980). These attempts vary extensively depending on how 
one chooses to view depression. Currently used categories have 
classified this syndrome according to whether the cause is internal or 
external (endogenous versus exogenous), the nature of the response 
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pattern (autonomous versus reactive), the level of anxiety (agitated 
versus retarded), the occurrence of manic episodes (unipolar versus 
bipolar), the level of reality testing (psychotic versus neurotic), and 
whether the depression is the main difficulty or if it is resulting from 
another disorder (primary versus secondary) (Boyd s Levis, 1980). 
Subtypes of depression have also been classified along personality 
dimensions such as passive-dependent, obsessive, hysteriod, paranoid, 
schizoid, bipolar-manic, and schizo-affective (Becker, 1977). 
This dissertation was concerned with the theoretical distinction of 
endogenous versus exogenous depression because of its close association 
with the dexamethasone suppression test. Therefore, a review of this 
distinction is warranted. 
The Endogenous-Exogenous Distinction 
The endogenous-exogenous distinction is one of the most widely used 
but highly controversial distinctions in depression. This distinction 
has been conceptualized in terms of the behaviors associated with each 
category, the etiology that is implied by each category, and the 
response to treatment based on each category. 
Endogenous depressions, based on factor analytic studies, have 
consistently been found to have a set of characteristic behaviors or 
symptoms including terminal sleep disturbance, weight loss, difficulty 
concentrating, psychomotor retardation, severely depressed mood, and an 
inability to respond to pleasant changes in the situation or environment 
(Rosenthal & Klerman, 1966). Exogenous depression is often 
characterized by behaviors or symptoms including low self-esteem, 
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feelings of helplessness, irritability, anger, unhappiness, a histronic 
attitude, self-pity, responsivity of mood, sudden onset, initial 
insomnia, and precipitating factors (Klein, 1974). In other words, 
endogenous depressions involve depressions with primarily negatative 
disturbances, while exogenous depressions involve more of an emphasis on 
subjective feelings of depression. 
Based on the above symptom clusters, different etiologies for 
endogenous versus exogenous depression have often been inferred. As 
Sachar (1982) points out, the distinction was based on the following 
observation: the clinical syndrome of endogenous depression was 
associated with several symptoms suggesting hypothalamic dysfunction, 
such as disturbances in mood, sex drive, sleep, appetite, and autonomic 
activity. He goes on to state that if endogenous depression is 
associated with hypothalamic dysfunction, then it is possible that 
neuroendocrine function would also be disturbed. In addition, the same 
neurotransmitters implicated in the chemical pathology of depressive 
illness (e.g., noradrenaline, serotenin, and acetylcholine) also 
regulate the secretion of the hypothalamic neuroendocrine cells which 
control pituitary function. Therefore, deficiencies in the functional 
activity of these neurotransmitters would be expected to be reflected in 
the hormonal responses they regulate. This has been supported by 
studies showing significant abnormalities in the secretion of Cortisol, 
growth hormone (HGH), and thyroid stimulating hormone (TSH) in 
endogenous depressions (Brown, Johnston & Mayfield, 1979? Checkley, 
1979; Gold, Goodwin, & Wehr, 1976; Maeda, Kato, & Ohgo, 1975; Prange, 
Wilson, & Lara, 1972; Sachar, 1975; Van Praag & Korf, 1979; Whybrow & 
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Hurwitz, 1976). In addition, studies examining amine metabolite 
abnormalities (e.g., MHPG, HVA, and 5HIAA) have also supported this 
distinction (Asberg, Thoren, S Traskman, 1976; Goodwin & Potter, 1979; 
McLeod & McLeod, 1972; Post & Goodwin, 1974; Subrahmanyan, 1975). These 
data led many to view endogenous depression as a depression that was 
caused from "within," while exogenous depression was believed to be 
caused from "without." Since it is so difficult to determine whether a 
depression is caused by some precipitating event, many researchers 
simply define endogenous depression phenomenologically, that is, on the 
basis of symptomatology. In fact, Klein (1974) has proposed that the 
term "endogenomorphic" depression be used instead, while the Diagnostic 
and Statistical Manual (American Psychiatric Association, 1980) uses the 
term "with melancholia" to refer to endogenous depressions. 
Nevertheless, these types of depressions are often viewed as having some 
type of faulty biological system (e.g., pleasure mechanism) whether a 
precipitating event is evident or not (Klein, 1974). 
Finally, the response to treatment has also been examined based on 
this endogenous-exogenous distinction. As Andreasen (1982) points out: 
"the clinical and neurochemical or neuroendocrine findings are fairly 
strong in the support of such a distinction, and the endogenous syndrome 
appears to be a healthy predictor of response to treatments such as 
tricyclics or ECT." Several studies have examined the effectiveness of 
a chemotheraputic approach (e.g., tricyclic antidepressants) using this 
distinction, finding that the endogenous depressions usually respond 
well to antidepressants (Bielski & Friedel, 1976;, Kiloh, Ball, & 
Garside, 1962; Paykel, 1972; Rao s Coppen, 1979; Raskin s Crook, 1976), 
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as compared to the exogenous depressions. These treatment studies have 
also been used to support the biochemical abnormalities in the etiology 
of endogenous depressions. The relation of this distinction to the 
dexamethasone suppression test, in addition to relevant philosophical/ 
conceptual issues, are discussed later in this introduction. The 
cognitive model of depression along with the biological-disease model 
are briefly reviewed next, in addition to the relevant treatment 
associated with each model. 
Cognitive Model of Depression: Beck 
The theory relating depression to cognitive variables was proposed 
by Beck and his. associates (1967, 1972, 1979). Beck maintains that 
negative thought patterns developed during childhood and adolescence can 
be later activated by environmental stresses, which makes the individual 
susceptible to depression. Beck conceptualizes a "primary triad" which 
consists of the distorted perceptions that the depressed person holds 
about himself/herself, the present, and the future. These distortions 
occur when the person commits the following logical errors despite 
disconfirming evidence: (a) arbitrary inference - the person draws 
conclusions which cannot be supported by environmental data; (b) 
selective abstraction - the person emphasizes some details and not 
others; (c) overgeneralization - the person draws conclusions about his 
or her ability, performance, or worth on the basis of a single incident; 
(d) magnification/minimization - the individual exaggerates or slights 
the importance of events; (e) all-or-none thinking - the person thinks 
in absolute terms. Beck goes on to say that the classic emotional, 
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motivational, behavioral, and vegetative signs of depressions follow 
these distorted, negative, logical errors in thought. Beck states that 
the relationship between depressive symptoms and negative thoughts 
results in a "vicious circle causing the downward spiral of depression." 
Over the years, there has been considerable accumulation of 
empirical data that supports the cognitive theory of depression. 
Several review articles have provided summaries of the data available 
(Hollon & Beck, 1979; Lewinsohn & Hoberman, 1981; Wright & Beck, 1983). 
Lewinsohn and Hoberman (1981) organized the data in terms of looking at 
the effects of success and failure, perceptual distortion, and negative 
experiences in depressed individuals. 
Lewinsohn and Hoberman (1981) report on a number of studies that 
focused on the differential effects of success and failure experiences 
on self-esteem, mood, and expectation of future success on task-and-
performance evaluation in depressed and nondepressed groups. For 
example, Filippo and Lewinsohn (1971) found that when "success" and 
"failure" were experimentally produced by either manipulating the time 
allowed for completing the task or by manipulating the length of the 
task, that systematic change in the depressed individual's self-esteem 
occurred. In addition, other relevant studies have also suggested that 
increases in depressive's expectations after successful performance were 
related to subsequent improved performance (Klein & Seligman, 1976; 
Loeb, Beck, & Diggory, 1971). 
With regard to perceptual distortion, depressed subjects have been 
found to overestimate the amount of negative feedback and underestimate 
the amount of positive feedback they receive after performing 
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experimental tasks (DeMonbreun S Craighead, 1977; Nelson & Craighead, 
1977). In addition, depressed subjects have difficulties in assessing 
the accuracy of feedback. For example, Hammen and Krantz (1976) and 
Rizley (1978) found that in experiments in which feedback was not 
related to actual performance, depressed subjects readily accepted the 
validity of false negative feedback and attributed their "failure" to 
personal inadequacies such as lack of effort or poor ability. Subjects 
who were not depressed attributed successful performance to their own 
personal abilities, even though this success was due to luck. These 
studies have been used in support of a cognitive theory of depression. 
Studies examining memory distortion have also shown findings 
relevant to the cognitive theory of depression. While studies have 
shown that depressed subjects have recall deficits on most memory tasks, 
the differences between depressed subjects and control subjects 
increases on tasks involving higher degrees of complexity, abstraction, 
or effort (Braff & Beck, 1974; Cohen, Weingartner, & Smallberg, 1982; 
Miller, 1975). Also, deficits in memory can be amelioriated by 
improvements in mood by either antidepressants or by success 
experiences (Glass, Uhlenhuth, Weinrub, Fischman, & Teuch, 1978). 
Finally, expected relationships between negative expectancies and 
mood have also been found (Beck, 1972). In addition, high levels of 
hopelessness have been found consistently among depressed patients 
(Beck, Kovacs, & Weissman, 1975; Minkoff, Bergman, & Beck, 1973; Rush, 
Beck, & Kovacs, 1982). 
In summary, the above studies have been used to support Beck's view 
of the relationship between dysfunctional cognitions and depression. In 
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spite of these studies, a number of studies have also questioned this 
relationship. For example, Rosenzweig (1960) did not find depressed 
subjects to be more negative than nondepressed subjects following a 
success or failure experience. Also, Alloy and Abramson (1979) studied 
the ability of depressed and nondepressed subjects to detect the degree 
of contingency between responding and outcome in a series of problems 
that varied in the actual degree of objective contingency between the 
performance responses and outcomes obtained. No differences were found 
between depressed and nondepressed subjects. Furthermore, nondepressed 
subjects judged that they had more control (erroneously) in a "win" 
situation than a "lose" situation, while depressed subjects accurately 
reported the amount of control in both situations (Lewinsohn & Hoberman, 
1981). Lewinsohn, Mischel, Chaplin, and Barton (1980) found that 
depressives' ratings of their social competence were likely to match 
objective observers' ratings of the depressives' competence, while 
psychiatric and normal controls were likely to rate themselves more 
positively than the observers did. In another study by Lewinsohn, 
Steinmetz, Larson, and Franklin (1981), a longitudinal study was 
conducted to assess whether cognitions known to be correlated with 
depression precede, accompany, or follow an episode of depression. 
While the results were generally consistent with the hypothesis that 
depression-related cognitions arise concomittantly with an episode of 
depression, subjects who were to become depressed later during the 
course of the study did not differ from controls on the cognitive 
measures, and depressive cognitions did not seem to be permanent 
residuals of a depressive episode. The authors concluded that this 
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study supported the notion that cognitive dysfunction was a correlate of 
and not an antecedent of a depressive episode. In a similar vein, 
Silverman, Silverman, and Eardley (1984) administered the Dysfunctional 
Attitude Scale (DAS) and found that dysfunctional thinking was more 
prominent while the subject was depressed versus when the subject was 
asymptomatic as the result of antidepressant treatment. Similarly, 
Simons, Garfield, and Murphy (1984) treated depressed patients with 
medication or cognitive therapy and found identical changes on cognitive 
measures for both groups. In all, these studies argue that 
dysfunctional thinking may be a "result" or "correlate" of depression 
rather than the "cause." 
In conclusion, while there are a number of studies supporting the 
relationship between dysfunctional thinking and depression, a number of 
studies question the causal nature of this relationship. Therefore, at 
this time, Beck's theory of depression cannot be accepted as a 
comprehensive, all encompassing explanation of depression. 
Nevertheless, Beck's model has resulted in the development of a 
comprehensive and powerful therapy for depression, which Beck describes 
in detail in his book Cognitive Therapy of Depression (Beck, Rush, Shaw, 
& Emery, 1979). 
Beck's time-limited therapy package focuses not only on modifying 
dysfunctional thoughts, but also focuses on modification of overt 
behavior (e.g., graded task assignments, activity schedules, assertion 
training) as a way to generate data contradictory to the client's 
negative self-perception. Cognitive modification procedures teach the 
client that his/her depression is related to maladaptive thought 
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patterns and trains the client to identify and logically challenge the 
erroneous assumptions underlying these cognitions. These basic 
assumptions are conceptualized as hypotheses to be tested. The client 
learns to challenge the validity of his/her negative attitudes by 
examining the disconfirmatory data. In summary, Beck's strategy is as 
follows: (a) teach the client that a relationship exists between 
thoughts, feelings, and behavior; (b) teach the client to monitor 
his/her automatic thoughts and to determine the underlying depressogenic 
assumptions; (c) teach the client to identify logical errors and 
depressive assumptions made; (d) help the client evaluate and look for 
alternative explanations for negative thoughts and logical errors; (e) 
teach the subject to evaluate and correct dysfunctional thoughts and 
assumptions by learning to cope with logical errors and designing 
experiments; and (f) help the client test out his/her hypotheses and 
adjust dysfunctional thoughts and faulty assumptions accordingly. 
Outcome data on Beck's cognitive therapy has been quite impressive, 
particularly when the subject population has been nonpsychotic, 
nonbipolar depressed outpatients. Several reviews summarize the outcome 
data (Kendall, 1984; Lewinsohn & Hoberman, 1981; Wright & Beck, 1983). 
To illustrate, Kovacs, Rush, and Beck (1981) randomly assigned unipolar, 
depressed outpatients to either cognitive therapy or imipramine therapy 
with medicine checks. The results showed that patients receiving 
cognitive therapy showed greater improvement in depressive symptoms than 
patients receiving imipramine. Although both groups were significantly 
improved after therapy, the cognitive therapy group was more likely to 
maintain its gains at a three-month follow-up when compared to the 
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imipramine group. While not statistically significant, this trend 
continued at a six-month follow-up and at a one-year follow-up. This 
study was essentially a replication in methodology and results of a 
study done by Rush, Beck, Kovacs, and Hollon in 1977. While these 
studies had similar methodological difficulties (e.g., mainly the 
adequacy of drug therapy was questioned in terms of blood levels), they 
conclusively showed the effectiveness of cognitive therapy. Other 
studies have also shown this effectiveness of cognitive therapy. For 
example, Shaw (1977) found that depressed outpatients treated 
individually with cognitive therapy improved to a significant degree 
when compared to a behavioral group therapy, a nondirective group 
therapy, or no therapy. McLean and Hakstain (1979) studied 170 
outpatients who were significantly depressed according to the Research 
Diagnostic Criteria (RDC) and the Beck Depression Inventory (BDI). The 
patients were randomly assigned to treatment with cognitive therapy, 
psychodynamically oriented therapy, relaxation training, or 
amitriptyline therapy (adequacy of this therapy was measured by blood 
levels). Cognitive therapy was shown to be superior to the other three 
groups. Finally, Blackburn, Bishop, and Glen (1981) compared cognitive 
therapy with pharmacotherapy and combined treatment. Overall, the 
combined treatment gave the best results, with cognitive therapy alone 
and pharmacotherapy alone also producing significant improvements. 
In summary» Wright and Beck (1983) conclude that "to date, all 
outcome studies on outpatients who met the Research Diagnostic Criteria 
for depression have found cognitive therapy to be an effective 
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treatment. Cognitive therapy has been at least equal to pharmacotherapy 
in all studies comparing the two treatments." 
Biological-Disease Model of Depression 
The biological-disease model of depression assumes that factors 
such as genetics or a malfunction of some biochemical system is the 
cause of the disorder. Therefore, the "signs" and "symptoms" of 
depression serve to reflect the underlying organic disorder. Since the 
cause is seen as an organic factor, medicines are often used to treat 
the underlying malfunction. Data used to support this approach to 
depressive disorders are: (1) genetic studies; (2) biogenic amine 
metabolism studies; and (3) studies of endocrine abnormalities. This 
section briefly reviews these studies, with emphasis on endocrine 
studies due to the close relation with the dexamethasone suppression 
test. Effective chemotheraputic approaches to the treatment of 
depression are also examined. 
The role of heredity in psychopathology, and particularly 
depressive disorders, is inferred from evidence on correlations of 
depression among members of the same family. Methodologies commonly 
used to examine the genetic influence on psychopathology are the 
pedigree analysis; the family method; twin studies; and adoption 
studies. A number of reviews of the above methodologies as they relate 
to depression are available (Dunner, Gershon, & Goodwin, 1976; Gershon, 
Baron, & Leckman, 1975; Gershon, Bunney, & Leckman, 1976; Hutchings & 
Mednick, 1975; Mendlewicz, Pleiss, & Frene, 1975; Rieder & Gershon, 
1978; Suslak, Shopsin, Silbey, Mendlewicz, & Gershon, 1976; Winokur & 
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Cadoret, 1977). As Winokur and Cadoret (1977) conclude, the research 
involving genetic studies in depressive disorders shows that: (a) 
family members of depressive patients are more likely themselves to be 
ill with an affective disorder than are members of the general 
population; and (b) in twins where one member has a depression, 
concordance is greater in monozygotic pairs than dizygotic pairs. In 
spite of this conclusion, it cannot be concluded that depression is an 
inherited disorder. The fact that correlations or concordance rates are 
not 100% argues for environmental influences. In addition, there are 
several methodological difficulties present in many studies that examine 
genetic influences, such as inaccurate diagnoses, the use of different 
diagnostic systems, an inability to locate family members, and small 
sample sizes. 
Biogenic amine metabolism studies have been examined in relation to 
depressive disorders. As Zis and Goodwin (1982) point out, the biogenic 
amine hypothesis of affective disorders grew out of associations between 
observations of the clinical effects of certain drugs and the 
neurochemical effects of these drugs in animal brain. In its most basic 
form, this hypothesis points that depression results from an absolute or 
relative deficiency of the catecholamines norepinephrine and dopamine, 
and of the indoleamine serotonin at functionally important adrenergic 
receptors in the brain. All of the above compounds are known as 
monoamines collectively. The physiological activity of monoamines can 
be altered by interfering with any of the processes involved in 
synthesis, in storage, in release, in metabolism, or in controlling the 
sensitivity of receptors to one or another monoamine (Schildkraut, 
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1977a). Evidence for the biogenic amine hypothesis has been 
accumulated, based on (a) the physiological effects of substances that 
appear to induce depression; (b) the physiological effects of drugs that 
alleviate it; and (c) the levels of metabolic by-products of the 
activity of these brain chemicals which show up in body fluids. These 
data are briefly reviewed. 
Reserpine, a drug used as an anti-hypertensive medication, was 
found to induce depressive symptoms in some individuals. Animal studies 
revealed that the drug's primary mode of action was to impair the 
capacity of neurons to retain monoamines in storage granules, and that 
the brain levels of the biogenic amines, norepinephrine, dopamine, and 
serotonin, were depleted after administration of reserpine 
(Schildkraut, 1977a). Zis and Goodwin (1982) conclude that "overall, 
drugs that increase the functional output of catecholamine systems act 
either as stimulants and precipitants of mania or as antidepressants. 
Conversely, drugs that decrease the functional output of these systems 
act as sedatives or antimanics." They are also quick to point out that 
not all of the drug findings are consistent in connecting the biogenic 
amines to affective disorders. Zis and Goodwin (1982) cite several 
studies showing contradictory results (Coppen, Gupta, & Montgomery, 
1976; Davis, Colburn, Murphy, & Robinson, 1979; Fann, Davis, S Janowsky, 
1973; Murphy, Campbell, & Costa, 1978; Shopsin, Gershon, Goldstein, & 
Friedman, 1975; Van Praag, 1978). 
The effectiveness of antidepressant drugs has been used as support 
for the biogenic amine hypothesis. The two main classes of drugs used 
to treat depression are: (a) tricyclics, and (b) monoamine oxidase 
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inhibitors. It has been found that monamine oxidase inhibitors, which 
were initially used in the treatment of tuberculosis, also have 
antidepressant effects in some patients. These drugs, as the name 
implies, inhibit the enzyme monoamine oxidase, resulting in increases of 
norepinephrine, dopamine, and serotonin in the brain (Becker, 1977; 
Schildkraut, 1977b). In addition, tricyclic antidepressants, which 
operate differently than monoamine oxidase inhibitors, interfere with 
the re-uptake of norepinephrine and serotonin once they are released at 
receptor sites. Even though this information supports the biogenic 
amine hypothesis, problems in accounting for certain phenomena exist. 
For example, the immediate effect of administering either an monoamine 
oxidase inhibitor or a tricyclic antidepressant is the increase in 
available norepinephrine or serotonin, but clinical improvement requires 
two or three weeks (Fraser, 1975). In addition, chronic administration 
of tricyclic antidepressants results in a decrease in sensitivity of 
various receptor sites, without the concomitant behavioral changes 
(Mendels & Fraser, 1974). 
Finally, examination of amine metabolites in the cerebrospinal 
fluid (CSF) and urine in depressed versus normal controls has been used 
to support the biogenic amine hypothesis. These metabolites consist of 
3-methoxy-4-hydroxyphenylglycol (MHPG), which is considered the major 
product of norepinephrine, and 5-hydroxyindol-eacetic acid (5HIAA), 
which is considered the major by-product of serotonin (Zis & Goodwin, 
1982). In their review of the literature, Zis and Goodwin report 
several studies which report decreased baseline levels in depressives of 
5HIAA as compared to "control" groups (Asberg, Thoren, & Traskinan, 
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1976? Ashecroft, Crawford, & Eccleston, 1966; Coppen, Prange, S Whybrow, 
1972; Denker, Malm, Roos, & Werdinius, 1966; McLeod & McLeod, 1972; 
Subrahmanyan, 1975; Van Praag & Korf, 1971), while others do not 
find differences (Berger, Faull, & Kilkowski, 1980; Bowers, Heninger, & 
Gerbode, 1969; Fotherby, Ashcroft, & Affleck, 1963; Goodwin, Post, & 
Dunner, 1973; Papeschi & McClure, 1971). Likewise, Schildkraut (1977a) 
reports several studies showing lower MHPG levels in depressives versus 
"control" subjects (Bond, Jenner, S Sampson, 1972; Greenspan, 
Schildkraut, Gordon, Baer, Aranoff, & Durell, 1970; Jones, Maas, 
Dekirmenyian, & Fawcett, 1973; Schildkraut, Keeler, Rogers, S Draskoczy, 
1973) , while other studies do not find this relationship (Bunney, 
Goodwin, Murphy, House, & Gordon, 1972; Shopsin, Wilk, Gershon, Roffman, 
& Goldstein, 1973). 
In summary, a number of different types of data have been used to 
support the biogenic amine hypothesis of depression. As Zis and Goodwin 
point out, these various studies have not provided clear, unequivocal 
support for the "too little-too much" amine hypotheses. They note that 
many confounding variables, such as non-standardized diagnostic systems, 
inconsistent demographic variables across studies, a person's amount of 
activity, and phase differences in terms of what phase of the illness 
the data are collected may account for many of the discrepancies found 
in the data. Prange (1974) has revised the biogenic amine hypothesis 
(calling it the "permissive biogenic amine hypothesis") in order to try 
and account for some of the data. He espouses the belief that a deficit 
in a central indoleaminergic transmission (e.g., serotonin) is a 
necessary, but not sufficient cause. If a deficit is accompanied by 
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lower catecholaminergic transmission (e.g., norepinephrine), then 
depression occurs. While Prange (1974) does not speculate on the cause 
of the changes in the levels of these transmitters, the person's 
genetics are seen as playing the major role. 
As was mentioned earlier, studies have examined the role of the 
endocrine system in depressive disorders. As Sachar (1982) points out, 
the rationale in examining the endocrine system was based on the 
observation that "endogenous" or "melancholic" depressions have symptoms 
suggestive of hypothalamic dysfunction (e.g., disturbances in sleep, sex 
drive, appetite, mood), which would indicate a possible dysfunction in 
the neuroendocrine system. Furthermore, the same neurotransmitters 
previously mentioned (e.g., norepinephrine, serotonin) are involved in 
the functioning of the hypothalamic neuroendocrine cells. Three types 
of data have been used to examine the effects of neuroendocrine function 
in depressives: (a) Cortisol; (b) growth hormone (HGH); and (c) thyroid 
stimulating hormone (TSH). 
Various techniques have been used to examine Cortisol secretion as 
it relates to depressive disorders (e.g., isotope dilution methods). 
Sachar (1975, 1982) has found that half of the patients with major 
depression have substantially increased Cortisol levels, which appear to 
remit with improvement in the client's condition. They also report that 
in examining the 24 hour plasma Cortisol pattern that depressives 
disproportionately secrete excess Cortisol in the afternoon, evening, 
and early morning hours. During these times, Cortisol secretion is 
usually minimal. Another index of Cortisol secretion is the 
dexamethasone suppression test. Carroll (1978, 1980) has reported that 
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a significant subgroup of depressives (approximately 40%) exhibit 
abnormal secretion of Cortisol 17 to 24 hours after ingesting 1 mg. of 
dexamethasone, which would normally inhibit Cortisol secretion. One 
hypothesis concerning this finding suggests that the inability of 
depressives to respond to the administration of dexamethasone is due to 
a deficiency of norepinephrine in the hypothalamic pathways (Carroll, 
1978; Sachar, Asnis, & Nathan, 1980). Another theory asserts that the 
primary abnormality in this subtype of depression is an excess of plasma 
Cortisol, which results in a deficiency of brain serotonin (Hatotani, 
1979; Nomura & Inoue, 1979). These theories are consistent with the 
"permissive biogenic amine hypotheses" by Prange (1974) presented 
earlier. Since the nature of this dissertation involves the 
dexamethasone suppression test, it is examined in detail later. 
As Becker (1977) asserts, evidence for possible neuroendocrine 
dysfunction associated with biogenic amines comes from growth hormone 
(GH) response to insulin-induced hypoglycemia, which appears to be 
involved with the monoamines. Carroll (1978) reports that growth 
hormone response is diminished in major "endogenous" depressions. 
Gruen, Sachar, and Altman (1975) matched females in terms of age and 
phase of menopause (pre-menopause is associated with lower growth 
hormone response, therefore all subjects were post-menopause) and found 
depressives to have a lower growth hormone response when compared to 
"normal" controls. 
Finally, studies have examined thyroid function and thyroid 
stimulating hormone (TSH). Results have been conflicting, with some 
studies showing no abnormality in thyroid function in depressives 
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(Kirkegaard, Norlein, & Lauridsen, 1975) while other studies have shown 
depressives to have a deficient thyroid stimulating hormone response 
(Maeda, Kato, & Ohgo, 1975; Prange, Wilson, & Breeze, 1976). 
In summary, there have been a number of conflicting findings in the 
examination of neuroendocrine systems as they relate to depressive 
disorders. As with studies in the genetic area and the biogenic amine 
research, the neuroendocrine studies have provided support for a 
biological-disease model for depression, but the heterogeniety in the 
findings has prevented a biological-disease model from being accepted as 
a comprehensive, all encompassing explanation of depression. 
Even though much controversy surrounds the biological-disease model 
of depression, effective chemotherapeutic approaches have been 
established over the last twenty years. This dissertation was concerned 
with the antidepressants called tricyclic antidepressants (e.g., 
imipramine, nortriptyline, doxepin, desipramine). Much is known about 
their beneficial effects in treating depressive disorders and about 
their unwanted side effects. Several review articles are available 
concerning tricyclic medications (Bennett, 1966; Klein & Davis, 1969; 
Mandel & Klerman, 1979; Mindham, 1982;.Morris & Beck, 1973; Wechsler, 
Grosser, & Greenblatt, 1965). Overall, these studies report that 
tricyclic antidepressants are the most effective when compared to other 
types of antidepressants; that tricyclic antidepressants are 
consistently superior to placebos; and that little difference in 
effectiveness has been found when comparing different tricyclics to each 
other. Therefore, as Mindham (1982) concludes, "the weight of evidence 
is certainly in favor of the tricyclic drugs being superior to placebo 
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in the treatment of depressive patients." Finally, several studies have 
shown both cognitive therapy and chemotherapy (using mainly tricyclic 
antidepressants) to be essentially equal in effectiveness for the 
treatment of depressive disorders (Blackburn, Bishop, & Glen, 1981; 
Kovacs, Rush, & Beck, 1981; Wright & Beck, 1983). 
Dexamethasone Suppression Test 
Since this dissertation dealt specifically with the dexamethasone 
suppression test, closer examination of this test is needed. It was 
previously mentioned that studies of neuroendocrine abnormalities have 
supported a biological-disease model of depression. It was also pointed 
out that examination of Cortisol secretion is one method of assessing 
neuroendocrine function. One index of Cortisol secretion that is 
frequently used in psychiatry is the dexamethasone suppression test. 
Clinical application of the dexamethasone suppression test consists of 
administration orally of 1 mg. of dexamethasone (a synthetic 
corticosteroid) which is ingested and affects the Cortisol "feedback" 
receptors in the brain and normally turns off the endogenous secretion 
of Cortisol (e.g., causes suppression of Cortisol). Blood tests to 
assess plasma Cortisol levels are then drawn 17 to 24 hours later. An 
abnormal dexamethasone suppression test (e.g., a positive dexamethasone 
suppression test) results in nonsuppression of Cortisol 17 to 24 hours 
later. This procedure has been standardized (Carroll, 1980), with the 
accepted Cortisol level for abnormality being greater than or equal to 5 
ug/dl. 
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This test was introduced in 1960 to study Cushing's syndrome, with 
the results used to support the hypothesis of Cortisol hypersecretion in 
patients with this syndrome (Flori & Davis, 1984). It also supported 
hypothalamus dysfunction since Cortisol was not being suppressed. 
Since depression in patients with Cushing's disease was well documented, 
this led to the use of the dexamethasone suppression test to determine 
whether endocrine abnormalities (e.g., disturbance with the 
hypothalamic-pituitary-adrenal (HPA) axis) was occurring in depression. 
Approximately ten years ago, Carroll (1976) reported that a 
significant subgroup of depressives (approximately 40%) exhibited 
abnormal results according to the dexamethasone suppression test. It 
was also shown by this author that these results were not due to stress, 
agitation, or the administration of psychotropic drugs. In addition, 
abnormal dexamethasone suppression test results were not found in 
populations of normals, schizophrenics, drug abusers, and character 
disorders. Subsequent studies confirmed these results (Brown S Shuey, 
1979; Carroll, Feinberg, s Greden, 1981; Stokes, Pick, & Stoll, 1975) 
while other studies refuted these results (Holsboer, Bender, & Benkert, 
1980; Sachar, Asnis, & Nathan, 1980; Shopsin & Gershon, 1971). As Brown 
and Shuey (1979) and Sachar (1982) point out, much of the inconsistency 
from study to study may have been a result of conducting and evaluating 
the dexamethasone suppression test differently. For example, some 
studies gave 1 mg. of dexamethasone, while others gave 2 mg. Some 
studies sampled plasma Cortisol levels at 4, 8, 16, or 24 hours after 
ingestion of dexamethasone. Also, various studies used different 
Cortisol levels to determine abnormality. Finally, diagnostic 
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classification was inconsistent across studies. As mentioned above, 
this led to research to standardize the procedure, which consists of 1 
mg. of dexamethasone administered and Cortisol measured 17 to 24 hours 
later, with the criteria for an abnormal dexamethasone suppression test 
set at greater than or equal to 5 mg/dl plasma Cortisol secretion 
(Carroll, 1980). 
Controversy currently exists as to the clinical definition of the 
subgroup of depressives showing abnormal results on the dexamethasone 
suppression test. Carroll, Feinberg, and Greden (1981) have presented 
strong data showing that the dexamethasone suppression test correctly 
identified 96% of inpatients who were depressed with a diagnosis of 
melancholia. They argue that this result represents the subgroup of 
depressives that are characterized as "endogenomorphic" depression as 
presented by Klein (1974) , with the assumption that this class of 
depressives have a biological defect that would respond well to 
antidepressants. Other studies using similar criteria as Carroll et 
al. (1981) have found abnormal dexamethasone suppression test results in 
depressed patients not exhibiting melancholia (Coppen, Rao, fi Ruthven, 
1980; Stokes, Pick, s Stoll, 1975). It has also been argued that 
abnormal results on the dexamethasone suppression test distinguish 
between primary versus secondary depressions. Brown, Johnson, and 
Mayfield (1979) along with Schlesser, Winokur, and Sherman (1979) report 
results suggesting that an abnormal dexamethasone suppression tests 
indicates a primary depression while only 0% to 4% of schizophrenics, 
drug abuses, normals, or character disorders have an abnormal 
dexamethasone suppression test. In contrast, Insel and Goodwin (1983) 
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present results which assert that the dexamethasone suppression 
test does not distinguish between depressives and patients with 
obsessive-compulsive disorders, dementia, or eating disorders. These 
authors state that "to conclude from dexamethasone suppression data such 
disorders are actually variants of depression is, at this point, to beg 
the question of the diagnostic usefulness of the test." Finally, Brown 
et al. (1979) points out that another problem with the dexamethasone 
suppression test is that consistent clinical differences between 
depressed patients who have normal versus abnormal results on this test 
have not been found. 
In summary, a great deal of controversy exists over what subgroup 
of depressives, if any, the dexamethasone suppression test defines. A 
comprehensive review by the National Institute of Mental Health 
(Hirschfeld, Kaslow, & Kupfer, 1983) on the clinical utility of the 
dexamethasone suppression test concludes that: (a) clinical differences 
in patients with affective disorders between dexamethasone suppression 
test suppressors and nonsuppressors should be investigated further; (b) 
while some diagnostic strategies have yielded promising results (e.g., 
primary versus secondary; endogenous versus exogenous), further 
investigation and replication is needed; and (c) prevalence rates of 
dexamethasone suppression test nonsuppressors must be accurately 
determined in large groups of patients whose conditions have been 
carefully described and diagnosed (e.g., depressive subtypes, 
schizophrenia, organic brain syndromes). In a separate review of the 
dexamethasone suppression test, Insel and Goodwin (1983) conclude that 
this test is most useful in the research arena since diagnostic groups 
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are often well diagnosed and delineated. They also assert that further 
research is needed before the clinician can confidently use the 
dexamethasone suppression test to differentiate between diagnostic 
groups. 
In spite of the controversy over using the dexamethasone 
suppression test to differentiate between types of depressions and 
diagnostic groups, it is generally believed by most researchers and 
clinicians examining and using this neuroendocrine test that 
nonsuppression (an abnormal test) is a manifestation of some abnormal 
neuroendocrine state requiring some type of chemotheraputic approach for 
its treatment (Brown, Johnson, fi Mayfield, 1979; Brown & Shuey, 1979; 
Carroll, 1980; Fraser, 1975; Greden, Albala, & Haskett, 1980; Gwirtsman, 
Gerner, & Sternbach, 1982; Insel & Goodwin, 1983; Nemeroff & Evans, 
1984; Sachar, 1982; Schlesser, Winokur, & Sherman, 1979). This is 
exemplified by the quote by Akiskal and McKinney (1975): 
It would appear that no matter what interpersonal factors 
mobilize depressive behaviors, once the latter reach 
melancholic stage, they become biologically autonomous and 
refractory to psychotheraputic intervention. 
Even though this is widely believed, the review of the dexamethasone 
suppression test by The National Institute of Mental Health (Hirschfeld 
et al., 1983) and by Nemeroff and Evans (1984) concludes that no studies 
have definitely answered the question of whether suppression or 
nonsuppression at the time of original examination predicts response to 
various types of treatment, and that "the search should continue for 
possible specificity of treatment modality on the basis of the 
dexamethasone suppression test" (National Institute of Mental Health, 
Hirschfeld et al., 1983). In other words, whether the dexamethasone 
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suppression test is a biological marker for a subtype of depression 
that responds well to biological treatments has not been demonstrated. 
There have been no well-controlled studies looking at this question, 
although a few preliminary reports show a relationship between an 
abnormal dexamethasone suppression test and a good response to tricyclic 
antidepressants (Brown, Johnson, & Mayfield, 1979; Brown S Shuey, 1979; 
Greden, Albala, & Haskett, 1980). Others have questioned whether 
cognitive therapy can be effective for abnormal dexamethasone 
suppression test responders (Carroll, Feinberg, & Greden, 1981; Rush, 
1982; Williams, 1984). These studies have numerous methodological 
difficulties, such as small sample sizes, poor outcome measures, poor 
diagnostic procedures, and a post hoc examination of treatment response. 
Nemeroff and Evans (1984), along with other researchers (Bowie & Beaini, 
1985; Greden et al., 1980; Herschfeld, Kaslow, & Kupfer, 1983; Spar & 
Rue, 1983) have found that the dexamethasone suppression test normalizes 
after successful treatment of the depression with medications, and that 
depressives whose test failed to normalize showed significantly less 
clinical improvement and a high risk of relapse. These studies also had 
various methodological difficulties, and the results are in need of 
replication. Finally, there have been no studies examining the 
relationship between the dexamethasone suppression test and 
non-chemotheraputic treatment approaches to depression (e.g., cognitive 
therapy) (Insel & Goodwin, 1983). This dissertation attempted to 
examine whether the possible specificity of treatment modalities used to 
treat depression can be made based on the dexamethasone suppression test 
in order to maximize treatment effectiveness. In other words, the 
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"treatment validity" of the dexamethasone suppression test was examined. 
The "treatment validity" approach is examined next. 
Treatment Validity: Contribution of Assessment to 
Treatment Effectiveness and its Relation to Depression 
One of the main questions examined in this dissertation is the 
contribution of the dexamethasone suppression test to treatment 
effectiveness. In the area of behavioral assessment, this has been 
termed "treatment validity" (Nelson & Hayes, 1979). Since the goals of 
behavioral assessment are to "identify meaningful response units and 
their controlling variables for the purpose of understanding and 
altering behavior" (Nelson S Hayes, 1979), the concept and study of 
treatment validity has allowed for the evaluation of the quality of the 
data generated by behavioral assessment. While the treatment validity 
approach has been mainly applied to the data generated by behavioral 
assessment, this dissertation utilized this concept and the associated 
methodology to examine the treatment validity of the dexamethasone 
suppression test. Therefore, a review of the treatment validity 
approach, along with its relevance to depression is warranted. 
Review of Treatment Validity 
During the last ten years, behavioral assessment has come to be 
viewed as an assessment approach with its own unique set of assumptions 
and goals. Prior to this time, behavioral clinical psychology was 
mainly concerned with treatment interventions and independent variables. 
The initial developments in behavioral assessment often mirrored those 
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in behavior therapy. As a result, behavioral assessment was not well 
defined. In its early emergence as a separate topic, behavioral 
assessment was thought to be merely a sub-area of traditional 
psychological assessment. Only recently has behavioral assessment 
become well-defined and concerned with its own research questions. This 
interest has been manifested by the advent of journals such as 
Behavioral Assessment (Pergamon and the Association for Advancement of 
Behavior Therapy) and Journal of Behavioral Assessment (Plenum), along 
with the emergence of several books by Hersen and Bellack (1976), Cone 
and Hawkins (1977), Ciminero, Calhoun, and Adams (1977), Haynes (1978), 
Haynes and Wilson (1979), Keefe, Kopel, and Gordon (1978) , Barlow 
(1981), Mash and Terdal (1981) , and Nelson and Hayes (1981). 
One critical question that was facing behavioral assessors was: 
How do we evaluate the quality of behavioral assessment? As behavioral 
assessors seriously began to consider this question, it became evident 
that methods used to evaluate traditional assessment, such as 
psychometric theory or generalizability theory, were quite limited in 
their usefulness in evaluating behavioral assessment. For example, 
psychometric theory is mainly concerned with the reliability and 
validity of data. Reliability, on the one hand, involves the 
consistency of the measure being used and is expressed as a correlation. 
Consistency across time (test-retest reliability), across test items 
(split-half reliability), and across different forms of the test 
(parallel forms reliability) is seen as an indication of a good 
assessment device because more of the "true" score is being measured 
instead of measurement error (Cronbach, 1970). Validity, on the other 
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hand, examines "the extent to which a test measures what it purports to 
measure" (Cronbach, 1970). One type of validity is criterion-related 
validity, which is the extent to which the test (an assessment device) 
results correlate with some external variable which supposedly measures 
the same variable as the test does. The two types of criterion-related 
validity are: concurrent validity, which is the extent to which test 
results correlate with some other concurrent measure of the same 
variable, and predictive validity, which is the extent to which the test 
(any assessment device) results correlate with some future behavior. 
Other types of validity are: content validity, which involves the extent 
to which relevant samples of the criterion situation are represented in 
the test situation; convergent validity, which involves taking several 
assessment devices which are supposedly related and actually examine the 
degree of relationship; and finally, construct validity, which is the 
extent to which the test measures a theoretical construct or trait. 
These traditional psychometric standards have also been relabelled 
according to generalizability theory (Cronbach, Gleser, Nanda, & 
Rajaratnam, 1972). This was accomplished by relabelling the different 
types of reliability and validity as universes of generalization 
(conditions of the assessment situation) which could affect the 
generalizability of behavioral assessment techniques. These are: (a) 
scores (parallel forms reliability); (b) items (split-half reliability); 
(c) time (test-retest reliability); (d) settings (temporal consistency 
or external validity; (e) method (convergent validity); (f) dimension 
(construct validity, concurrent validity, and discriminant validity). 
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By using analyses of variance, the proportion of variance accounted for 
by each "universe of generalization" can be determined. 
While Nelson and Hayes (1981) and Hayes, Nelson, and Jarrett (in 
press) acknowledge specific uses for psychometric and generalizability 
theory in the area of behavioral assessment, they conclude that these 
theories do not provide an adequate means of evaluating the quality of 
behavioral assessment. Hayes et al. (in press) assert that psychometric 
theory and generalizability theory are not adequate because (a) their 
assumptions about behavior; (b) level of analysis; and (c) model of 
causality differences from a behavioral perspective. For example, 
psychometric theory (reliability and validity) assume that behavior is 
enduring and stable, and consistency is seen as a hallmark of a good 
assessment device (Hayes et al., in press). Behavioral assessment, 
however, assumes that behavior is not necessarily enduring and 
consistent, and that inconsistency in measurement may be the result of 
actual changes in behavior rather than an imprecise behavior assessment 
technique. Psychometric theory is also based on the level of analysis 
involving group data, while behavioral assessment focuses on the 
analysis of the individual. As Hayes et al. (in press) note: "the 
issue is not one of number (few versus many) but of the level of 
analysis (individual versus group) upon which principles and findings 
are based." Finally, psychometric theory and behavioral assessment 
differ fundamentally in their view of causality. As Hayes et al. 
argue: "In psychometrics, events can be explained based on the 
structure of the organism (e.g., the structure of the mind). That is, 
structure can assume causal status. In modern behaviorism, the 
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structure of the organism is itself something to be explained by the 
functional interaction between the organism and the world over both 
short time frames (e.g., in the lifetime of the individual) and long 
time frames (e.g., in the lifetime of the species). Structure is not 
unimportant in this view, but it is not a cause. Instead it is a host 
for causal agents." 
Therefore, in response to the above arguments against psychometric 
and generalizability theory in evaluating behavioral assessment, Nelson 
and Hayes (1979) put forth the idea that in order to evaluate the 
quality of behavioral assessment, one must consider the function served 
by behavioral assessment. Nelson and Hayes (1979) state that at least 
two functions seem critical: the function of behavioral assessment in 
increasing our understanding of behavior, which is termed "conceptual 
validity," and the function of behavioral assessment in contributing to 
treatment effectiveness, which is termed "treatment validity." 
Conceptual validity, according to Nelson and Hayes (1979), asks the 
question, "Does the design of this procedure or experiment and its 
results enable us to support, extend, modify, or elaborate behavioral 
principles and assumptions?" Conceptual validity cannot be measured 
quantitatively, and becomes apparent only after the passage of time as 
more general and conceptually consistent principles of behavior are 
evolved (Nelson & Hayes, 1979). Nelson and Hayes (1979) also assert 
that "treatment validity" can be shown by examining the extent to which 
behavioral assessment contributes to treatment effectiveness. The 
treatment validity approach was be examined in this research project and 
therefore is considered in greater detail. 
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Hayes et al. (in press) assert that treatment validity can be 
demonstrated empirically by showing that a particular behavioral 
assessment led to a better treatment than would have occurred without 
the treatment. Hayes et al. reviewed the multiple methodologies 
available to examine treatment validity. These methodologies are 
reviewed in the context of their relevance to depression. Treatment 
validity in the area of depression is examined when one attempts to 
match the depressive's "characteristics" or problematic target behaviors 
to specific types of treatment for depression. Special emphasis will be 
placed on the treatment validity methodology being utilized in this 
dissertation. 
Treatment Validity Methodologies and Their Relation to Depression 
According to Hayes et al. (in press), the treatment validity 
approach can be used to examine questions such as: Does the quality of 
assessment devices or strategies, or the nature of theoretical 
distinctions, or the quantity of assessment contribute to the 
effectiveness of treatment? Hayes et al. (in press) divide the 
methodologies used to examine these questions into three main 
categories: (a) post hoc identification of dimensions; (b) a 
priori-single dimension studies which are sub-divided into manipulated 
assessment, manipulated match, and observed differences studies; and (c) 
a priori-multiple dimension studies. These type of methodologies can be 
done in a group or single- subject design format. 
Post hoc identification of dimensions involves administering 
treatments to many persons and identifying post hoc aspects of the 
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assessment devices which help predict therapy responders. For example, 
Hayes et al. (in press) report a study by Bielski and Friedel (1976) 
which showed that higher social class, insidious onset, anorexia, weight 
loss, middle and late insomnia, and psychomotor disturbance were all 
positively related to a favorable response to tricyclic medication. In 
contrast, neurotic, hypochondriacal, and hysterical traits, multiple 
prior episodes, and delusions predicted a poor response to imipramine 
and amityptyline. 
A priori-single dimension studies, as mentioned before, are 
subdivided into (a) manipulated assessment, (b) manipulated match, and 
(c) observed differences studies. The manipulated assessment treatment 
validity studies focus on the utilization of assessment data; A single 
group of subjects is divided into two groups, and a single aspect of 
assessment is varied systematically. Hayes et al. (in press) gives the 
example of information collected on all subjects but made available to 
therapist in one group and not the other. The therapist in the former 
group would design and implement the treatment according to the 
assessment data available. Differential outcomes between groups would 
confirm the treatment validity of the assessment characteristics 
manipulated. Manipulated match treatment validity studies manipulate 
the correspondence between assessment information and treatment. A 
study by McKnight, Nelson, Hayes & Jarrett (1984) manipulated the 
correspondence between three target behaviors (high frequency of 
irrational thoughts, social skill deficits, or both irrational thoughts 
and social skill deficits) and treatment (social skills training versus 
cognitive therapy) in depressives. Results showed that not only the 
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global measures of depression, but also the specific measures of each 
related target behavior (e.g., irrational beliefs or social skill 
deficits) improved more when treatment was matched to the target 
behavior than when it was not. Finally, observed differences treatment 
validity studies divide subjects into groups non-randomly based on 
assessment differences. Subjects then receive one type of treatment. 
Differences between these groups then shows the treatment validity of 
these differences. For example, depressed subjects with a high 
frequency of irrational beliefs with and without anxiety might all be 
given cognitive therapy. If only those without anxiety showed changes 
in their depression and irrational beliefs, then the treatment validity 
of the distinction between these two groups would be established. 
A priori-multiple dimension studies involve various combinations of 
the subgroups described above, such as: manipulated assessment-
manipulated match studies; manipulated assessment-observed differences 
studies; manipulated match-observed differences studies; manipulated 
assessment-manipulated match-observed differences studies; and observed 
differences with two or more treatments studies (Hayes et al., in 
press). Since this dissertation employed the observed differences with 
two or more treatments methodology, it is examined in detail. 
Hayes et al. (in press) assert that one way "observed differences 
with two or more treatments studies" are conducted is to cross distinct 
patient groups with two or more distinct treatment approaches. Hayes et 
al. feel that this type of research is "elegant when the nature of each 
patient group seems to imply a distinct treatment approach." They go on 
to say the factorial design that results tests not only the treatment 
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validity of the patient group distinctions but also the conceptual and 
theoretical distinctions which gave use to them and their implied 
therapies. This dissertation employed this particular strategy, with 
the two distinct patient groups being depressives with normal versus 
abnormal dexamethasone suppression test responders, and the two distinct 
treatment approaches being a chemotheraputic approach (tricyclic anti­
depressants) and a psychological approach (cognitive therapy). 
Therefore this methodology examined the treatment validity of the 
patient group distinctions and their contribution to treatment 
effectiveness. More specifically, does abnormal dexamethasone 
suppression test findings result in a chemotheraputic approach being 
more effective than a psychological approach? There are also 
implications for the theoretical distinctions (e.g., in this case, the 
endogenous versus exogenous distinction as related to the dexamethasone 
suppression test) and the related therapies (chemotherapy versus 
cognitive therapy) previously discussed. In order to effectively 
address these issues, it was necessary to select a psychological 
treatment as effective as medication. Therefore, all subjects were 
chosen with a high frequency of dysfunctional in order to give cognitive 
therapy a chance to be effective. As Hayes et al. conclude, this 
particular treatment validity design can improve our understanding of 
behavior and contribute to an inductive clinical science. When a 
procedure or experiment contributes to the establishment of general and 
conceptually consistent principles, it is said to have "conceptual 
validity" or "theoretical validity" (Hayes et al., in press). In 
dealing with treatment validity studies that also have "theoretical 
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validity," certain philosophical/conceptual issues, such as the 
relationship between etiology and treatment, along with the mind-body 
problem, need to be addressed. 
Acknowledgment of Important Philosophical/Conceptual Issues 
Relationship Between Etiology and Treatment 
In the study of depressive disorders, there is an interactive role 
between etiology and treatment outcome. Many times etiological research 
leads to treatment suggestions, or successful treatment leads to 
suggestions concerning etiological research. This is quite evident in 
the review of the biological and cognitive etiological models of 
depression and their associated treatments. A problem arises, however, 
when a researcher tries to validate a particular theory by utilizing the 
effectiveness of a particular treatment. Examples of logical errors 
involved in the relationship between etiology and treatment will clarify 
this problem. For example, Rimland (1964) points out the error of 
inferring etiology from treatment by using the "aspirin analogy." He 
coined this term after a review of the literature on autism in which an 
etiological hypothesis was made on the basis of treatment effectiveness. 
He points out the logical error of assuming that because contingency 
management can improve some response classes of autistic children, then 
autism must be "caused" by poor parental contingency management. This 
is logically the same as saying that if aspirin can help a headache, it 
must be the lack of aspirin that caused the headaches. Therefore, the 
success of cognitive therapy in treating depressives does not 
necessarily mean that irrational beliefs actually "caused" the 
depression. 
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This dissertation avoided the above-mentioned logical error by not 
asserting that the treatment outcome of this study proves the related 
theory associated with the theoretical distinctions examined. While 
this study may support the theoretical distinction and related theories, 
it can only provide speculation for future etiological research. 
Mind-Body Issue 
The relationship between etiology and treatment overlaps with the 
mind-body problem in this discussion. The mind-body problem dates back 
to the days of De Cartes and is primarily a philosophical religious 
issue. The issue deals with whether the mind and the body are separate 
systems (dualism), or are both composed of the same physical matter and 
are part of the same physical system (physical monism). In reference to 
the above discussion, the question becomes: With regard to one's view 
on etiology, how can nonphysical treatment (e.g., cognitive therapy) 
alter a disorder that has physical cause or how can a physical treatment 
(e.g., chemotherapy) have an effect on an affective disorder caused by 
irrational beliefs? A dualist might propose an interactionist position 
and say that the mind and body interact. Psychological treatments 
affect the "mind" which in turn affects (causes changes) in the physical 
body. Also, physical treatments affect the body resulting in 
corresponding changes in the "mind." 
The view adopted for this dissertation is the physical monist view, 
which says both types of treatments are effective because they are both 
dealing with the same thing, physical matter. The only difference 
between the two treatments is the level of intervention. Therefore, the 
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physical system can be affected at a biochemical level of intervention, 
or an environmental level of intervention resulting in corresponding 
changes physiologically. Changes in cognitions, feelings, etc., are 
changes in physiology, or physical matter (it is realized that this is 
merely speculation). This study primatively addressed this mind-body 
position by examining the effects of medication on dysfunctional 
beliefs, and the effects of cognitive therapy on the dexamethasone 
suppression test. 
Statement of Purpose 
The research presented here examined the value of the dexamethasone 
suppression test in selecting subjects who are responsive to different 
types of treatment for depression. In other words, the "treatment 
validity" of the dexamethasone suppression test was evaluated by testing 
whether the treatment of abnormal or normal dexamethasone suppression 
test responders was maximized by using either a biologically-oriented 
treatment (antidepressant medication) or a psychologically-oriented 
treatment (cognitive therapy), respectively. Specifically, the question 
examined was: Does an abnormal dexamethasone suppression test, which 
many believe represents a biologically-based depression, respond better 
to a biologically-oriented treatment (antidepressant therapy) versus a 
psychologically-oriented treatment (cognitive therapy), and conversely, 
does a normal dexamethasone suppression test, which many believe 
represents a psychologically-based depression, respond better to a 
psychologically-oriented treatment versus a biologically-oriented 
treatment? Related to this question, the theoretical distinction of 
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endogenous versus exogenous depression was explored in terms of its 
function in predicting behaviors associated with the distinction 
(presence or absence of melancholic symptoms) and its function in 
predicting treatment response. This project also examined a second 
question: If a conversion from an abnormal to normal dexamethasone 
suppression test after somatic treatment indicates clinical recovery, 
what effect does a psychological treatment (cognitive therapy) have on 
the dexamethasone suppression test? Finally, this study examined the 
question: What effect does a biologically-oriented treatment and a 
psychologically-oriented treatment have on a subject's dysfunctional 
thoughts? 
The treatment validity design employed was observed differences 
with two or more treatments design. This design allowed the crossing of 
two distinct patient groups (normal versus abnormal dexamethasone 
suppression test results) with two distinct, effective treatment 
approaches (chemotherapy versus cognitive therapy). Therefore, not only 
was the treatment validity of the patient group distinctions tested, but 
also the theoretical distinctions associated with each patient group was 
examined (endogenous versus exogenous depressions). 
Prediction of Outcome 
The first set of predictions involved the effectiveness of the two 
treatments along with the differential effectiveness of the treatments 
based on whether the subjects were classified as normal or abnormal 
dexamethasone suppression test responders. First, it was predicted that 
overall, subjects in this study would report significantly less 
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depressive symptoms at post-intervention. This prediction was based on 
the body of research supporting the effectiveness of both cognitive 
therapy and tricyclic antidepressant medication as treatments for 
depression. Second, it was predicted that abnormal dexamethasone 
suppression test responders would report a significantly greater change 
in depressive symptoms after receiving antidepressant medication versus 
cognitive therapy, while normal dexamethasone suppression test 
responders would show significantly greater change in depressive 
symptoms after receiving cognitive therapy versus antidepressant 
medication. In other words, it was predicted that the "treatment 
validity" of the dexamethasone suppression test would be supported. 
This prediction was based on studies suggesting that abnormal results on 
the dexamethasone suppression test may represent a biological marker for 
depression which may respond well to biologically-oriented treatments 
(Brown et al., 1979; Brown & Shuey, 1979; Greden et al., 1980). Second, 
it was predicted that cognitive therapy would not impact on abnormal 
dexamethasone suppression test results, whereas antidepressant treatment 
would result in a significant reduction in dexamethasone suppression 
test scores for abnormal responders. This prediction was based on 
studies suggesting that an abnormal dexamethasone suppression test 
result represents an "endogenous" depression which is suggestive of a 
biological abnormality and treatable only by a biologically-oriented 
treatment (antidepressant medication), along with studies showing 
conversion from abnormal to normal results on the dexamethasone 
suppression test after administration of antidepressant medication 
(Bowie & Beaini, 1985; Brown et al., 1979; Brown & Shuey, 1979; Greden 
44 
et al., 1980; Fraser, 1975; Spar & Rue, 1983). Therefore, it was 
predicted that cognitive therapy would have no effect on the 
dexamethasone suppression test for abnormal responders. The final 
prediction was based on Beck's (1967, 1972, 1979) assertion that 
negative thought patterns and distorted perceptions that the depressed 
person holds about himself/herself, the present, and the future result 
in depression. Therefore, Beck's cognitive therapy of depression 
focuses directly on modifying dysfunctional thoughts and overt behavior 
in order to change the patient's negative self-perception and by doing 
so alleviating the patient's depression. Based on this rationale and 
the effectiveness of Beck's treatment for depression, it was predicted 
that cognitive therapy would have a significant impact on the subject's 
dysfunctional thoughts (i.e., significantly reduce the number of 
dysfunctional thoughts) while antidepressant medication would not. 
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CHAPTER II 
METHOD 
Subject Description and Selection Procedures 
Subjects for this research-treatment project consisted of 43 
depressed females who met certain criteria in a two-stage screening 
process. Subjects for this study were obtained by several means. 
First, area physicians were informed of this project so that they could 
give their patients the opportunity to participate in the study (see 
Appendix A). In addition, an article about the study was placed in a 
local university newspaper and in the local community newspaper (see 
Appendix B). Finally, various community organizations (e.g., churches, 
women's organizations) were notified of this project and sent a 
descriptive flyer (see Appendix C). 
Women who were interested in outpatient treatment for depression 
were requested to telephone Charter Mandala Psychiatric Center to 
schedule a screening interview. Only subjects who displayed the 
following characteristics were eligible for the first screening stage. 
First, subjects were female, 18 years or older. Second, subjects signed 
a statement affirming that they were free of any tranquilizing drugs or 
antidepressant medication for a minimum of two weeks, and were not 
presently under a physician's, psychiatrist's, or psychologist's care 
for the treatment of depression (see Appendix D). However, if the 
subject were under care elsewhere for depression, she submitted a 
"physician's statement" (see Appendix E) stating that she had been 
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allowed to discontinue drug use and was appropriate for psychological-
psychiatric treatment. Third, subjects were required to sign a consent 
form which described the initial screening interview and procedures (see 
Appendix F). 
Screening stage one consisted of the following battery: (a) the 
Minnesota Multiphasic Personality Inventory (MMPI), Depression Scale 
(Hathaway & McKinley, 1942) (Note: The MMPI is not included in the 
Appendix due to its familiarity); (b) the Diagnostic and Statistical 
Manual of Mental Disorders, third edition (DSM-III, American Psychiatric 
Association, 1980) used in conjunction with The Schedule for Affective 
Disorders and Schizophrenia interview outline (SADS) (Endicott & 
Spitzer, 1978) (see Appendix G-l and G-2); (c) the Beck Depression 
Inventory (Beck, Ward, Mendelsohn, Mock, & Erbaugh, 1961) (see Appendix 
H); and (d) the Lubin Depression Adjective Checklist (DACL, Lubin & 
Levitt, 1979) (see Appendix I). These measures are described in detail 
later in this section. Subjects met the criteria specified below for 
inclusion in this study: (1) MMPI (Minnesota Multiphasic Personality 
Inventory). T-score ̂  70 on depression scale (equivalent to a raw 
score of 29). (2) DSM-III (Diagnostic and Statistical Manual of Mental 
Disorders, third edition). Depression categorized as Major Depressive 
Episode and was major presenting psychopathology. (3) Beck Depression 
Inventory. Score 20. (4) Lubin Depression Adjective Checklist. 
Score 18. 
Finally, during this stage, subjects were questioned about any 
suicidal thoughts they may have had. Such questions were included in 
The Schedule for Affective Disorders and Schizophrenia interview outline 
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used with the Diagnostic and Statistical Manual of Mental Disorders (see 
Appendix G-l). In addition, each subject completed the Scale for 
Suicide Ideation (Appendix J) (Beck & Rush, 1978). If the subject 
scored eight or above on this scale, or stated that she was seriously 
considering suicide, she was not considered suitable for the study. If 
a subject did not meet the criteria outlined in this screening stage, 
the subject was given a list of appropriate referrals (see Appendix K) 
along with it being the staff psychiatrist's and principal 
investigator's full responsibility to assure that adequate care was 
received. 
In total, 212 people inquired about participating in the 
investigation. Of these 212 inquiries, 115 participated in screening 
stage one. The remaining inquiries were disqualified over the telephone 
because of either violating the criteria (e.g., were on medicine, were 
seeing a psychiatrist/psychologist for care and were not willing to 
discontinue their treatment and/or medicine), were not interested, or 
were not willing to pay for the laboratory fees. In any case, all of 
these people were mailed a list of referrals, along with referrals made 
over the telephone. Of the 115 people who participated in screening 
stage one, 75 met the criteria for screening stage one. Of the 40 
subjects not accepted at screening stage one, 21 did not obtain a raw 
score of 29 or greater (or a T score of 70 or greater) on the Depression 
Scale of the Minnesota Multiphasic Personality Inventory, 9 did not 
obtain a raw score of 20 or greater on the Beck Depression Inventory, 7 
did not qualify based on the Diagnostic and Statistical Manual of Mental 
Disorders, third edition, either because they did not receive a 
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diagnosis of Major Depressive Disorder, or depression was not their 
major presenting pathology (e.g., one subject's major problem area was 
alcoholism with secondary depression), two did not qualify because of 
strong suicidal ideation, and one did not qualify due to not having a 
score of 18 or greater on the Lubin Depression Adjective Checklist. The 
remaining 75 subjects were scheduled for screening stage two. 
If a subject met the criteria of screening stage one, she was asked 
to return for screening stage two. This stage included identifying 
subjects with the response class of irrational cognitions, which is 
assumed to be problematic for many individuals labelled "depressed." To 
accomplish this, the assessor administered the Personal Beliefs 
Inventory (Munoz & Lewinsohn, 1976) (see Appendix L). In addition, 
subjects were administered the Dexamethasone Suppression Test (Carroll, 
Martin, & Davies, 1968) in order to identify abnormal and normal 
responders. It should also be noted that the Beck Depression Inventory 
and the Lubin Depression Adjective Checklist were re-administered during 
screening stage two. These devices are described in greater detail in 
this section. 
Criteria used in screening stage two for inclusion in this study 
were as follows: (1) Personal Beliefs Inventory. Score of three or 
greater. (2) Dexamethasone Suppression Test. Identification of 
subjects as either abnormal or normal responders. Prior to the 
treatment phase of the study, 21 subjects were chosen as abnormal 
responders, 25 as normal responders. Abnormal responders were defined 
as having a serum Cortisol level greater than or equal to 5 ug/dl, while 
normal responders were defined as having a serum Cortisol level less 
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than 5 ug/dl according to blood samples. There was a clear dichotomous 
split between abnormal and normal responders, with normal responders 
overall having an average dexamethasone suppression test score of .84 
ug/dl (with a range of 0.0 to 3.5 ug/dl), while abnormal responders 
overall having an average dexamethasone suppression test score of 5.7 
ug/dl (with a range of 5.1 to 6.1 ug/dl). (3) Beck Depression 
Inventory. Score ̂  20. (4) Lubin Depression Adjective Checklist. 
Score 18. 
Finally, subjects were interviewed individually by a staff 
psychiatrist at Charter Mandala Center (Dr. Jarrett Barnhill) in order 
to eliminate subjects showing any contradiction to the use of 
antidepressant medication. Only patients who were in sound physical 
health, lacked cardiovascular disease, and lacked any other metabolic 
and/or physiological disorders were included in the study. Pregnancy 
was an absolute contraindication both for the antidepressant medication 
and the dexamethasone suppression test. In addition, both the staff 
psychiatrist and principal investigator met with each subject 
individually to assess for suicidal ideation. This assessment was 
accomplished by interviewing the subject along with administering the 
Suicide Ideation Questionnaire (see Appendix J). The interview 
consisted mainly of questioning the subjects about any suicidal thoughts 
or intentions she may have had, and were approached by asking the 
subject if she had reached the point where life just did not seem worth 
living anymore, or if the subject ever thought she might be better off 
dead. Subjects indicating suicidal intent or ideation, along with 
subjects scoring eight or greater on the Suicide Ideation Questionnaire 
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(according to Beck & Rush, 1978, who developed the questionnaire) were 
dropped from the study and referred elsewhere. It was the staff 
psychiatrist's and principal investigator's full responsibility to 
assure that appropriate treatment was arranged, including 
hospitalization at Charter Mandala Center, if necessary. 
Seventy-five subjects were scheduled for screening session two, 
with 71 subjects actually completing the screening. Four subjects 
cancelled because of personal reasons or they decided not to continue 
with the study. Nine subjects did not obtain scores of three or greater 
on the Personal Beliefs Inventory, two did not maintain their scores on 
the Beck Depression Inventory (20 or greater), one did not maintain her 
score on the Lubin Depression Adjective Checklist (18 or greater), two 
developed strong suicidal ideation, one was determined by the staff 
psychiatrist to be unable to take antidepressant medication because of. 
medical reasons, and 10 were not accepted into the study because of the 
inability to accept additional normal dexamethasone suppression test 
responders into the study. All subjects who were excluded from the 
study for any reason were given appropriate explanations and referrals. 
In summary, a total of 46 subjects were selected prior to 
treatment. All of the subjects were diagnosed as depressed and were 
exhibiting a high degree of irrational cognitions. Forty-three subjects 
completed the study, with 20 of the subjects exhibiting abnormal results 
on the Dexamethasone Suppression test and 23 subjects exhibiting normal 
results on the Dexamethasone Suppression test. Three subjects (two with 
normal dexamethasone suppression test results, both receiving medicine; 
one with abnormal dexamethasone suppression test results receiving 
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cognitive therapy) dropped out after treatment began. Two of the 
subjects developed complications with the medicine, while the third 
subject developed strong suicidal ideation which warranted treatment 
elsewhere. No subjects were dropped during treatment because of 
increases in their Lubin Depression Adjective Checklist scores. 
Subjects not meeting the criteria in screening stages one and/or two or 
who dropped out after treatment began, were given a list of appropriate 
referrals, including Charter Mandala Psychiatric Center, community 
mental health centers, and psychologists/ psychiatrists in private 
practice (see Appendix K). Again, it was the staff psychiatrist's and 
principal investigator's full responsibility to assure that appropriate 
treatment was arranged, and adequate precautions were taken. 
Forty-three subjects completed the project without complication. These 
43 female subjects had an average age of 37.5 years and ranged in age 
from 24 years to 63 years of age (see Table 1, Appendix M). Subjects' 
occupations included housewives, salespeople, students, nurses, 
secretaries, reservationists, managers, computer operators, and retired 
(see Table 1, Appendix M). Every marital status was represented, with 
many of the subjects having children. There seemed to be no differences 
between subjects in the different groups in terms of previous treatment 
or family history of affective illness (see Table 1, Appendix M). 
Experimental Design 
The design employed for this investigation was a two (abnormal or 
normal dexamethasone suppression test results) by two (cognitive therapy 
or antidepressant medication) by two (pre-post) factorial design (see 
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Table 2, Appendix M). In actuality, difference scores were used in the 
statistical analysis. This design allowed an examination of whether it 
was theoretically worthwhile to classify depressed clients using the 
dexamethasone suppression test, by manipulating the correspondence 
between the assessment results (abnormal or normal responders on the 
dexamethasone suppression test) and treatment (antidepressant 
medication or cognitive therapy). In other words, the "treatment 
validity" of the dexamethasone suppression test was examined. 
Once subjects passed screening stages one and two and were clearly 
experiencing a Major Depressive episode along with exhibiting a great 
deal of cognitive distortion, they were divided as to whether they were 
abnormal or normal responders according to the dexamethasone suppression 
test. Once identified as normal or abnormal responders, subjects were 
randomly assigned to one of the two treatment conditions. Half of the 
abnormal responders and half of the normal responders received eight 
weeks of an antidepressant medication, while the other abnormal and 
normal responders received eight sessions of cognitive therapy. This 
resulted in half of the abnormal responders receiving a supposedly 
related treatment of medication, while the other half received a 
supposedly unrelated treatment of cognitive therapy. Likewise, half of 
the normal responders received a related treatment of cognitive therapy, 
while the other half received a supposedly unrelated treatment of 
medication (see Tables 2, 3, and 4, Appendix M). 
The primary investigator conducted the cognitive therapy (and was 
not informed as to who were abnormal or normal responders) while 
medication was administered and monitored by the staff psychiatrist (who 
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was also blind to who were abnormal or normal responders). Further 
information concerning the treatments can be found later in this 
section. 
Measurements taken during this study consisted of (a) pre-post 
global measures of depression, (b) pre-post measures of cognitions and 
the dexamethasone suppression test, (c) a mid-study and post measure of 
the amount of antidepressant medication, and (d) within-treatment 
session assessments. These are described below. 
Pre-Post Global Assessment of Depression 
The pre-post global assessment of depression consisted of the three 
measures taken during screening stage one. These three measures were 
repeated after treatment was completed. Both times, they were 
administered by the principal investigator. These measures were: (a) 
the Minnesota Multiphasic Personality Inventory (MMPI), (b) the Beck 
Depression Inventory, and (c) the Lubin Depression Adjective Checklist. 
In addition, subjects were diagnosed pre- and post-treatment using the 
Diagnostic and Statistical Manual of Mental Disorders, third edition. 
The MMPI (Hathaway & McKinley, 1942) is one of the best known 
self-report measures for depression (Lewinsohn & Lee, 1981). The 
depression scale of the MMPI consists of 60 true-false MMPI items, with 
no specific time limits for completion. Lewinsohn and Lee (1981) report 
that the MMPI has both high reliability and validity. For inclusion in 
this study, the criteria for the depression scale required subjects to 
have a T-score of 70 or above (which is a raw score of 29, and two 
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standard deviations above the mean). According to the norms, the 
average score on the MMPI-D scale is 50 (or a raw score of 19). 
The Beck Depression Inventory (see Appendix H) was also used as a 
pre-post global measure of depression. The Beck Depression Inventory 
consists of 21 items which assess numerous characteristics of 
depression. Each item is scored on a range of 0 to 3, with the total 
possible score ranging from 0 to 63. The larger the score, the more 
severe the depression. Subjects must have had a score equal to or 
greater than 20 at pre-treatment. Again, the Beck Depression Inventory 
has been shown to have high reliability and validity (Lewinsohn & Lee, 
1981). 
The Lubin Depression Adjective Checklist (see Appendix I) was also 
used as a pre-post global assessment of depression, and as a weekly 
session measure of depression (see section on within-treatment session 
assessments). The Lubin Depression Adjective Checklist (DACL) consists 
of seven parallel lists of adjectives designed to measure an 
individual's "mood" at a particular moment in time. The subject is 
asked to check the words which describe "How You Feel Now—Today." The 
number of positive adjectives not checked plus the number of negative 
adjectives checked constitutes the mood score. The higher the score, 
the more depressed the person is judged to be. Normative data available 
(Lubin & Levitt, 1979) indicate that for females the average score on 
the DACL is 8, with a standard deviation of 5. Of all the self-report 
depression scales, the Lubin Depression Adjective Checklist has been 
given the most extensive psychometric development and has the highest 
reliability and validity (Lewinsohn & Lee, 1981). Subjects that were 
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included in this study had DACL scores ranging from 18 upward (two 
standard deviations above the mean). The same scores are applicable to 
all seven lists of the DACL. Versions of the DACL used with each 
subject were selected randomly for both the pre-post measures and the 
session-by-session measures. However, the version used for a particular 
subject at pre-intervention (screening stage one) was also used at 
post-intervention assessment. It should be noted that the Lubin 
Depression Adjective Checklist and the Beck Depression Inventory were 
also given during screening stage two. 
The Diagnostic and Statistical Manual for Mental Disorders, third 
edition (DSM-III) (American Psychiatric Association, 1980) , was used 
with the interview outline provided by the Schedule of Affective 
Disorders and Schizophrenia (Endicott & Spitzer, 1978) (see Appendix G-l 
and G-2). The DSM-III attempts to provide clear criteria (number and 
kinds of symptoms required, severity level, duration, differential 
diagnosis) and is very similar to the Research Diagnostic Criteria (RDC, 
Spitzer, Endicott, & Robins, 1978) which is known to be highly reliable 
(Lewinsohn & Lee, 1981). Field trials examining the reliability of the 
DSM-III for diagnosis of Major Affective Disorder revealed high 
reliability (Kappa coefficient = .80). The field trials did not 
differentiate specifically for the diagnosis of melancholia. Subjects 
were interviewed by the principal investigator using the Schedule of 
Affective Disorders and Schizophrenia (see Appendix G) and fell in the 
category of Major Depressive Episode according to the DSM-III (see 
Appendix G-2). Reliability in using the interview outline to complete 
the DSM-III diagnosis was taken by a licensed master's level 
56 
psychological associate at the end of the study (this was done by 
audio-taping (see Appendix N) the interview by the principal 
investigator). The reliability checker was blind to (a) which tapes 
were pre-post, (b) which treatment the subjects received, and (c) the 
subject's classification on the dexamethasone suppression test. 
Reliability was calculated by taking the number of diagnostic agreements 
divided by the number of diagnostic agreements and disagreements. The 
total number of tapes listened to by the agreement judge was 62 (41 
pre-intervention tapes and 21 post-intervention tapes). This number 
included both subjects who were included and not included in this study. 
This high percentage was chosen because the principal investigator 
conducted both the interview phases and the cognitive therapy. The 
Diagnostic and Statistical Manual of Mental Disorders, third edition, 
was quantified by recording the frequency of subjects who were 
classified as depressed or not depressed. Inter-judge agreement was 
calculated to be .887. 
It should also be mentioned that not only were subjects diagnosed 
as Major Depression, but also the principal investigator diagnosed 
subjects as with or without melancholia, based on the specific criteria 
presented in the DSM-III (see Appendix G-2 for criteria). Diagnoses are 
presented in Table 4, Appendix M. Reliability was again taken by the 
licensed master's level psychological associate under the same 
conditions as previously mentioned, and was recalculated by taking the 
number of diagnostic agreements divided by the number of diagnostic 
agreements and disagreements. Inter-judge agreement was calculated to 
be .806. 
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Pre-Post Assessment of Irrational Cognitions 
and the Dexamethasone Suppression Test 
During screening stage two and again after the treatment ended, the 
response class of irrational cognitions was sampled, and the 
dexamethasone suppression test was administered. 
Irrational Cognitions 
The response class of irrational cognitions was assessed by the 
Personal Beliefs Inventory (Munoz s Lewinsohn, 1976) (see Appendix L). 
The Personal Beliefs Inventory consists of 30 items involving various 
irrational thoughts (similar to Albert Ellis' eleven irrational beliefs, 
Ellis & Grieger, 1977) that an individual may believe. Subjects rate 
their extent of agreement or disagreement with each item on a five-point 
scale, with a one indicating total disagreement, and a five indicating 
complete agreement. Subjects included in this study had an average 
score of three or greater. 
Dexamethasone Suppression Test 
All subjects included in this study were administered the 
Dexamethasone Suppression Test (Carroll et al., 1968). The 
dexamethasone suppression test measures Cortisol levels in the blood 
stream by the use of a blood test. Abnormal results are produced by the 
non-suppression of Cortisol in the blood stream, which is presumably 
indicative of endogenous depression. Normal results are produced by the 
suppression of Cortisol in the blood stream, which is supposedly related 
to exogenous depression. Half of the subjects in this study were 
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selected for abnormal results; the other half were selected for normal 
results. Administration of this test consisted of the staff 
psychiatrist providing the subject with 1 mg. of dexamethasone that was 
ingested at 11:00 p.m., then having blood drawn at 4:00 p.m. the next 
afternoon at a local laboratory. Through the blood test, Cortisol 
levels in the blood stream were determined. The results of the blood 
tests were sent to Charter Mandala Center, where they were interpreted 
by a staff psychologist who assigned subjects to groups without the 
knowledge of the experimenters. 
Within-Treatment Session Assessments 
At the beginning of each treatment session, all subjects were 
administered the Lubin Depression Adjective Checklist, which has already 
been described in detail. The purpose of administering this 
questionnaire during each treatment session was to monitor the subject's 
mood, particularly if it worsened. If a subject's score on this 
questionnaire worsened, that is, her score on this checklist increased 
(worsened) by five points relative to her original score (one standard 
deviation according to normative data), she was taken out of the study. 
This did not occur during the course of the study. Also, prior to each 
treatment session, all subjects met with both the principal investigator 
and the staff psychiatrist to assess the patient's condition and suicide 
risk. Suicide risk was assessed at the beginning of each session by (a) 
asking each subject if she were seriously entertaining the notion of 
suicide, and (b) having each subject complete the Scale for Suicide 
Ideation (Beck & Rush, 1978) (see Appendix J). If a subject scored 
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eight or above on this scale, or verbalized suicide intent, she was 
taken out of the study. One subject was excluded for this reason, after 
treatment was initiated. If a subject became suicidal, or her condition 
worsened, it was the principal investigator's and the staff 
psychiatrist's full responsibility to assure the subject received 
adequate care, including hospitalization at Charter Mandala Center, if 
necessary (see Appendix K). 
Finally, subjects were required at treatment session four and at 
post-treatment to have a blood test taken in order to assure that the 
subjects receiving medication were receiving a therapeutic level of the 
medication, and that no subjects in the study were taking mood altering 
drugs. This was done at a local laboratory. The lab results are 
described later. 
Treatments 
Twenty-two of the subjects in this study received a cognitive 
therapy approach consisting of a strategy first employed by Beck (1967, 
1972; Beck, Rush, Shaw, & Emery, 1979) which is similar to Ellis' 
rational-emotive therapy (RET) (Ellis & Greiger, 1977) through which 
negative thought patterns are restructured. Therapy consisted of (a) 
giving the subject the rationale for the therapy, (b) teaching the 
subject to self-monitor her own thought patterns, (c) teaching the 
subject to identify logical errors and depressive assumptions made, (d) 
helping the client evaluate and look for alternative explanations for 
negative thoughts, (e) teaching the subject to evaluate and correct 
dysfunctional thoughts and assumptions by coping with logical errors, 
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and (f) helping the subject to design "experiments" to test out her 
hypotheses and adjust dysfunctional thoughts and faulty assumptions 
accordingly. This treatment was modeled after the cognitive-behavioral 
treatment detailed in Cognitive Therapy of Depression by Beck and his 
associates (1979). Details of this treatment package can be found in 
Appendix 0. Therapy was administered to subjects individually by the 
principal investigator for eight one-hour sessions. The cognitive 
therapy was individualized in terms of each subject's particular 
cognitive distortions and her related problems. The purpose of the 
treatment package was to provide a general framework to be used by the 
principal investigator in order to apply the cognitive therapy approach. 
Twenty-one subjects received a chemotherapeutic approach consisting 
of the class of tricyclic antidepressants. The class of tricyclic 
medications is relatively safe as compared to other classes of 
antidepressant medications, such as the MAO inhibitors, which require 
strict diets (Blackwell, Marley, Price, & Taylor, 1967). Typical 
side-effects of this class of antidepressants consist mainly of dryness 
of mouth or slight dizziness if one stands up too quickly. The most 
serious but rare side-effects are constipation, palpitations, or 
postural hypotension, which necessitates stopping the medication 
(Asberg, Cronholm, Sjogvist, & Tuck, 1970). Medication in this study 
was administered and monitored by a qualified staff psychiatrist at 
Charter Mandala Center (Dr. Jarrett Barnhill). The pharmacotherapy 
involved eight weekly individual sessions in which the focus was 
medication and the biological approach to treating depression. These 
sessions varied in length (not to exceed one hour) depending on the 
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individual, and were conducted by the staff psychiatrist. These 
individual sessions were variable in length in order to more closely 
approximate clinical reality. The psychiatrist followed a general 
outline during the sessions that emphasized the medicine and the 
biological approach to depression. Patients receiving medication 
typically see a psychiatrist for medication checks and to ask questions 
about the medication, rather than receiving active psychotherapy. The 
staff psychiatrist also determined which tricyclic antidepressant to use 
based on the subject's symptoms. For example, if a depressed subject 
was experiencing anxiety, then she may have received Elavil 
(amitriptyline) or nortriptyline which have sedative effects. If a 
subject was experiencing a retarded-type depression, then imipramine or 
desipramine (norpramine) may have been used for their stimulant 
properties. The staff psychiatrist wrote prescriptions weekly to guard 
against overdoes. Thirteen subjects received Elavil (amitriptyline) 
while eight subjects received desipramine (norpramine). These medicines 
were evenly distributed across the two medication groups (Table 4, 
Appendix M). The starting dosages at treatment session one for the 
tricyclic antidepressants was 75 mg. at bedtime. For session two and 
three, the dosage was raised to 150 mg. daily. At session four, 
subjects had a blood test done at the local lab to assess whether the 
level of antidepressant medication in the blood stream was at the 
therapeutic plasma level of 125 to 250 ng/ml. At this stage, fifteen 
subjects had therapeutic plasma levels, while six did not (two in the 
normal dexamethasone suppression test-antidepressant group, four in the 
abnormal dexamethasone suppression test-antidepressant group). If it 
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was not, the dosage at session four was raised anywhere from 200 mg. 
daily to 250 mg. daily, depending on plasma levels. This dosage was 
maintained until session eight, wherein another blood sample was drawn 
to assure therapeutic levels of the medication. All subjects receiving 
either antidepressant medication at post-intervention had therapeutic 
plasma levels of 125 to 250 ng/ml according to the blood tests. The two 
subjects experiencing serious side-effects were dropped from the study 
and given appropriate referrals. (See section on Subject Withdrawal and 
Referral.) 
Experimente rs 
The experimenters in this study consisted of a principal 
investigator, a Charter Mandala Center staff psychiatrist, and a Charter 
Mandala staff psychologist who was a reliability checker for the 
Diagnostic and Statistical Manual for Mental Disorders, third edition, 
along with interpreting the results from the dexamethasone suppression 
test. 
The principal investigator, a sixth-year male graduate student in 
clinical psychology and a full-time therapist at Charter Mandala Center, 
was responsible for conducting screening stage one, conducting screening 
stage two in conjunction with the staff psychiatrist, administering the 
cognitive therapy treatment approach, administering post-treatment 
assessment, and debriefing subjects at the end of the study. The 
principal investigator was qualified in carrying out these 
responsibilities; he has experience in assessing and treating 
depression, is licensed as a Psychological Associate by the North 
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Carolina State Board of Examiners, has been trained in the treatment 
packages being utilized (research projects conducted at UNC-G, Charter 
Mandala Center), and has had experience in writing treatment packages. 
In addition, these activities occurred under the supervision of a 
faculty member in clinical psychology (Dr. Rosemery Nelson) and the 
staff psychiatrist (Dr. Jarrett Barnhill). 
The Charter Mandala staff psychiatrist was responsible for 
evaluating subjects in screening stage two for possible medication use, 
administered and monitored all medication usage, and prescribed all 
laboratory tests conducted (i.e., administration of the dexamethasone 
suppression test, administration of blood tests to assess therapeutic 
levels of antidepressant medication prescribed). This person has been 
in psychiatry for seven years, is a full-time psychiatrist at Charter 
Mandala Center, and service chief of the 400 unit with twenty-one beds, 
and routinely conducts and administers the medications and laboratory 
work utilized in this project. 
Reliability in using the Diagnostic and Statistical Manual of 
Mental Disorders, third edition, in conjunction with the interview 
outline provided by the Schedule of Affective Disorders and 
Schizophrenia was taken by a full-time master's level psychological 
associate at Charter Mandala Center at the end of this study. In 
addition, this person interpreted the results of the dexamethasone 
suppression test (which merely requires looking at the laboratory work 
with the Cortisol levels on it) and assigned subjects to groups. This 
person has worked at Charter Mandala Center for six years and is 
licensed as a Psychological Associate by the North Carolina State Board 
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of Examiners, in addition to routinely utilizing the Diagnostic and 
Statistical Manual of Mental Disorders in her work along with 
interpreting the dexamethasone suppression test. 
Procedure 
Subjects were recruited by the various methods mentioned on the 
first page of this section. During screening stage one, the principal 
investigator met with potential subjects to explain the subject 
selection procedures and obtained subject's informed consent for 
participation (see Appendix F). Emphasis was placed on the fact that 
this was a screening process only, with the intention of correcting any 
misconceptions which could have occurred due to non-acceptance in the 
project. 
Clients were also required to sign a statement affirming that they 
were free of any tranquilizing drugs or antidepressant medication for a 
minimum of two weeks and would remain free of any drugs for the duration 
of this project unless the medication was part of this project and were 
not under a physicians' or psychologists' care for the treatment of 
depression (see Appendix D). However, if the subjects were under the 
care of a physician for depression, she was given a "physician's 
statement" stating that she was allowed to discontinue drug use and was 
appropriate for psychological/psychiatric treatment (see Appendix E). 
One subject was included in this category, in which she was placed on an 
antidepressant (was only on it for three day) and obtained permission to 
discontinue it. 
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The principal investigator administered the Minnesota Multiphasic 
Personality Inventory, the Beck Depression Inventory, the Lubin 
Depression Adjective Checklist, and interviewed subjects and made a 
diagnosis based on the Diagnostic and Statistical Manual for Mental 
Disorders (third edition). Subjects were also questioned about suicide 
and administered the Scale for Suicide Ideation. Subjects who were 
eligible based on previously cited criteria were telephoned and 
scheduled for screening stage two. All subjects not meeting the 
criteria were referred to Charter Mandala Center, to mental health 
centers, and to private psychologists/psychiatrists (see Subject 
Withdrawal and Referral). 
At screening stage two, the principal investigator and the staff 
psychiatrist reviewed the subject selection procedure (including 
costs totaling $106.00 for laboratory work, plus costs for medicine, and 
the $50.00 refundable deposit) and obtained informed consent (see 
Appendix P). Each subject was then administered the Personal Beliefs 
Inventory, the Beck Depression Inventory, and the Lubin Depression 
Adjective checklist, in addition to questioning subjects about suicide 
and administering the Scale for Suicide Ideation. Subjects meeting the 
previously cited criteria were then evaluated by the staff psychiatrist 
for the possibility of being placed on an antidepressant medication 
(e.g., obtained a medical history, assured that the subject was not at 
high-risk for taking antidepressant medication). Finally, subjects 
were administered the Dexamethasone Suppression Test. This was 
accomplished by the staff psychiatrist providing 1 mg. of dexamethasone 
to each subject to be taken at 11:00 p.m. Each subject then had blood 
66 
drawn at 4:00 p.m. the next day at a local laboratory. The laboratory 
results were sent to Charter Mandala Center where each subject was 
classified as abnormal or normal responders based on the previously 
mentioned criteria for screening stage two. The lab technicians were 
also blind to which subjects were assigned to which treatment. These 
results were seen only by the staff psychologist at Charter Mandala 
Center in order for her to assign subjects to groups, without the 
principal investigator or staff psychiatrist knowing who were abnormal 
or normal responders. Subjects who did not meet the previously cited 
criteria, who showed a contradiction to taking medication, or who 
refused to consider the possibility of taking medication were 
appropriately referred. Forty-three subjects completed the study, 
twenty being abnormal responders and twenty-three subjects being normal 
responders according to the dexamethasone suppression test. 
The treatment contract was thoroughly explained to each subject 
accepted into the study (see Appendix Q) . It should be noted here that 
an element of the treatment contract was the requirement of each subject 
to make a fifty dollar ($50.00) deposit. The subject was told that this 
amount would be refunded if she attended all eight treatment sessions 
and participated in the post assessment. The contract stated that if 
she failed to do any of the requirements above, a certain portion of her 
deposit would have been forfeited. In actuality, at the end of the 
study, the subject's deposit was returned regardless of performance. 
Therefore, the subjects that could not continue after the treatment 
phase were refunded their $50.00 deposit. The purpose of the mild 
deception was to increase the client's motivation for participating in 
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the project once she had signed the contract. This deposit was separate 
from the costs of the laboratory tests (e.g., three blood tests) and the 
cost of the medication, which was explained to the subjects. 
The principal investigator met with 22 of the subjects individually 
in order to apply the treatment strategy of cognitive therapy. These 
subjects were seen for eight one-hour sessions. The cognitive therapy 
treatment strategy was preplanned, and broken down into eight steps (see 
Appendix 0). The staff psychiatrist met with 21 of the subjects 
individually to administer and monitor the tricyclic antidepressant 
medication on a weekly basis. Medication was prescribed on a weekly 
basis to minimize the chances of overdose. At the beginning of each 
treatment session, all subjects were administered the Lubin Depression 
Adjective Checklist, were interviewed by both the principal investigator 
and the staff psychiatrist individually, in order to assess suicidal 
ideation, and were administered the Scale for Suicide Ideation. The 
purpose of this was to drop subjects from the study (and utilize 
appropriate referrals) who developed suicidal ideation or whose mood 
significantly worsened after the study began. Finally, all subjects 
were required at session four to have blood drawn in order to check the 
blood level of antidepressant medication (for those in the medication 
group) and to assure that no mood altering drugs were being taken. 
After each subject completed the eight week treatment program, she 
again met with the principal investigator and staff psychiatrist. This 
post-treatment phase consisted of each subject receiving the following: 
(a) the questionnaires, Minnesota Multiphasic Personality Inventory, 
Beck Depression Inventory, Lubin Depression Adjective Checklist, and 
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Personal Beliefs Inventory; (b) a diagnosis based on the Diagnostic and 
Statistical Manual of Mental Disorders, third edition used in 
conjunction with the Schedule of Affective Disorders and Schizophrenia 
interview outline; (c) a blood test in order to evaluate the 
dexamethasone suppression test and evaluate levels of antidepressant 
medication for those receiving medication. After this was completed, 
the principal investigator then gave each subject a written and verbal 
debriefing of the project (see Appendix R), and offered continued 
treatment and appropriate referrals. The subject's deposit was then 
returned in full. 
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CHAPTER III 
RESULTS 
Overview 
The results section is divided into four major sections. The first 
section examines the pre-post dependent measures of depression and is 
organized according to the following questions: Was there the predicted 
interaction between the classification of depressives on the 
dexamethasone suppression test and the effectiveness of the two 
treatments? Were the treatments effective, and was one treatment more 
effective overall than the other? And, finally, did one type of subject 
(e.g., abnormal vs. normal dexamethasone test responder) change more 
than the other type? 
The second section examines the analysis of the pre-post 
dexamethasone suppression test, and asks the question: Did the 
dexamethasone suppression test results change over the course of 
treatment? 
The third section describes the analysis of the pre-post Personal 
Beliefs Inventory scores, and examines the question of whether 
irrational beliefs changed during the course of the treatment. 
Finally, the fourth section presents a post hoc analysis examining 
the presence or absence of melancholic symptoms. 
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Analysis of Pre-Post Dependent Measures of Depression 
The data analyzed in this first section were collected at two 
measurement occasions—pre-intervention and post-intervention. 
Difference scores were calculated, and subjected to 2 (dexamethasone 
suppression test result) x 2 (treatment) multivariate and univariate 
analyses of variance. There were three measures of depression: the 
Depression Scale of the Minnesota Multiphasic Personality Inventory, the 
Beck Depression Inventory, and the Lubin Depression Adjective Checklist. 
Least squared means were utilized as post hoc tests. 
In addition, a binoimal test was performed on the post-treatment 
diagnoses, based on the Diagnostic and Statistical Manual of Mental 
Disorders, third edition (American Psychiatric Association, 1980). The 
probability of subjects being diagnosed major depressive versus 
non-depressed at post-intervention was examined. 
The results in this first section are organized into three 
questions: Was the predicted interaction between the dexamethasone 
suppression test and the two treatments significant? Were the two 
treatments effective, and was one treatment more effective overall than 
the others? And, finally, did one type of subject (e.g., abnormal vs. 
normal dexamethasone suppression test responder) change more than the 
other type? 
Was the Interaction Significant? 
Based on the 2 (abnormal vs. normal dexamethasone suppression test) 
x 2 (cognitive therapy vs. antidepressant medication) multivariate and 
univariate analyses of variance on the three depression measures, it was 
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predicted that there would be a significant interaction between the 
dexamethasone suppression test (abnormal vs. normal results) and the two 
treatments (cognitive therapy vs. antidepressant medication). More 
specifically, it was believed that these results would support the 
prediction that subjects with abnormal dexamethasone suppression test 
results would improve significantly more when administered 
antidepressant medication versus cognitive therapy, while subjects with 
normal dexamethasone suppression test results would improve 
significantly more when treated with cognitive therapy versus 
antidepressant medication. 
The predicted interaction effect was not supported by either the 
multivariate analysis of variance or the analysis of variance. The 2 
(dexamethasone suppression test result) x 2 (treatment) multivariate 
analysis of variance on the difference scores from the three depression 
measures (Depression Scale of the Minnesota Multiphasic Personality 
Inventory; the Beck Depression Inventory; and the Lubin Depression 
Adjective Checklist) revealed a nonsignificant dexamethasone suppression 
test results x treatment interaction with a Wilk's lambda of .904, which 
is equivalent to F (3, 37) = 1.31, p = .29 (Table 5). The 2 
(dexamethasone suppression test result) x 2 (treatment) analysis of 
variance on the difference scores from the Depression Scale of the 
Minnesota Multiphasic Personality Inventory also showed a nonsignificant 
dexamethasone suppression test x treatment interaction, F (1, 39) = 
3.31, £ = .08 (Table 6, Appendix M). This interaction, however, is 
marginally significant, so an examination of the means is worthwhile. 
This examination revealed that the mean difference scores did not 
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clearly support the predicted interaction. Rather, the least squared 
means post hoc comparisons showed that the normal dexamethasone 
suppression test responder—cognitive therapy group improved 
significantly more than the abnormal dexamethasone suppression test 
responders—cognitive therapy group { £ = .002, mean difference scores 
of 14.9 vs. 9.5 respectively) and also more than the abnormal 
dexamethasone suppression test responders—antidepressant medication 
group ( £ = .05, mean difference scores of 14.9 vs. 11.6 respectively). 
The other mean difference scores did not differ significantly from each 
other (Table 6, Appendix M). Similarly, nonsignificant dexamethasone 
suppression test x treatment interactions were also found on the Beck 
Depression Inventory, F (1, 39) = .00, £ = .97 (Table 8, Appendix M), 
and for the Lubin Depression Adjective Checklist, F (1, 39) = .17, £ = 
.68 (Table 10, Appendix M). The means for the various groups on the 
various measures are located in Tables 7, 9, and 11, Appendix M. 
Therefore, the prediction of significant interactions on these three 
depression measures were not supported. 
Were the Treatments Effective, and Was One Treatment More Effective 
Overall Than the Other? 
It was predicted that, overall, subjects in this study would 
significantly improve on the three depression measures from 
pre-intervention to post-intervention, with no significant differences 
between the two treatments. This prediction was made because of the 
research that supports the effectiveness of the two treatments in 
treating depression. 
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The predictions were supported on the multivariate analysis of 
variance and the univariate analyses of variance performed on the 
difference scores from the Depression Scale of the Minnesota Multiphasic 
Personality Inventory, the Beck Depression Inventory, and the Lubin 
Depression Adjective Checklist. The main effect for treatment on these 
measures was not significant, showing that the two treatments were not 
differentially effective. On the least squared means analyses, 
difference scores from both treatments differed significantly from zero, 
but did not differ significantly from each other. These results show 
that both treatments were effective, but not differentially so. These 
results are now described in greater detail. 
Least squared means post hoc comparisons on the Depression Scale of 
the Minnesota Multiphasic Personality Inventory revealed that subjects 
in both the cognitive therapy and antidepressant medication groups 
significantly improved with regard to their depression pre-intervention 
to post-intervention ( £ .0001), with no difference in effectiveness 
between the two treatments ( £ = .97). Mean difference score for the 
cognitive treatment was 12.2, and for the antidepressant group it was 
12.1. The lack of differential effectiveness was also supported by the 
2 (dexamethasone suppression test results) x 2 (treatment) analysis of 
variance on this measure which showed a nonsignificant effect for 
treatments, F (1, 39) = .05, £ = .82 (Table 6, Appendix M). 
Furthermore, least squared means post hoc comparisons showed that 
subjects in both the cognitive therapy and antidepressant medication 
groups significantly improved according to their depression 
pre-intervention to post-intervention based on the Beck Depression 
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Inventory ( p ̂  .0001) and the Lubin Depression Adjective Checklist 
( £ ̂  .0001), with no difference in effectiveness between the two 
treatments according to the Beck Depression Inventory ( £ = .6205), and 
the Lubin Depression Adjective Checklist ( £ = .4859). Mean difference 
scores on the Beck Depression Inventory were 17.7 for the cognitive 
therapy group and 16.5 for the antidepressant group, while the mean 
difference scores on the Lubin Depression Adjective Checklist was 10.8 
for the cognitive therapy group and 12.1 for the antidepressant group. 
Again, the lack of differential treatment effectiveness was supported by 
the 2 (dexamethasone suppression test result) x 2 (treatment) analysis 
of variance performed on the difference scores from these two measures, 
with nonsignificant treatment effects being found on the Beck Depression 
Inventory, F (1, 39) = .30, £ = .59, and on the Lubin Depression 
Adjective Checklist, F (1, 39) = .38, £ = .54 (Tables 8 and 10, Appendix 
M). In addition, the above results on the three depression measures of 
no differential treatment effectiveness were supported by the 2 
(dexamethasone suppression test result) x 2 (treatment) multivariate 
analysis of variance performed on the difference scores from three 
measures which showed a nonsignificant treatment effect with a Wilk's 
lambda of .969, which is equivalent to F (3, 37) = .39, £ = .76 (Table 
5, Appendix M). Therefore, based on analyses of these three depression 
measures, the predictions that subjects overall would significantly 
improve with regard to their depression, with no differential treatment 
effectiveness, was supported. Figures 1, 2, and 3, Appendix S also show 
this result. 
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Finally, the above prediction was also supported by the binomial 
test performed on the subjects' diagnoses. Based on the Diagnostic and 
Statistical Manual of Mental Disorders, third edition, using the 
Schedule for Affective Disorders and Schizophrenia interview outline, at 
pre-intervention, all 43 subjects were given the diagnosis of Major 
Depression. After receiving one of the two treatments offered 
(cognitive therapy or antidepressant medication), only six subjects at 
post-intervention continued to meet the criteria for a major depressive 
disorder according to the principal investigator's diagnoses. One of 
these subjects fell in the normal dexamethasone suppression test 
responder—cognitive therapy group, while three of these subjects fell 
in the abnormal dexamethasone suppression test responder—cognitive 
therapy group and two subjects fell in the abnormal dexamethasone 
suppression test responder—antidepressant medication group. The 
probability of obtaining six depressive diagnoses at post-intervention 
was compared to the expected probability of .50. The binomial test 
demonstrated that the probability of obtaining six depressive diagnoses 
after treatment by chance was .05, therefore supporting the 
prediction that subjects would not be depressed after treatment. 
Pre-intervention and post-intervention diagnoses can be found in Table 
4, Appendix M. 
Did One Type of Subject (Abnormal vs. Normal Dexamethasone Suppression 
Test Responders) Change More Than the Other Type? 
It has already been shown that the interaction between the 
dexamethasone suppression test (normal vs. abnormal responders) and the 
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treatments (cognitive therapy vs. antidepressant medication) proved to 
be nonsignificant. A remaining question is whether normal or abnormal 
dexamethasone suppression test responders responded differently to 
treatment, regardless of whether the treatment was cognitive therapy or 
antidepressant medication. 
The least squared means analyses, along with the multivariate 
analysis of variance and the analysis of variance performed on the 
difference scores from the Depression Scale of the Minnesota Multiphasic 
Personality Inventory, the Beck Depression Inventory, and the Lubin 
Depression Adjective Checklist revealed that both normal and abnormal 
dexamethasone suppression test responders improved with therapy; but the 
normal responders consistently improved more than the abnormal 
responders. These results are now presented in detail. 
Least squared means post hoc analysis on the Depression Scale of 
the Minnesota Multiphasic Personality Inventory revealed that while both 
normal ( p ̂  .0001) and abnormal ( p .0001) dexamethasone 
suppression test responders significantly improved on this measure, 
subjects with normal dexamethasone suppression test results improved 
significantly more on this measure than abnormal dexamethasone test 
responders ( £ = .0085) regardless of the type of treatment. Mean 
difference scores for the normal responders was 13.8, while for the 
abnormal responders, it was 10.5. In other words, subjects with 
abnormal dexamethasone test results did not do as well according to this 
measure in treatment (whether that treatment was antidepressant 
medication or cognitive therapy) as subjects with normal dexamethasone 
suppression test results. The differential effectiveness based on the 
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dexamethasone suppression test was also supported by the 2 
(dexamethasone suppression test result) x 2 (treatment) analysis of 
variance which revealed a significant main effect for the dexamethasone 
suppression test on this measure, F (1, 39) = 7.90, £^ .01 (Table 6). 
These results can also be seen on the graphed data, Figure 1, Appendix 
S. 
Similar results were also found when the Beck Depression Inventory 
was examined. Least squared means post hoc comparisons also showed that 
both normal ( £ Z. .0001) and abnormal ( £ / .0001) dexamethasone 
suppression test responders significantly improved on this measure, with 
subjects having normal dexamethasone suppression test results improving 
significantly more on this measure than abnormal dexamethasone test 
responders ( £ = .0252). Mean difference scores for the normal 
responders was 19.9, while for the abnormal responders, it was 14.2. 
Again, the differential effectiveness based on the dexamethasone 
suppression test was supported by the 2 (dexamethasone suppression test 
result) x 2 (treatment) analysis of variance which revealed a 
significant main effect for the dexamethasone suppression test on this 
measure, F (1, 39) = 5.42, £ ̂  .025 (Table 8). These results can be 
seen on the graphed data, Figure 2, Appendix S. 
The same results were also found when examining the Lubin 
Depression Adjective Checklist. Least squared means comparisons 
revealed again that both normal ( £ ̂  .0001) and abnormal ( £^ .0001) 
dexamethasone test responders significantly improved on this measure, 
while subjects with normal test results improved significantly more on 
this measure than abnormal dexamethasone test responders ( £ = .0061). 
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Mean difference scores for normal responders was 14.2, while for 
abnormal responders, it was 8.8. As with the Depression Scale on the 
Minnesota Multiphasic Personality Inventory and the Beck Depression 
Inventory, based on the Lubin Depression Adjective Checklist, subjects 
with abnormal dexamethasone suppression test results did not do as well 
in treatment (whether the treatment was antidepressant medication or 
cognitive therapy) as subjects with normal dexamethasone suppression 
test results did. The 2 (dexamethasone suppression test result) x 2 
(treatment) analysis of variance showed a significant main effect for 
the dexamethasone suppression test on this measure, F (1, 39) = 8.46, p 
= .006 (Table 10). These results can be seen on the graphed data, 
Figure 3, Appendix S. 
Finally, the above results according to the Depression Scale of the 
Minnesota Multiphasic Personality Inventory, the Beck Depression 
Inventory, and the Lubin Depression Adjective Checklist were supported 
by the 2 (dexamethasone suppression test result) x 2 (treatment) 
multivariate analysis of variance which showed a significant main effect 
for the dexamethasone suppression test results with a Wilk's lambda of 
.747, which is equivalent to F (3, 37) = 4.17, P ̂  .01 (Table 5, 
Appendix M). 
In conclusion, the predictions based on the three depression 
measures utilized in this study that said subjects with abnormal 
dexamethasone suppression test results would improve significantly more 
when administered antidepressant medication versus cognitive therapy 
while normal responders would improve significantly more when treated 
with cognitive therapy rather than antidepressant medication were not 
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supported. Rather, calculated difference scores on the three depression 
measures subjected to 2 (dexamethasone suppression test results) x 2 
(treatment) multivariate and univariate analysis of variance along with 
least squared means post hoc tests and the graphed data revealed that 
while both normal and abnormal dexamethasone suppression test responders 
significantly improved on these measures, subjects with normal 
dexamethasone suppression test results improved significantly more on 
these measures than abnormal dexamethasone test responders, regardless 
of treatment. 
Analysis of Pre-Post Dexamethasone Suppression Test Scores— 
Did the Dexamethasone Suppression Test Scores Change? 
This question was important to examine due to the fact that if the 
"treatment validity" of the dexamethasone suppression test was to be 
supported, then one would expect that scores in the abnormal range on 
the dexamethasone suppression test would be reduced only after the 
administration of an antidepressant medication rather than cognitive 
therapy. As far as normal scores on the dexamethasone suppression test, 
no change would be expected. In spite of the fact that the interaction 
between the dexamethasone suppression test and the treatments was not 
significant, the question of whether a psychologically-oriented 
treatment (cognitive therapy) can effect improvement on an abnormal 
biological system as represented by abnormal dexamethasone suppression 
test responders was interesting to examine. 
A one way analysis of variance was performed on the pre-post 
difference scores from the dexamethasone suppression test, with the 
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analysis of variance first performed on subjects who had normal 
dexamethasone suppression test results at pre-intervention, then again 
with subjects who had abnormal dexamethasone suppression test results at 
pre-intervention. The between-subject factor was the two treatments 
(antidepressant medication versus cognitive therapy). Least squared 
means were utilized as post hoc tests. 
For the analysis of variance on the subjects who had normal 
dexamethasone suppression test results at pre-intervention, it was 
predicted that there would be no significant change from 
pre-intervention to post-intervention on the dexamethasone suppression 
test nor would the two treatments differentially affect the 
dexamethasone suppression test difference scores. In other words, it 
was predicted that subjects with normal dexamethasone suppression test 
results at pre-intervention would maintain the normal dexamethasone 
suppression test results at post-intervention, regardless if the 
subjects received cognitive therapy or antidepressant medication. 
The results from the 2 (treatment) one way analysis of variance on 
the difference scores from the dexamethasone suppression test for 
subjects who had normal dexamethasone suppression test results at 
pre-intervention showed a nonsignificant effect for treatments, F = (1, 
21) = .22, £ = .64 (Table 14, Appendix M). Least squared means post hoc 
comparisons revealed that there were no significant changes from 
pre-intervention to post-intervention for subjects receiving cognitive 
therapy ( £ = .93) or subjects receiving antidepressant medication ( p 
.47), and there were no significant differences between subjects 
receiving cognitive therapy or antidepressant medication on the 
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dexamethasone suppression test at post intervention ( £ = .64). Mean 
difference scores for the cognitive therapy group was .02, while for the 
antidepressant group it was .24. Therefore, the predictions were 
supported in that for subjects with pre-intervention normal 
dexamethasone suppression test results there were no significant changes 
in the dexamethasone suppression test at post-intervention, and the 
difference scores were not significantly different between subjects who 
received cognitive therapy or antidepressant medication. Examination of 
Figure 5 also confirms these results. Inspection of the individual data 
(Table 4, Appendix M) shows that all subjects remained in the normal 
range ( ̂  5 ng/dl) according to the dexamethasone suppression test. 
For the analysis of variance on the subjects who had abnormal 
dexamethasone suppression test results at pre-intervention, it was 
predicted that there would be a significant change from pre-intervention 
to post-intervention on the dexamethasone suppression test for those 
subjects who received antidepressant medication and not for those 
subjects who received cognitive therapy. Therefore, a treatment effect 
was predicted, with the belief that the "treatment validity" of the 
dexamethasone suppression test would be supported. 
The results from the 2 (treatment) one way analysis of variance on 
the difference scores from the dexamethasone suppression test for 
subjects who had abnormal dexamethasone suppression test results at 
post-intervention revealed a nonsignificant effect for treatments, F (1, 
18) = .58, p = .45 (Table 15, Appendix M). Least squared means post hoc 
comparisons showed that there were significant changes from 
pre-intervention to post-intervention for subjects receiving cognitive 
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therapy ( £ .02) along with significant changes from pre-intervention 
to post-intervention for subjects receiving antidepressant medication 
( £ = .0024). In addition, there were no significant differences 
between subjects receiving cognitive therapy or antidepressant 
medication on the dexamethasone suppression test at post-intervention 
( p = .46). Mean difference scores for the cognitive therapy group was 
1.3, while for the antidepressant group it was 1.8 (Table 15, Appendix 
M). These results did not support the predictions that there would be a 
significant effect for treatments with a significant (reduction) from 
pre-intervention to post-intervention on the dexamethasone suppression 
test for only subjects receiving antidepressant medication and not for 
those receiving cognitive therapy. Rather, a significant reduction in 
the dexamethasone suppression test was found for subjects who received 
either cognitive therapy or antidepressant medication, with no 
significant differences between the two groups at post intervention. 
Figure 5 confirms this. Inspection of the individual data (Table 4, 
Appendix M) showed that for subjects receiving cognitive therapy with 
initial abnormal dexamethasone suppression test results (totalling 10 
subjects), at post-intervention five subjects had dexamethasone 
suppression test results in the normal range. For subjects receiving 
antidepressant medication with initial abnormal test results (totalling 
10 subjects), at post-intervention five subjects also had normal 
dexamethasone suppression test results. Therefore, the "treatment 
validity" of the dexamethasone suppression test was not supported. 
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Analysis of Pre-Post Cognitive Questionnaire— 
Did the Irrational Beliefs Change? 
A 2 (dexamethasone suppression test) x 2 (treatment) analysis of 
variance was performed on the pre-post difference scores obtained from 
the Personal Beliefs Inventory. The between-subject factors were the 
treatments (cognitive therapy versus antidepressant medication) and the 
pre-treatment results from the dexamethasone suppression test (normal 
versus abnormal results). Least squared means were utilized as post hoc 
tests. 
It was predicted that there would be a significant main effect for 
treatment with subjects (regardless of the initial dexamethasone 
suppression test result) receiving cognitive therapy having 
significantly larger pre- to post-intervention difference scores on this 
measure than subjects receiving antidepressant medication. This is 
based on the rationale that since all subjects exhibited a high level of 
irrational beliefs at pre-intervention based on this high measure, only 
those receiving cognitive therapy would exhibit any change on this 
measure. 
The results from the analysis of variance on the difference scores 
from the Personal Beliefs Inventory revealed a significant main effect 
for treatments, F (1, 39) = 6.37, p = .01 (Table 12, Appendix M). The 
difference scores was greater for subjects receiving cognitive therapy 
(x = .65) than drug therapy (x = .31). The main effect for the 
dexamethasone suppression test F (1, 39) = 2.11, £ = .154, and the 
treatment x dexamethasone suppression test interaction F (1, 39) = .94, 
p = .339 were not significant (Table 12, Appendix M). Examination of 
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the least squared means showed that subjects (regardless of 
dexamethasone suppression test results) who received cognitive therapy 
( p = .0001) or antidepressant medication ( p = .0024) significantly 
improved on this measure. In addition, subjects improved significantly 
more on this measure ( £ = .0158) after receiving cognitive therapy 
rather than antidepressant medication. While the cognitive therapy had 
a significantly greater effect on this measure as predicted, the 
significant improvement on this measure for subjects who received 
antidepressant medication was unexpected. Inspection of the individual 
data (Table 3, Appendix M) showed that for the 22 subjects receiving 
cognitive therapy, 17 had normal scores on the Personal Beliefs 
Inventory (Zl3.0) at post-intervention, while for the 21 subjects 
receiving antidepressant medication, 11 had normal results at 
post-intervention. These results can be examined on the graphed data 
found in Figure 4, Appendix S. 
Post Hoc Analysis of Diagnoses 
Using With or Without Melancholia 
When the principal investigator made the initial diagnoses 
utilizing the Diagnostic and Statistical Manual of Mental Disorders, 
third edition, it was recorded whether there was a presence or absence 
of melancholic symptoms (see Appendix G-2 and Table 4, Appendix M). 
While most studies do not record the presence or absence of melancholic 
symptoms, it was decided that it would be important to examine if 
melancholic symptoms covaried with results from the dexamethasone 
suppression test, and if dividing subjects based on the presence or 
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absence of melancholic symptoms would reveal the same results as 
subjects divided based on normal or abnormal dexamethasone suppression 
test results. Therefore, a point-biserial correlation was utilized post 
hoc to examine if melancholic symptoms correlated with dexamethasone 
suppression test results. In addition, 2 (presence or absence of 
melancholia) x 2 (treatment) multivariate and univariate analyses of 
variance utilizing difference scores were performed on the Depression 
Scale of the Minnesota Multiphasic Personality Inventory, the Beck 
Depression Inventory, and the Lubin Depression Adjective Checklist, 
along with a 2 (presence or absence of melancholia) x 2 (treatment) 
analysis of variance on the difference scores from the Personal Beliefs 
Inventory, and a one-way analysis of variance (treatments) using 
difference scores from the dexamethasone suppression test being 
performed first on subjects without melancholic symptoms, then again for 
subjects with melancholic symptoms. The number of subjects in each 
group was as follows: 9 in the with melancholia-cognitive therapy 
group; 13 in the without melancholia-cognitive therapy group; 7 in the 
with melancholia- antidepressant group; and 14 in the without 
melancholia-antidepressant group. 
A point-biserial correlation was performed between abnormal and 
normal dexamethasone suppression test results and the presence or 
absence of pre-intervention melancholic symptoms (see Table 4, Appendix 
M). The point-biserial correlation allows one to correlate data where 
one variable is continuous and one variable is dichotomous. The 
correlation between abnormal responders and melancholic symptoms was 
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.74. Therefore, abnormal dexamethasone suppression test results 
correlated highly with the presence of melancholic symptoms. 
The 2 (presence or absence of melancholic symptoms) x 2 (treatment) 
multivariate and univariate analyses of variance on the difference 
scores from the depression measures (Depression Scale of the Minnesota 
Multiphasic Personality Inventory, Beck Depression Inventory, and the 
Lubin Depression Adjective Checklist), using least squared means as post 
hoc tests, revealed a nonsignificant treatment effect and nonsignificant 
treatment x melancholia interaction according to the multivariate and 
univariate analyses on these depression measures, while the presence or 
absence of melancholia effect was significant (Tables 17, 18, 19, and 
.20, Appendix M). Least squared post hoc tests showed that overall, 
subjects with or without melancholic symptoms significantly improved 
with regard to their depressive symptoms, regardless of treatment. 
Furthermore, subjects without melancholia improved significantly more on 
these measures than subjects with melancholia (Tables 17, 18, 19, and 
20, Appendix M). Therefore, the results obtained by dividing subjects 
based on the presence or absence of melancholic symptoms match the 
results and conclusions arrived at by dividing subjects on the basis of 
normal or abnormal dexamethasone suppression test results. In other 
words, the "treatment validity" of dividing subjects according to the 
presence or absence of melancholia was not supported. 
The 2 (presence or absence of melancholia) x 2 (treatment) 
univariate analysis of variance on difference scores from the Personal 
Beliefs Inventory (Table 21, Appendix M) revealed a significant effect 
for treatments, along with a nonsignificant effect for melancholia 
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(presence or absence) and a nonsignificant effect for the treatment x 
melancholia (presence or absence) interaction. Examination of least 
squared means showed that subjects (regardless of the presence or 
absence of melancholia) who received cognitive therapy or antidepressant 
medication significantly improved on this measure, with subjects 
improving significantly more after receiving cognitive therapy rather 
than antidepressant medication (Table 21, Appendix M). Again, these 
results parallel the results obtained when subjects were divided based 
on the dexamethasone suppression test. 
Finally, the one-way (treatment) analysis of variance using 
difference scores from the dexamethasone suppression test for subjects 
without melancholia showed a nonsignificant effect for treatments (Table 
22, Appendix M). Least squared means showed no significant changes 
pre-intervention to post-intervention on this measure for subjects 
without melancholia (Table 22, Appendix M). Since there was a high 
correlation between normal dexamethasone suppression test results and 
the absence of melancholia, this finding is not surprising. 
For the one-way (treatment) analysis of variance using difference 
scores from the dexamethasone suppression test for subjects with 
melancholia, this showed a nonsignificant effect for treatments (Table 
23, Appendix M). Least squared means revealed that there were 
significant changes from pre-intervention to post-intervention on the 
dexamethasone suppression test for subjects receiving either cognitive 
therapy or antidepressant medication (Table 23, Appendix M). Again, 
this is not surprising in light of the high correlation between the 
presence of melancholic symptoms and abnormal dexamethasone suppression 
test results. 
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CHAPTER IV 
DISCUSSION 
The research presented here examined the value of the dexamethasone 
suppression test in selecting subjects who are responsive to different 
types of treatment for depression. In other words, the "treatment 
validity" of the dexamethasone suppression test was evaluated by testing 
whether the treatment of abnormal or normal dexamethasone suppression 
test responders was maximized by using either a biologically-oriented 
treatment (antidepressant medication) or a psychologically-oriented 
treatment (cognitive therapy), respectively. Specifically, the question 
examined was: Does an abnormal dexamethasone suppression test, which 
many believe represents a biologically-based depression, respond better 
to a biologically-oriented treatment (antidepressant therapy) versus a 
psychologically-oriented treatment (cognitive therapy), and conversely, 
does a normal dexamethasone suppression test, which many believe 
represents a psychologically-based depression, respond better to a 
psychologically-oriented treatment versus a biologically-oriented 
treatment? Related to this question, the theoretical distinction of 
endogenous versus exogenous depression was explored in terms of its 
function in predicting behaviors associated with the distinction 
(presence or absence of melancholic symptoms) and its function in 
predicting treatment response. This project also examined a second 
question: If a conversion from an abnormal to normal dexamethasone 
suppression test after somatic treatment indicates clinical recovery, 
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what effect does a psychological treatment (cognitive therapy) have on 
the dexamethasone suppression test? Finally, this study examined the 
question: What effect does a biologically-oriented treatment and a 
psychologically-oriented treatment have on a subject's dysfunctional 
thoughts? 
In short, the results showed that for both treatments, subjects 
overall reported significantly less depressive symptoms according to 
global measures of depression from the Depression Scale of the Minnesota 
Multiphasic Personality Inventory, the Beck Depression Inventory, the 
Lubin Depression Adjective Checklist, and diagnoses based on the 
Diagnostic and Statistical Manual of Mental Disorders, third edition. 
These measures also showed that normal dexamethasone suppression test 
responders reported a significantly greater change in depressive 
symptoms at post-intervention than abnormal dexamethasone suppression 
test responders, regardless of type of treatment. Furthermore, while 
normal dexamethasone suppression test responders showed no significant 
change on the dexamethasone suppression test from pre-intervention to 
post-intervention, the abnormal dexamethasone suppression test 
responders did show significant reductions in the dexamethasone 
suppression test (indicating improvement) from pre-intervention to 
post-intervention after receiving either antidepressant medication or 
cognitive therapy, with no difference at post-intervention between the 
two types of treatment (50% were "normal" responders at 
post-intervention). Finally, there was a significant reduction overall 
in depressives' dysfunctional thoughts (according to the Personal 
Beliefs Inventory) after receiving either antidepressant medication or 
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cognitive therapy, with subjects receiving cognitive therapy having 
significantly fewer dysfunctional thoughts than subjects receiving 
antidepressant medication. 
The preceding pattern of results raised the following questions: 
(a) What is the meaning of the fact that the "treatment validity" of 
the dexamethasone suppression test was not supported?; (b) Why did 
normal dexamethasone suppression test responders report a significantly 
greater change in depressive symptoms at post-intervention than abnormal 
dexamethasone suppression test responders, regardless of the treatment 
utilized?; (c) Why did a psychological treatment result in significant 
reductions (improvement) on dexamethasone suppression test scores?; 
(d) How did a biologically-oriented treatment result in a significant 
reduction in depressives' dysfunctional thoughts? As these questions 
are being discussed, the research findings are compared to initial 
predictions and past research. 
Predictions, Results, and Discussion 
Overall Treatment Effectiveness and Differential Effectiveness Based on 
Dexamethasone Suppression Test in Treating Depression 
The first set of predictions involved the effectiveness of the two 
treatments along with the differential effectiveness of the treatments 
based on whether the subjects were classified as normal or abnormal 
dexamethasone suppression test responders. First, it was predicted that 
overall, subjects in this study would report significantly less 
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depressive symptoms at post-intervention. This prediction was based on 
the body of research supporting the effectiveness of both cognitive 
therapy and tricyclic antidepressant medication as treatments for 
depression. Second, it was predicted that abnormal dexamethasone 
suppression test responders would report a significantly greater 
change in depressive symptoms after receiving antidepressant medication 
versus cognitive therapy, while normal dexamethasone suppression test 
responders would show significantly greater change in depressive 
symptoms after receiving cognitive therapy versus antidepressant 
medication. In other words, it was predicted that the "treatment 
validity" of the dexamethasone suppression test would be supported. 
This prediction was based on studies suggesting that abnormal results on 
the dexamethasone suppression test may represent a biological marker for 
depression which may respond well to biologically-oriented treatments 
(Brown et al., 1979; Brown & Shuey, 1979; Greden et al., 1980). 
Overall effectiveness of cognitive therapy and antidepressant 
medication. The present data are consistent with the demonstrated 
effectiveness of both cognitive therapy and tricyclic antidepressants in 
the treatment of depression. That is, based on the present 
investigation, subjects overall reported less depressive symptoms 
according to all global measures of depression, the Depression Scale of 
the Minnesota Multiphasic Personality Inventory, the Beck Depression 
Inventory, the Lubin Depression Adjective Checklist, and diagnoses based 
on the Diagnostic and Statistical Manual of Mental Disorders, third 
edition, after being exposed to either cognitive therapy or tricyclic 
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antidepressants. These data parallel past studies which support the 
effectiveness of cognitive therapy (Blackburn et al., 1981; Kendall, 
1984; Kovacs et al., 1981; Lewinsohn & Hoberman, 1981; McLean & 
Hakstain, 1979; Rush et al., 1977; Shaw, 1977; Wright & Beck, 1983) and 
the effectiveness of tricyclic antidepressants (Bennett, 1966; Klein & 
Davis, 1969; Mandel S Klerman, 1979; Mindham, 1982; Morris & Beck, 1973; 
Wechsler et al., 1965). The fact that neither treatment was 
significantly more effective than the other is consistent with the 
conclusion from other studies (Blackburn et al., 1981; Kendall, 1984; 
Kovacs et al., 1981; Lewinsohn & Hoberman, 1981; McLean & Hakstain, 
1979; Rush et al., 1977; Wright & Beck, 1983). Wright and Beck (1983) 
concluded that, "Cognitive therapy has been at least equal to 
pharmacotherapy in all studies comparing the two treatments." 
It should be mentioned that while this study cannot assert that the 
two treatments utilized in this study produce results that are superior 
to control conditions, other studies strongly show that both tricyclic 
antidepressants and cognitive therapy produce superior results to 
control conditions (Bennett, 1966; Blackburn et al., 1981; Kendall, 
1984; Klein & Davis, 1969; Kovacs et al., 1981; Lewinsohn & Hoberman, 
1981; Mandel & Klerman, 1979; McLean & Hakstain, 1979; Mindham, 1982; 
Morris & Beck, 1973; Rush et al., 1977; Shaw, 1977; Wechsler et al., 
1965; Wright & Beck, 1983). To illustrate, Figure 6 (Appendix S) 
contains data utilizing the Beck Depression Inventory and shows the 
relative effectiveness of cognitive therapy and antidepressant 
medication over control groups. The top graph in Figure 6 (Appendix S) 
contains data from Shaw (1977) and Rush et al. (1977) and shows, based 
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on the Beck Depression Inventory, that both cognitive therapy and 
antidepressant medication are significantly more effective in reducing 
self-reported depression over control conditions, and are comparable in 
effectiveness. The bottom graph in Figure 6 (Appendix S) is data from 
Simons et al. (1984) and shows virtually identical results in that based 
on the Beck Depression Inventory, both cognitive therapy and 
antidepressant medication are comparable in effectiveness, and are 
significantly more effective over control conditions. There are no 
studies available comparing antidepressant medication to a placebo 
medication that utilizes the Beck Depression Inventory. Because of 
these consistent findings, the inclusion of a waiting-list control group 
in this particular investigation was deemed both unnecessary and 
unethical. 
Differential Effectiveness of Treatments Based on Dexamethasone 
Suppression Test Results 
Treatment validity of the dexamethasone suppression test. The 
prediction was not supported that the "treatment validity" of the 
dexamethasone suppression test would be shown with abnormal responders 
reporting significantly less depressive symptoms after antidepressant 
medication rather than cognitive therapy, and normal responders 
reporting less depressive symptoms after cognitive therapy versus 
antidepressant medication. Rather, analysis of all three global measures 
of depression (Depression Scale of the Minnesota Multiphasic Personality 
Inventory; Beck Depression Inventory; and Lubin Depression Adjective 
Checklist) showed that regardless of type of treatment, normal 
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dexamethasone suppression test responders overall reported a 
significantly greater reduction in depressive symptoms than abnormal 
dexamethasone suppression test responders at post-intervention. Stated 
differently, while subjects overall significantly improved pre-
intervention to post-intervention on the depression measures after being 
exposed to either antidepressant medication or cognitive therapy, normal 
dexamethasone suppression test responders responded significantly better 
to the treatment of their depression (whether the treatment was 
medication or cognitive therapy) than abnormal dexamethasone suppression 
test responders. Therefore, the use of the dexamethasone suppression 
test in making treatment decisions (in this case, between a biologically 
versus psychologically-oriented treatment) in order to maximize 
treatment outcome was not supported. The predicted treatment validity 
of the dexamethasone suppression test came from the fact that many 
researchers operating from the biological-disease model of depression 
have attempted to operationalize the endogenous-exogenous distinction, 
through the dexamethasone suppression test. Concomitantly, abnormal 
dexamethasone suppression test results were taken to represent an 
endogenous or biologically-based depression that responds well to 
somatic-oriented treatments, while normal dexamethasone suppression test 
results were taken to represent an exogenous-based depression that 
responds well to psychologically-oriented treatments. In fact, many of 
these researchers have presented data suggesting that abnormal 
dexamethasone suppression test responders show more improvement after 
receiving tricyclic antidepressants than normal responders (Brown et 
al., 1979; Brown & Shuey, 1979; Carroll, 1982; Fiori & Davis, 1984; 
95 
Fraser, 1975; Greden et al., 1980; Gwirtsman, Gerner, & Sternbach, 1982; 
Nemeroff & Evans, 1984) while others have questioned whether cognitive 
therapy can be effective for abnormal dexamethasone suppression test 
responders (Carroll, Feinberg, & Greden, 1981; Rush, 1982; Williams, 
1984). These studies have been plagued by methodological difficulties 
such as small sample sizes, poor outcome measures, poor diagnostic 
procedures, and post hoc examination of treatment response. The present 
study did not support the views that abnormal responders on the 
dexamethasone suppression test should improve significantly more with 
antidepressant medication than normal responders, or that cognitive 
therapy should be ineffective for abnormal responders. The present 
study is the first to date that examines directly the effects of two 
different treatments (antidepressant medication versus cognitive 
therapy) based on the classification of subjects according to their 
responses to the dexamethasone suppression test. Other studies, 
however, have not supported the relationship between abnormal responders 
and significant improvement with antidepressant medication as compared 
to normal responders (Bowie & Beaini, 1985; Hirschfeld et al., 1983; 
Insel & Goodwin, 1983; Klein, Bender, & Mayr, 1984; Spar & Rue, 1983). 
This present study was different from other studies in that it showed 
that significant improvement in terms of depression for both normal and 
abnormal responders on the dexamethasone suppression test could result 
from receiving either antidepressant medication or cognitive therapy, 
with normal responders improving significantly more with regard to their 
depressive symptoms relative to abnormal responders. 
There are several possible reasons why the prediction was not 
supported. First, the dexamethasone suppression test may not make the 
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endogenous-exogenous distinction. In other words, the dexamethasone 
suppression test is an indirect measure of hypothalamic-pituatary-
adrenal functioning which is believed to be directly related to the 
neurotransmitters implicated in depression (e.g., serotonin, dopamine). 
It may be that the dexamethasone suppression test does not actually 
measure this system. Second, it may be that the dexamethasone 
suppression test is unreliable in and of itself. It may be, as Bowie & 
Beaini (1985) suggest, that there is a class of dexamethasone 
suppression test responders who naturally fluctuate over time, making it 
difficult to draw conclusions from only pre-post measures of Cortisol. 
Third, it may be that the endogenous-exogenous distinction functionally 
does not distinguish between treatments. It may be that the distinction 
is useful in serving other functions (e.g., predicting behaviors 
associated with the depressive episode, predicting course of treatment), 
but is useless in treatment selection. Finally, it may be that 
treatment choice is not dependent on etiology. Even when the etiology 
of a disorder is known, different treatments unrelated to the etiology 
might none-the-less be effective. A simple example of this is known as 
"the aspirin analogy" (Rimland, 1964). Aspirin alleviates a headache, 
but the substances in aspirin may be totally unrelated to the etiology 
of the headache. This last position is viable in light of the 
theoretical argument involving physical monism, which is discussed in 
2 
detail later. 
Interpretation of differential effectiveness of treatments based on 
dexamethasone suppression test results. This investigation showed that 
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overall subjects significantly improved on the various depression 
measures, with normal responders improving significantly more than 
abnormal responders on the dexamethasone suppression test regardless of 
type of treatment. These results support the growing body of literature 
suggesting that the dexamethasone suppression test may have prognostic 
value, and that normalization of the test (abnormal to normal results) 
parallels clinical improvement (Bowie & Beaini, 1985; Greden et al., 
1980; Hirschfeld et al., 1983; Insel & Goodwin, 1983; Nemeroff & Evans, 
1984; Spar & Rue, 1983). In addition, one author found that failure to 
convert from an abnormal to normal responder after treatment resulted in 
significant chances for relapse (Nemeroff & Evans, 1984). 
The prognostic value of the dexamethasone suppression test was 
supported in this study by the fact that a normal response predicted 
better outcome than an abnormal response. These results are consistent 
with a recent study by Spar and Rue (1983) which showed that for elderly 
patients (age ̂  65), both normal and abnormal responders significantly 
improved on a number of measures (e.g., depression, cognitive 
impairment, agitation), with normal responders improving significantly 
more on these measures than abnormal responders. Therefore, abnormal 
responders may have a more intractable depression, requiring a longer 
period of treatment. Another explanation may be that there are a number 
of "systems" that can be affected during a depressive episode (e.g., 
biochemical, cognitive, behavioral systems). The abnormal responders in 
this study had at least two systems affected, the biochemical and the 
cognitive (all subjects had a high level of dysfunctional beliefs), 
according to the measures taken. It may require greater time to show 
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improvements in two systems. Relatedly, two types of treatment may be 
needed to affect two systems. Presently, only one system was treated 
(half the abnormal responders received cognitive therapy, the other half 
antidepressant medication). 
This study also supports the research that suggests normalization 
of the dexamethasone suppression test parallels clinical improvement. 
Abnormal responders showed significant improvement in terms of their 
depression along with significant decreases with regard to their 
Cortisol levels on the dexamethasone suppression test. This result can 
also be seen by examining the individual data (see Tables 3 and 4, 
Appendix M). (This finding is explored in detail in the next section.) 
This is consistent with a recent study performed by Bowie and -Beaini 
(1985) that examined serial dexamethasone suppression test results; 
decreases of serum Cortisol on the test along with normalization of the 
test were highly correlated with clinical recovery. Therefore, as Klein 
et al. (1984) concluded, the dexamethasone suppression test may be much 
more useful as a measurement of the "present state" of a patient's 
depression rather than as a diagnostic tool. This would also suggest 
that, if there is an incomplete reduction in the dexamethasone 
suppression test and in depressive symptomology, it would be important 
to continue treatment until full clinical recovery is achieved. 
The dexamethasone suppression test and melancholic symptoms. Many 
researchers utilizing the endogenous-exogenous distinction based on the 
dexamethasone suppression test assert that abnormal dexamethasone 
suppression test results correlate with melancholia. The rationale is 
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based on the fact that the dexamethasone suppression test indirectly 
measures hypothalamus functioning and that many of the melancholic 
symptoms are suggestive of hypothalamic dysfunction (e.g., disturbances 
in sex drive, sleep, appetite, autonomic activity). Since many of the 
neurotransmitters implicated in the chemical pathology of depression 
(e.g., nonadrenaline, serotonin, acetylcholine) also regulate the 
hypothalamic function, deficiencies in the functional activity of these 
neurotransmitters would be reflected in the hormonal responses they 
regulate. Therefore, one would expect high correlations between 
abnormalities in Cortisol secretion based on the dexamethasone 
suppression test and melancholic symptoms. Several studies have found 
high correlations between abnormal dexamethasone suppression test results 
and melancholia (Brown et al., 1979; Calloway, Fonagy, DeSouza, & 
Wakeling, 1984; Carroll et al., 1981; Johnson, Hunt, Kerr, & Catersan, 
1984; Sachar, 1975; Zung, Mahorney, & Davidson, 1984) while others have 
not found a correlation (Beeber, Kline, Pies, S Manring, 1984; Coryell, 
Gaffney, & Burkhardt, 1982; Morphy, Fava, Perini, Molnar, Zielezny, & 
Lisansky, 1985; Rabkin, Quitkin, Stewart, McGrath, & Piug-Antich, 1983). 
In addition, it has also been suggested that depressives with 
melancholic symptoms respond better to antidepressant medication than 
depressives with nonmelancholic symptoms (Bielski & Friedel, 1976; Kiloh 
et al. , 1962; Paykel, 1972; Rao & Coppen, 1979; Raskin & Crook, 1976). 
Because of the studies suggesting that melancholic symptoms covary with 
abnormal dexamethasone suppression test results, and that melancholic 
depressives may respond better to antidepressant medication, melancholia 
was examined in a post hoc fashion in this present investigation. 
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Diagnoses were made by the principal investigator using the specific 
criteria from the Diagnostic and Statistical Manual of Mental Disorders, 
third edition (see Appendix G-2). Therefore, questions asked were: (a) 
Did melancholic symptoms correlate highly with abnormal responses to the 
dexamethasone suppression test; and (b) Were there differential 
treatment effects, depending on the presence or absence of melancholic 
symptoms? 
As reported earlier, a high correlation (.74) was found between 
abnormal dexamethasone suppression test results and melancholic symptoms 
based on the Diagnostic and Statistical Manual of Mental Disorder, third 
edition (see Appendix G-2 and Table 4, Appendix M). Therefore, 
melancholic symptoms were highly correlated with abnormal results, which 
support the above mentioned studies. The treatment validity of the 
presence or absence of melancholia was not supported. Similar results 
were found for the treatment validity of the dexamethasone suppression 
test and for the presence or absence of melancholia. In other words, 
overall subjects with or without melancholia significantly improved with 
regard to depressive symptoms regardless of type of treatment, with 
non-melancholic subjects improving significantly more than melancholic 
subjects. The effectiveness of cognitive therapy for melancholies was 
supported by Kovacs et al. (1981) and Blackburn (1981) who did not find 
any evidence that "endogenous" or "melancholic" symptoms in 
non-psychotic depression predicted any worse outcome in response to 
cognitive therapy. Other studies have also not found the distinction of 
presence or absence of melancholia useful in predicting response to 
chemotherapy (Raskin S Crook, 1976; Zimmerman, Coryell, & Pfohl, in 
press). 
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There are several possibilities as to why the above results were 
found. First, it may be that the diagnosis of melancholia in its 
present state is unreliable, with different researchers using different 
criteria. Second, it may be that the presence or absence of melancholic 
symptoms does not make the endogenous-exogenous distinction, and that 
this distinction may be based on other factors (e.g., family history, 
occurrence of manic symptoms). Third, the distinction of the presence 
or absence of melancholic symptoms may be useless in the selection of 
treatment. As with results from the dexamethasone suppression test, the 
melancholic distinction may be useful in serving other functions (e.g., 
such as a predictor for the course of treatment) but does not help in 
selecting treatment. Finally, while the presence or absence of 
melancholic symptoms may represent the "etiology" of a depressive 
illness, treatment choice may not be dependent on etiology. 
Effects of Cognitive Therapy and Antidepressant Medication 
on the Dexamethasone Suppression Test 
Of particular interest here was the impact of cognitive therapy and 
antidepressant medication on subjects who had abnormal dexamethasone 
suppression test results. It was predicted that cognitive therapy would 
not impact on abnormal dexamethasone suppression test results, whereas 
antidepressant treatment would result in a significant reduction in 
dexamethasone suppression test scores for abnormal responders. This 
prediction was based on studies suggesting that an abnormal 
dexamethasone suppression test result represents an "endogenous" 
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depression which is suggestive of a biological abnormality and treatable 
only by a biologically-oriented treatment (antidepressant medication), 
along with studies showing conversion from abnormal to normal results on 
the dexamethasone suppression test after administration of 
antidepressant medication (Bowie & Beaini, 1985; Brown et al., 1979; 
Brown & Shuey, 1979; Fraser, 1983; Greden et al., 1980; Spar & La Rue, 
1983). Therefore, it was predicted that cognitive therapy would have no 
effect on the dexamethasone suppression test for abnormal responders. 
In actuality, there was a significant reduction in dexamethasone 
suppression test scores for abnormal responders after being exposed to 
either antidepressant medication or cognitive therapy. As was mentioned 
earlier, several studies have shown that treatment with antidepressant 
medication is associated with significant reductions in dexamethasone 
suppression test scores (e.g., conversion from abnormal to normal 
results) and clinical improvement. This is the first study to examine 
and show that a psychological treatment for depressed outpatients, 
cognitive therapy, was also associated with significant reductions on 
the dexamethasone suppression test (in addition to conversions from 
abnormal to normal results) and significant clinical improvement. 
While several studies have shown a clear correlation between 
clinical improvement in depression and significant reductions in 
Cortisol levels based on the dexamethasone suppression test (and the 
lack of reduction in Cortisol without clinical improvement) (Bowie & 
Beaini, 1985; Brown et al., 1979; Brown & Shuey, 1979; Carroll, 1980; 
Greden et al., 1980; Fraser, 1983; Sachar, 1982; Spar & La Rue, 1983), 
none of these studies, including the present investigation, has utilized 
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control groups to examine the dexamethasone suppression test over time 
without treatment. Therefore, the only support available that the 
dexamethasone suppression test would not change over time is the above 
studies showing strong correlations between Cortisol levels and clinical 
improvement. To illustrate, Bowie and Beaini (1985) showed that for 
abnormal responders on the dexamethasone suppression test, normalization 
either presided or coincided with good clinical response, while poor 
clinical response remained highly correlated with abnormal dexamethasone 
suppression test results. 
The question must be asked, "How can a psychological treatment 
impact on a biological system?" The theoretical position of physical 
monism may be of help here. This view says that both types of 
treatments are effective in altering the dexamethasone suppression test 
because they are both dealing with the same substance, physical matter. 
The only difference between the two treatments is the level of 
intervention. Therefore, the physical system can be affected by either 
a biochemical level of intervention, or by an environmental level of 
intervention. Antidepressant medication may impact on the biological 
system (represented here by the dexamethasone suppression test) by 
directly manipulating the neurotransmitters in the brain (e.g., 
increases in serotonin). Cognitive therapy may indirectly affect the 
biological system by altering dysfunctional thoughts. Depression may be 
unitary phenomenon that involves a physical system. Changes resulting 
from treatment (be it cognitive therapy or chemotherapy) depend on the 
level of intervention (biochemical, cognitive, behavioral). Another 
view might hold that there are different "systems" that are affected in 
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a depressive episode (e.g., biochemical, cognitive, behavioral). These 
systems are interrelated, so that if one system is affected, the other 
systems are affected also. Therefore, if the cognitive system is 
impacted through cognitive therapy, corresponding changes in the 
biochemical system could also occur. Similarly, changes in the 
biochemical system may result in corresponding changes in the cognitive 
system. Some researchers have objected to the use of the terms levels 
or interactions, and instead employ the term transaction since this term 
does not imply priority of one type of analysis over another and does 
not imply that the systems are independent, non-related systems. 
Effects of Cognitive Therapy and Antidepressant Medication 
on Dysfunctional Thoughts 
Beck (1967, 1972, 1979) maintains that negative thought patterns 
and distorted perceptions that the depressed person holds about 
himself/herself, the present, and the future result in depression. 
Therefore, Beck's cognitive therapy of depression focuses directly on 
modifying dysfunctional thoughts and overt behavior in order to change 
the patient's negative self-perception and by doing so alleviating the 
patient's depression. Based on this rationale and the effectiveness of 
Beck's treatment for depression, it was predicted that cognitive therapy 
would have a significant impact on the subject's dysfunctional thoughts 
(i.e., significantly reduce the number of dysfunctional thoughts) while 
antidepressant medication would not. This prediction was not supported 
in that both cognitive therapy and antidepressant medication resulted in 
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significant reductions of dysfunctional thoughts, while cognitive 
therapy produced significantly greater reductions than antidepressant 
medication (according to the Personal Beliefs Inventory). These results 
parallel very closely the results from a study conducted by Rush, Beck, 
Kovacs, Weissenburger, and Hollon (1982) which found significant 
reduction in hopelessness and a significant increase in self-esteem 
after depressives received either chemotherapy or cognitive therapy, 
with cognitive therapy producing a significantly greater change than 
chemotherapy. 
Again, the question must be asked: How can a somatic treatment 
result in significant reductions of dysfunctional thoughts? One answer 
is consistent with a growing body of research that suggests 
dysfunctional thinking is a "result," "symptom," or "correlate" of 
depression rather than a "cause" (Lewinsohn et al., 1981; Silverman et 
al., 1984; Simons et al., 1984). For example, Lewinsohn et al. (1981) 
in a longitudinal study, found that dysfunctional thoughts do not exist 
immediately prior to or after a depressive episode (with no treatment), 
but rather dysfunctional thoughts are a symptom or correlate 
accompanying the depression. Silverman et al. (1984) and Simons et al. 
(1984) used a methodology similar to that of this present study by 
examining directly the effect of chemotherapy on dysfunctional thoughts. 
Chemotherapy is believed to be treating the "depressive illness," which 
when alleviated ameliorates the "symptom" of dysfunctional thinking. 
Therefore, somatic treatments treat the underlying "depressive illness" 
resulting in the alleviation of the symptoms of dysfunctional thinking, 
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much like antibiotics treating the underlying virus which results in the 
alleviation of the symptoms such as nausea or fever. 
Another answer would again utilize the theoretical position of 
physical monism (see previous section). Both treatments are effective 
because they are both dealing with the same substance, physical matter. 
The only difference between the treatments is the level of intervention. 
Therefore, the physical system can be affected at either a biochemical 
level of intervention, or an environmental level of intervention. 
Changes in cognitions resulting from cognitive therapy are changes in 
physiology, while changes in biochemistry resulting from chemotherapy 
result in changes in cognitions. Depression may be a unitary phenomenon 
that affects the whole physical system. Changes resulting from 
treatment (chemotherapy or cognitive therapy) depend on the level of 
intervention (biochemical, cognitive, behavioral). 
Another view is consistent with Coyne (1980) and Blackburn and 
Bishop (1983) who argue that there is a circular system in depression 
involving mood, cognitions, and biochemical changes. Depending on the 
level of intervention or entry into the system, all these functions will 
change to the same degree depending on the efficacy of the intervention. 
This view is consistent with the present results in that both treatments 
resulted in reductions of dysfunctional thoughts (and depressive 
symptoms), with cognitive therapy resulting in significantly greater 
reductions of dysfunctional thoughts than chemotherapy. Based on this 
view, cognitive therapy would be a more direct intervention with regard 
to dysfunctional thoughts as compared to chemotherapy (therefore, the 
greater effectiveness of cognitive therapy). But because of the 
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circular system, chemotherapy results in changes in the related system 
of cognitions. 
A final comment is warranted in response to assertions that 
dysfunctional thoughts are not "causes" of depression but rather are 
"correlates" or "symptoms" of a depressive syndrome. It could be argued 
that dysfunctional thoughts or abnormal biochemistry (e.g., abnormal 
dexamethasone suppression test) may represent "proximal" causes or 
maintaining factors in depression. Manipulation of these "proximal" 
causes result in changes in these factors and consequently in the 
depression, along with changes in intercorrelated factors (e.g., changes 
in cognition resulting in changes in biochemistry). "Ultimate" causes 
of depression (e.g., experiences when young, predispositions to 
depression) may or may not be discovered for the individual patient, and 
if discovered, they may not be able to be manipulated. Therefore, while 
dysfunctional thoughts or abnormal brain chemistry may not represent 
"ultimate" causes, they may represent "proximal" causes or maintaining 
factors. 
Strengths and Limitations of the Present Investigation 
The present investigation has several major methodological 
strengths. First, the population ware carefully selected in terms of 
subjects having a Major Depression as their major presenting problem. 
This was based on the most commonly used questionnaires and criteria for 
depression, along with a structured interview to arrive at a diagnosis 
with high and measured reliability. Subjects with normal and abnormal 
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dexamethasone suppression test results also did not differ with regard 
to severity of their depressions according to the questionnaires. 
Second, factors affecting the dexamethasone suppression test were ruled 
out, such as physical illnesses, alcohol consumption, diabetes, 
pregnancy, and the ingestion of certain medicines. Third, the 
treatments were clearly defined and therapeutic levels of antidepressant 
were assured by the use of blood tests measuring blood plasma levels of 
the medicine. Next, both the principal investigator and the staff 
psychiatrist were blind to the dexamethasone suppression test results. 
Also, the presence or absence of melancholic symptoms were recorded and 
analyzed, which is seldom done in most studies on depression. In 
addition, there was a very low attrition rate for all groups unlike the 
study performed by Rush et al. (1977) which showed high attrition rates 
for the medicine group and not for the cognitive therapy group. Related 
to this, the present investigation allowed for the flexible 
administration of the tricyclic medicines to assure maximum 
effectiveness and to better mirror clinical reality. This has been a 
criticism of previous studies comparing cognitive therapy and 
antidepressant medications. Finally, subjects were selected at 
pre-intervention to have a high level of dysfunctional thoughts to 
assure that the treatments would be appropriate for all subjects. 
In addition to the major strengths, several limitations exist in 
the present investigation that may be important for future research. 
First, the defined population is restricted to outpatient depressives 
with a high level of dysfunctional thoughts. It may be that abnormal 
dexamethasone suppression test responders without dysfunctional thoughts 
109 
may respond to a purely biological approach (medications) and not to 
cognitive therapy. Further, the results may be different if this study 
were conducted with hospital inpatients. For example, the treatment 
validity of the dexamethasone suppression test may be valid for hospital 
inpatients. Their dexamethasone suppression test results may be more 
abnormal, representing a more severe biological abnormality that may 
render psychological interventions ineffective; biologically-oriented 
treatments might prove to be more expedient or cost-effective with these 
inpatients versus psychologically-oriented treatments. Since there are 
no studies directly examining similarities and differences between 
inpatient and outpatient depressives' with regard to the dexamethasone 
suppression test, this is an important area of future study. Also, some 
clinicians or researchers may question whether subjects in this project 
were "real" melancholies, and therefore question the diagnosis. Second, 
since different tricyclic antidepressants were prescribed by a single 
psychiatrist, it is difficult to generalize across tricyclics not used 
in this study, along with the fact that different psychiatrists may have 
prescribed different antidepressants than the psychiatrist in this 
investigation. In other words, this study cannot generalize across 
treatments for depression, either somatic or psychological, not utilized 
in this study. Further, while the psychiatrist meeting with the 
subjects receiving medication was instructed to focus on the biological 
model of depression, his sessions (and the cognitive therapy sessions) 
were not taped to assure compliance with the protocol (although the 
psychiatrist had no formal training in cognitive therapy and the 
cognitive therapy sessions were structured in a formal protocol). 
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Related to this, a confound existed in terms of different lengths of 
sessions for the two treatments. While the cognitive therapy sessions 
were one hour long, the medication sessions ranged from one-half hour to 
one hour in duration. Also, the principal investigator conducted the 
cognitive therapy rather than having unbiased therapists, in spite of 
taking precautions such as being blind to the dexamethasone suppression 
test results, having another person assign subjects to groups, score 
questionnaires, etc. Thirdly, there have been no studies examining the 
effect of time on the dexamethasone suppression test without treatment 
(this investigation did not employ a control group). Fourth, factors 
resulting in false positives on the dexamethasone suppression test may 
have influenced the results, such as the finding that caffeine can 
results in false positives (Uhde, 1985) or the influence of age on 
Cortisol levels (Lewis, Pfohl, Schlehte, & Coryell, 1984). Finally, 
the finding by Bowie and Beaini (1985) that a fluctuating nonsuppressor 
group exists based on the dexamethasone suppression test (subjects who 
alternate between normal and abnormal results over time) may represent a 
separate population that needs to be defined in future studies based on 
the dexamethasone suppression test. 
Conclusions 
This study compliments previous research by demonstrating that 
exposure to cognitive therapy or tricyclic antidepressants results in a 
significant reduction of depressive symptoms. This investigation also 
supports a growing body of research that suggests that the dexamethasone 
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suppression test (and the presence or absence of melancholic symptoms) 
does not support the functional utility of the endogenous-exogenous 
distinction in selecting treatments for depression. The dexamethasone 
suppression test may actually be more appropriate as an indicator of 
prognosis (with abnormal responders responding less well to treatment 
than normal responders) and a "present state" indicator of a 
depressive's course in treatment. Furthermore, this study supports the 
existing body of literature suggesting that the changing of 
dysfunctional thoughts by the use of cognitive therapy alleviates 
depression. Because of the fact that antidepressant medication also 
significantly lessened dysfunctional beliefs (although not as much as 
cognitive therapy), it cannot be concluded that dysfunctional thoughts 
"cause" depression. Also, this study was the first to show that a 
psychologically-oriented treatment (cognitive therapy) could impact on a 
biological system resulting in many cases "normalization" of that system 
(e.g., conversion from abnormal to normal results on the dexamethasone 
suppression test). Finally, reanalyzing the results in terms of the 
presence or absence of melancholic symptoms revealed the same 
conclusions that were made in dividing subjects based on normal or 
abnormal dexamethasone suppression test results. 
Future directions of research should first of all attempt to 
correct some of the limitations present in the current investigation. 
Control groups, if possible, should be utilized particularly with 
repeated administration of the dexamethasone suppression test. In 
addition, future research should examine the dexamethasone suppression 
test with different groups of depressives, such as hospital inpatients, 
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or dexamethasone suppression test responders without dysfunctional 
thoughts. Future research should also continue to examine other 
biological correlates (e.g., GH response, REM latency, EEG, Metyrapone 
tests) in terms of their relation to the dexamethasone suppression test 
and in terms of their treatment validity. Future studies should retain 
a diagnosis of melancholia, along with further examination of the 
relationship between the presence of melancholic symptoms and abnormal 
dexamethasone suppression test results. Finally, other uses of the 
dexamethasone suppression test should be examined, such as predicting 
suicide, prognosis, and prediction of relapse. 
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APPENDIX A 
Dear : 
(Physician's Name) 
We are conducting a psychiatric/psychological research-treatment 
project to examine the differential effectiveness of a chemotheraputic 
approach versus a cognitively-oriented approach in treating depressed 
female clients. The techniques we are using have been shown to be 
useful with this population in the past. Since in your medical practice 
you are in contact with women who report that they are depressed, we are 
requesting that you refer to us any client whom you think is an 
appropriate candidate for psychiatric/psychological treatment. 
We will be working only with female clients who are not suicidal 
and who have been free from tranquilizing or anti-depressant medications 
for a minimum of two weeks (or, if the patient is taking medication for 
depression, has your permission to discontinue drug use for the duration 
of the project). 
We are enclosing a flyer describing the project which you may give 
to any patient whom you refer. In addition, we are enclosing several 
"Physician Statements" which acknowledge that the patient you are 
referring has met the medical requirements specified. 
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If you have any questions concerning the specific procedures that 
we will use, you may contact Dennis McKnight at Charter Mandala Center 
(768-7710) between 9:00 a.m. and 5:00 p.m., Monday through Friday. 
Thank you very mcuh for your assistance. 
Sincerely, 
Dennis McKnight, M.A. 
Doctorial Candidate 
in Clinical Psychology 
Jarrett Barnhill, M.D. 
Staff Psychiatrist 
Charter Mandala Center 
Rosemery Nelson, Ph.D. 
Professor of Psychology 
University of North 
Carolina at Greensboro 
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APPENDIX B 
Newspaper Notice 
If you have been feeling depressed and are female, at least 18 years 
old, you may be interested in a research-treatment project being 
conducted at Charter Mandala Center in Winston-Salem. If you are 
interested and eligible for participation in this project, three 
assessment sessions and eight individual treatment sessions will be 
available to you for only the cost of laboratory work and medication, if 
prescribed, along with a $50.00 deposit that is fully refundable after 
completion of the study. 
If interested, call Dennis McKnight at Charter Mandala Center (768-7710 
between 9:00 a.m. and 5:00 p.m., Monday through Friday) to schedule a 
"screening interview". At the screening interview, your eligibility for 
participation will be further assessed, and additional details of 
treatment will be offered. 
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APPENDIX C 
Descriptive Flyer 
If you have been feeling depressed and are female, at least 18 years 
old, you may be interested in a research-treatment project being 
conducted at Charter Mandala Center in Winston-Salem. If you are 
interested in and eligible for participation in this project, three 
assessment sessions and eight individual treatment sessions will be 
available to you for only the cost of leiboratory work and medication, if 
prescribed. 
In order to participate in the project you must: 
1. be feeling depressed and be a female at least 18 years old 
2. have been free from anti-depressant or tranquilizing drugs for a 
minimum of two weeks 
3. if you are under a physician's care for depression, you must submit 
a "physician's statement" stating that you are free of 
anti-depressant or tranquilizing drugs and are appropriate for 
psychological treatment 
4. if interested, call Dennis McKnight at Charter Mandala Center in 
Winston-Salem (768-7710 between 9:00 a.m. and 5:00 p.m., Monday 
through Friday) to schedule a "screening interview". At the 
screening interview, your eligibility for participation will be 
further assessed, and additional details of treatment will be 
offered. 
Thank you for your interest 
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APPENDIX D 
Medication Statement 
This statement affirms that I, 
have been free from any tranquilizing drugs or anti-depressant 
medication for the past two weeks, and will remain free from this 
medication as long as I am a participant in this research-treatment 
project, unless medication is prescribed during this project. In 
addition, I am not currently under a physician's (or psychiatrist's or 
psychologist's) care for the treatment of depression or the symptoms 
relating to depression, and will not be for the duration of this 
project. Failure to comply with this statement will result in a 
discontinuation of my participation in this project. 
Signed 
Witness . 
Date 
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APPENDIX E 
Physician's Statement 
PLEASE RETURN TO: 
Dennis L. McKnight, M.A. Telephone 
Charter Mandala Center Charter Mandala Center: 768-7710 
3637 Old Vineyard Road Monday - Friday 9:00 a.m.-5:00 p.m 
Winston-Salem, NC 27104 
Date: 
This statement acknowledges that to my knowledge, based on a medical 
examination, , is an appropriate 
candidate for participation in a research project which compares the 
differential effectiveness of a chemotheraputic (medicine) and cognitive 
therapy (psychological) approach to treating depression. To the best of 
my knowledge, she has been free from anti-depressant or tranquilizing 
medication for at least two weeks prior to the date listed above, or has 
discontinued drug use from the date indicted and is appropriate for 
psychological treatment. In addition, it is my opinion that her 
symptoms of depression are not due to medication she is receiving under 
my supervision. 
Please check ( ) Free from drug use; minimum two weeks 
( ) Discontinued drug use from date indicated 
Date of last prescription for anti-depressant or tranquilizing 
medication: 
Date of last medical examination: 
Physician's Signature 
Office Telephone Number 
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APPENDIX F 
Consent Form I 
I understand that I will be interviewed and asked to complete 
questionnaires to be used in selecting subjects for a research 
investigation involving the assessment and treatment of depression. In 
addition, I have been informed that I may withdraw from this screening 
session at any time, and that all personal information (e.g., my name) I 
give is completely confidential, and will only be available to the 
experimenters. I further understand that specific numerical scores 
provided by laboratory tests and by questionnaires will be used (without 
my identity) for research purposes and publication. I understand that 
if I am not eligible for participation in this program, I will be given 
a list of referrals for assessment and treatment in Winston-Salem that I 
amy contact if I so desire. However, if I am eligible for this program, 
I understand that experimental procedures will be explained to me more 
fully before I decide to continue to participate. 
Signed: 
Witness: 
Date: 
136 
APPENDIX G-l 
SADS Interview Outline: Shortened Version 
How is it going? (Work, school, home life) 
Feeling good or bad about it? 
Worried? 
Feeling under pressure? From where? 
If things are bad, what are the prospects for improvement in the 
immediate or distant future? 
Major happenings during the past year: best? worst? 
Goals for the future? Expectations for attainment? 
Self-description: good points? bad points? 
Aspects of self that would be desirable to change? 
Mood: 
Ups and downs? How severe and long-lasting are the downs? Any highs? 
Any thoughts or ideas about suicide? Previous attempts? Plans? 
Describe Typical Day: 
Interests and activities that are enjoyable? 
Any change from previous level of activity or enjoyment? 
Difficulty in initiating action? 
Having to exert a lot of effort to do things? 
Problems making decisions? 
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Social-Interactional Problems: 
How involved with other people? 
Number of close friends? Acquaintances? 
Ability to share with friends? 
Are relationships a source of discomfort, anxiety, and/or conflict? 
Feelings of social adequacy/inadequacy? 
Guilt: 
Religious background; importance of religion at present? 
Concern for welfare of family and friends? 
Blame self for present condition? 
Perceive self as failure in important responsibilities? 
Material Burden: 
Depression attributed to external problems (e.g., finances, children, 
demands of relatives or employers)? 
If external problems could be resolved, would that affect the 
depression? 
Somatic Manifestations: (not attributable to physical condition) 
Feeling slow? Tired all the time? Without energy? 
Problems sleeping? Difficulty in falling asleep? Waking frequently 
during the night? Sleep not restful? Problems with waking 
early in the morning and not being able to get back to sleep? 
Sleeping more than usual? 
How is appetite? Any weight loss? 
Gastrointestinal problems? 
Headaches? 
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APPENDIX G-2 
Criteria for Major Depression and Melancholia based on the 
Diagnostic and Statistical Manual of Menal Disorders, third edition. 
A. Dysphoric mood or loss of interest or pleasure in all or almost all 
usual activities and pastimes. The dysphoric mood is characterized 
by symptoms such as the following: depressed, sad, blue, hopeless, 
low, down in the dumps, irritable. The mood disturbance must be 
prominent and relatively persistent, but not necessarily the most 
dominant symptom, and does not include momentary shifts from one 
dysphoric mood to another dysphoric mood, e.g., anxiety to 
depression to anger, such as are seen in states of acute psychotic 
turmoil. (For children under six, dysphoric mood may have to be 
inferred from a persistently sad facial expression.) 
B. At least four of the following symptoms have each been present 
nearly every day for a period of at least two weeks (in children 
under six, at least three of the first four): 
(1) Poor appetite or significant weight loss (when not dieting) or 
increased appetite or significant weight gain (in children 
under six, consider failure to make expected weight gains). 
(2) Insomnia or hypersomnia. 
(3) Psychomotor agitation or retardation (but not merely 
subjective feelings of restlessness or being slowed down) (in 
children under six, hypoactivity). 
(4) Loss of interest or pleasure in usual activities, or decrease 
in sexual drive not limited to a period when delusional or 
hallucinating (in children under six, signs of apathy). 
(5) Loss of energy; fatigue. 
(6) Feelings of worthlessness, self-reproach, or excessive or 
inappropriate guilt (either may be delusional). 
(7) Complaints or evidence of diminished ability to think or 
concentrate, such as slowed thinking, or indecisiveness not 
associated with marked loosening of associations or 
incoherence. 
(8) Recurrent thoughts of death, suicidal ideation, wishes to be 
dead, or suicide attempt. 
C. Neither of the following dominate the clinical picture when an 
affective syndrome is absent (i.e., symptoms in criteria A and B 
above): 
(1) Preoccupation with a mood-incongruent delusion or 
hallucination. 
(2) Bizarre behavior. 
D. Not superimposed on either Schizophrenia, Schizophreniform 
Disorder, or a Paranoid Disorder. 
139 
E. Not due to any Organic Mental Disorder or Uncomplicated 
Bereavement. 
F. With Melancholia. Loss of pleasure in all or almost all 
activities, lack of reactivity to usual pleasurable stimuli 
(doesn't feel much better, even temporarily, when something good 
happens), and at least three of the following: 
(a) Distinct quality of depressed mood, i.e., the depressed mood 
is perceived as distinctly different from the kind of feeling 
experienced following the death of a loved one. 
(b) The depression is regularly worst in the morning. 
(c) Early morning awakening (at least two hours before usual time 
of awakening). 
(d) Marked psychomotor retardation or agitation. 
(e) Significant anorexia or weight loss. 
(f) Excessive or inappropriate guilt. 
PLEASE NOTE: 
Copyrighted materials in this document 
have not been filmed at the request of 
the author. They are available for 
consultation, however, in the author's 
university library. 
These consist of pages: 
APPENDIX H: 140-142 
APPENDIX L: 147-148 
University 
Microfilms 
International 
300 N. ZEEB RD.. ANN ARBOR, Ml 48106 (313) 761-4700 
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APPENDIX I 
Lubin Depression Adjective Check List (DACL) 
The DACL check lists consist of 7 forms (A-G). Forms A-D consist 
of balanced sets of 22 positive and 10 negative adjectives from a pool 
of items which significantly differentiated between a group of 48 
depressed female psychiatric patients and a group of 179 normal females. 
Forms E-G consist of balanced sets of 22 positive and 12 negative 
adjectives from a pool of adjectives which significantly differentiated 
between a group of 47 depressed male psychiatric patients and a group of 
100 normal males. 
Intercorrelations among the 7 forms are high, regardless of sex of 
subject group (Lubin, 1967). Internal consistency indices range from 
0.79 to 0.90, and split-half reliabilites range from 0.82 to 0.93 for 
normals and from 0.86 to 0.93 for patients. All forms were cross-
validated in a large study using normals, and depressed and 
non-depressed patient groups. Correlations with the MMPI-D are 0.31 
(Nussbaum et al., 1963), 0.54-0.57 (Lubin, 1967), and 0.42-0.55 (Lubin, 
1967); with teh Zung SDS are 0.53 (Levitt and Lubin, 1975), 0.63 (Levitt 
& Lubin, 1975), 0.58 (Lubin, 1967), 0.27-0.38 (Lubin, 1967); and with 
the Beck DI are 0.66 (Nussbaum et al., 1963), and 0.38-0.50 (Lubin, 
1967). 
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One key will score all seven lists. The pattern of plus and minus 
adjectives on each list is the same. To score, place the stencil over 
the list and score one point for each (+) adjective that is checked and 
one point for each minus adjective (0) that is not checked. The score 
for each lists consists of the total number of plus (+) adjectives 
checked and minus (0) adjectives not checked. 
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APPENDIX J 
Scale for Suicide Ideation 
Name Date 
Characteristics of Attitude Toward Living/Dying 
1. Wish to live 
0. Moderate to strong 
1. Weak 
2. None 
2. Wish to die 
0. None 
1. Weak 
2. Moderate to strong 
3. Reasons for living/dying 
0. For living outweigh for dying 
1. About equal 
2. For dying outweigh for living 
4. Desire to make active suicide attempt 
0. None 
1. Weak 
5. Passive suicidal attempt 
0. Would take precautions to save life 
1. Would leave life/death to chance 
2. Would avoid steps necessary to save or maintain life 
(e.g. , diabetic ceasing to take insulin) 
146 
APPENDIX K 
Referrals for Continued Assessment and Treatment of Depression 
1. Forsyth County Mental Health 725-7777 
725 Highland Avenue 
Winston-Salem, NC 
2.** Salem Psychiatric Associates 768-6930 
Charlois Boulevard 
Winston-Salem, NC 
3.** Charter Mandala Center 768-7710 
3637 Old Vineyard Road 
Winston-Salem, NC 
4. Spectrum 761-0650 
1111 Brookstown Avenue 
Winston-Salem, NC 
5. NOTE; Practicing psychiatrists and psychologists in the Winston-
Salem area can be found in the yellow pages of the phone book. 
Can request Dennis McKnight or other staff psychiatrist or 
psychologist. 
APPENDIX M 
TABLES 
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TABLE 1 
Descriptive Data on Subjects Completing the Study 
SUBJECT GROUP® YEARS FAMILY HISTORY? 
NUMBER NUMBER AGE EDUCATED OCCUPATION PREVIOUS TREATMENT YES or NO 
1 1 30 12 Housewife None No 
2 1 36 14 Salesperson Counseling No 
3 1 37 14 Unemployed None Yes 
4 1 28 12 Secretary None No 
5 1 30 13 Beautician None Yes 
6 1 28 15 Student None No 
7 1 41 16 Nurse Trial on Antidepressant No 
8 1 28 12 Housewife Short-Term Therapy No 
9 1 63 14 Retired None Yes 
10 1 37 13 Housewife None No 
11 1 38 13 Secretary Counseling No 
12 1 48 14 Unemployed None Yes 
13 2 39 12 Secretary None Yes 
14 2 24 13 Secretary None Yes 
15 2 48 13 Health Professional None No 
16 2 52 13 Manager None No 
17 2 39 14 Unemployed Short-Term Therapy No 
18 2 36 12 Housewife None No 
19 2 35 14 Student Counseling Yes 
20 2 37 12 Secretary None Yes 
21 2 40 12 Housewife None No 
22 2 25 15 Student None Yes 
23 2 39 16 Salesperson Trial on Antidepressant No 
24 3 32 12 Housewife None No 
25 3 38 13 Clerical Worker Analysis No 
26 3 39 13 Clerical Worker None No 
27 3 26 14 Reservationist None No 
28 3 33 12 Housewife Short-Term Therapy Yes 
29 3 38 13 Secretary None Yes 
30 3 42 13 Secretary None Yes 
31 3 45 15 Computer Operator Counseling No 
32 3 50 14 Salesperson None No 
33 3 36 14 Health Professional None No 
34 4 37 15 Reservationist None Yes 
35 4 38 12 Clerical Worker Trial on Antidepressant No 
36 4 32 16 Salesperson Counseling Yes 
37 4 35 13 Housewife None No 
38 4 37 12 Salesperson Trial on Antidepressant No 
39 4 38 14 Computer Operator None No 
40 4 45 14 Unemployed None No 
41 4 48 12 Housewife None Yes 
42 4 29 13 Secretary None No 
43 4 36 13 Secretary None No 
Group 1 » Normal DexameChasone Suppression Test; Cognitive Therapy 
Group 2 « Normal Dexamethasone Suppression Test; Antidepressant Therapy 
Group 3 • Abnormal Dexamethasone Suppression Test; Cognitive Therapy 
Group 4 • Abnormal Dexamethasone Suppression Test; Antidepressant Therapy 
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TABLE 2 
Sketch of Experimental Design 
TREATMENT GROUP PRE POST 
COGNITIVE 
THERAPY 
Normal Dexamethasone 
Suppression Test 
Abnormal Dexamethasone 
Suppression Test 
ANTIDEPRESSANT 
MEDICATION 
Normal Dexamethasone 
Suppression Test 
Abnormal Dexamethasone 
Suppression Test 
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TABLE 3 
Raw Scores on Global Depression Measures and Cognitive Measure 
SUBJECT GROUP PRE- POST PRE- POSI- PRE-. POST- PRE- POSI-
NUMBER NUMBER* MIPI-D MMPI-D BDIC BDIC DACL DACL PBI* PBI® 
1 1 38 19 33 5 22 3 3.0 2.8 
2 1 45 40 40 37 21 18 3.0 3.0 
3 1 38 21 28 0 18 5 3.2 1.8 
4 1 33 18 26 0 18 1 3.2 2.6 
5 1 38 19 28 0 19 2 3.4 2.4 
6 1 36 17 27 5 12 10 3.1 2.5 
7 1 35 27 30 15 20 1 3.1 2.6 
8 1 37 20 29 1 18 3 3.2 1.7 
9 1 40 22 30 10 20 5 3.3 2.0 
10 1 37 21 32 12 22 8 3.5 2.2 
•U 1 44 25 33 15 25 10 3.2 2.6 
12 1 34 27 29 19 20 13 2.1 2.3 
13 2 34 20 26 4 18 9 3.0 2.7 
14 48 36 34 19 22 10 3.1 3.0 
15 2 31 18 29 4 25 6 3.2 2.2 
16 2 41 33 33 13 27 10 3.0 2.3 
17 2 40 24 24 2 25 2 3.0 3.1 
18 2 41 27 24 7 21 10 3.0 3.2 
19 38 26 25 3 19 10 3.3 3.0 
20 35 21 27 12 20 8 3.1 2.8 
21 2 40 27 26 8 25 6 3.4 3.2 
22 2 42 34 28 6 22 5 3.0 2.3 
23 2 33 17 30 13 18 7 3.5 3.0 
24 3 35 35 29 30 20 20 3.0 3.3 
25 3 40 31 45 21 31 8 3.7 2.5 
26 3 43 39 40 15 28 20 3.0 3.0 
27 3 41 30 30 15 19 13 3.3 2.3 
28 3 40 31 28 18 21 21 3.6 3.4 
29 3 37 27 37 21 26 3 3.1 3.0 
30 3 39 28 40 20 20 20 3.0 2.9 
31 3 40 25 29 28 25 15 3.4 2.1 
32 ' 3 48 35 36 21 19 17 3.0 2.8 
33 3 34 21 43 19 18 13 3.2 2.1 
34 4 40 31 23 20 19 14 3.1 2.6 
35 4 41 28 33 5 21 4 3.0 2.9 
36 4 38 25 28 4 18 3 3.0 2.9 
37 4 35 24 24 14 23 7 3.0 2.9 
38 4 30 21 22 5 19 11 3.0 3.1 
39 4 42 29 25 22 20 15 3.2 3.1 
40 4 37 24 22 8 21 4 3.1 2.6 
41 4 40 31 27 21 19 14 3.0 2.3 
42 4 34 21 30 3 18 16 3.4 3.0 
43 4 36 23 27 23 23 15 3.5 3.1 
*Group 1 » Normal Dexamethasone Suppression Test; Cognitive Therapy 
Group 2 * Normal Dexameehasone Suppression Test; Antidepressant Therapy 
Croup 3 » Abnormal Dexamethasone Suppression Test; Cognitive Therapy 
Ĝroup 4 • Abnormal Dexamethasone Suppression Test; Antidepressant Therapy 
MMPI-D • Raw Scores from the Depression Scale of the Minnesota Multiphasic Personality Inventory 
B̂DI » Raw Scores from the Beclc Depression Inventory 
DACL » Raw Scores from the Lubin Depression Adjective Checklist 
FBI • Raw Scores from the Personal Beliefs Inventory 
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TABLE 4 
Diagnosis and Dexamechasone Suppression tesc Score on Subjects Completing Che Study 
PRE-DIAGNOSIS 
( ALL MAJOR ANTIDEPRESSANT 
DEPRESSIVES WITH OR MEDICATION 
NUMBER NUMBER WITHOUT MELANCHOLIA) POST-DIAGNOSIS PRE-DST POST-DST ADMINISTERED 
1 1 Without Melancholia Major Depression 
Wichouc Melancholia 
0.0 0.6 None 
2 1 Without Melancholia None 0.2 0.1 None 
3 1 Without Melancholia None 0.3 0.2 None 
4 1 Without Melancholia None 0.1 0.1 None 
5 1 Without Melancholia None 0.1 0.4 None 
6 1 Without Melancholia None 0.0 0.2 None 
7 1 Without Melancholia None 0.2 0.6 None 
8 1 Without Melancholia None 1.2 0.3 None 
9 1 Without Melancholia None 1.5 1.3 None 
10 1 Wlehouc Melancholia None 0.8 0.7 None 
11 1 Wichouc Melancholia None 1.0 0.8 None 
12 1 Without Melancholia None 0.9 0.7 None 
13 2 With Melancholia None 3.5 1.2 Elavil 
14 2 With Melancholia None 2.9 0.7 Elavil 
15 2 Without Melancholia None 0.0 3.6 Elavil 
16 2 Without Melancholia None 0.4 0.2 Deslpramine 
17 2 Without Melancholia None 0.4 0.7 Elavil 
18 2 Without Melancholia None 0.0 0.2 Deslpramine 
19 2 Without Melancholia None 1.2 0.0 Deslpramine 
20 2 Without Melancholia None 2.1 1.9 Elavil 
21 2 Without Melancholia None 1.7 1.6 Deslpramine 
22 2 Without Melancholia None 0.8 0.2 Elavil 
23 2 Without Melancholia None 0.1 0.1 Elavil 
24 3 With Melancholia Major Depression 
Wlch Melancholia 
6.1 2.5 None 
25 3 With Melancholia None 5.6 4.5 None 
26 3 Without Melancholia Major Depression 
Without Melancholia 
5.1 2.8 None 
27 3 With Melancholia None 5.7 5.4 None 
28 3 With Melancholia None 5.6 5.3 None 
29 3 With Melancholia None 5.8 5.7 None 
30 3 With Melancholia None 6.1 2.7 None 
31 3 Wlch Melancholia None 6.1 4.6 None 
32 3 With Melancholia Major Depression 
Without Melancholia 
5.8 5.8 None 
33 3 Wlch Melancholia None 5.9 5.7 None 
34 4 Wlch Melancholia None 5.7 5.1 Deslpramine 
35 4 Wichouc Melancholia None 5.4 6.1 Elavil 
36 4 Wichouc Melancholia None 5.3 0.4 Elavil 
37 4 Wichouc Melancholia None 5.1 1.9 Elavil 
38 4 Wlch Melancholia None 5.8 5.1 Elavil 
39 4 Wichouc Melancholia Major Depression 
Without Melancholia 
5.1 5.1 Elavil 
40 4 Wlch Melancholia None ' 6.0 3.4 Deslpramine 
41 4 Wlch Melancholia Major Depression 
Wichouc Melancholia 
5.7 4.1 Deslpramine 
42 4 Wichouc Melancholia None 5.3 0.9 Elavil 
43 4 Wlch Melancholia None 6.1 5.0 Deslpramine 
*Group 1 " Normal Dexamechasone Suppression Test; Cognitive Therapy 
Group 2 " Normal Dexamethasone Suppression Tesc; Antidepressant Therapy 
Group 3 " Abnormal Dexaaechasone Suppression Test; Cognitive Therapy 
Group h • Abnormal Dexamethasone Suppression Tesc: Antidepressant Theraoy 
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TABLE 5 
2 (Dexamethasone Suppression Test Result) x 2 (Treatment) 
Multivariate Analysis of Variance 
Using Difference Scores for the Global Measures of Depression 
SOURCE WILKS' LAMBDA df F £ 
Treatment .969 3,37 .39 .76 
Dexamethasone 
Suppression Test 
Result 
.747 3,37 4.17 .01* 
Treatment x 
Dexamethasone 
Suppression Test 
Result 
.904 3,37 1.31 .29 
Subject (Treatment 
x Dexamethasone 
Suppression Test) 
* p Z .05 
** p .01 
*** p .001 
**** p ̂  .0001 
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TABLE 6 
2 (Dexamethasone Suppression Test Result) x 2 (Treatment) 
Univariate Analysis of Variance on Difference Scores from the 
Depression Scale of the Minnesota Multiphasic Personality Inventory 
With Least Squared Means 
SOURCE df MS F 
Treatment 1 0.75 0.05 
Dexamethasone 1 117.53 7.90** 
Suppression Test 
Result 
Treatment x 1 49.2 3.30 
Dexamethasone 
Suppression Test 
Result 
Subject (Treatment 39 14.9 
x Dexamethasone 
Suppression Test) 
Least Squared Means 
Treatment 
Difference 
Scores 
PROB ̂  T 
H0:LS MEAN=0 
PROBST HO: 
LS MEAN 1=LS MEAN 2 
Cognitive Therapy 12.2 
Antidepressant 12.1 
Medication 
,0001**** 
.0001**** 
.9700 
Dexamethasone 
Suppression 
Test Result 
Difference 
Scores 
P R O B T  
HO:LS MEAN=0 
PROB-^T HO: 
LS MEAN 1=LS MEAN 2 
Normal 
Abnormal 
13.8 
10.5 
.0001**** 
.0001**** 
.0085** 
156 
TABLE 6 (Continued) 
Treatment 
Dexameth-
asone 
Suppres- Dif-
sion erence PROB—ik T PROB 
Test Scores HO:LS MEANS I/J 
HO: LS MEAN (I) = 
LS MEAN (J) 
Cognitive Normal 14.9 
Therapy(1) 
.0001**** .0022** .1816 .0515* 
Cognitive Abnormal 9.5 
Therapy(2) 
.0001**** .0628 .2307 
Antidepres- Normal 12.7 
sant Medi­
cation (3) 
.0001**** .5074 
Antidepres- Abnormal 11.6 
sant Medi­
cation (4) 
.0001**** 
* p .05 
** p .01 
*** p ̂  .001 
**** p .0001 
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TABLE 7 
Group Means for Pre-Intervention and Post-Intervention 
Raw Scores from the Depression Scale 
of the Minnesota Multiphasic Personality Inventory 
Group Pre 
1 
2 
3 
4 
X = 37.9 
X = 38.5 
X = 39.7 
X = 37.3 
X = 38.35 
Post 
X = 23.0 
X = 25.7 
X = 30.2 
X = 25.7 
X = 26.15 
X = 30.45 
X = 32.1 
X = 34.95 
X = 31.5 
X = 32.25 
aGroup 1 = Normal Dexamethasone Suppression Test; Cognitive Therapy 
Group 2 = Normal Dexamethasone Suppression Test; Antidepressant Therapy 
Group 3 = Abnormal Dexamethasone Suppression Test; Cognitive Therapy 
Group 4 = Abnormal Dexamethasone Suppression Test; Antidepressant Therapy 
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TABLE 8 
2 (Dexamethasone Suppression Test Result) x 2 (Treatment) 
Univariate Analysis of Variance on Difference Scores 
from the Beck Depression Inventory 
With Least Squared Means 
SOURCE df MS F 
Treatment 1 19.2 .30 
Dexamethasone 1 344.9 5.42* 
Suppression Test 
Result 
Treatment x 1 .07 0.00 
Dexamethasone 
Suppression Test 
Result 
Subject (Treatment 39 63.7 
x Dexamethasone 
Suppression Test) 
Least Squared Means 
Treatment 
Difference 
Scores 
PROBA T 
HO:LS MEAN=0 
PROB At HO: 
LS MEAN 1=LS MEAN 2 
Cognitive Therapy 17.7 
Antidepressant 16.5 
Medication 
.0001**** 
.0001**** 
.62  
Dexamethasone 
Suppression 
Test Result 
Difference 
Scores 
PROB A T 
HO:LS MEAN=0 
PROB At HO: 
LS MEAN 1=LS MEAN 2 
Normal 
Abnormal 
19.9 
14.2 
.0001**** 
.0001**** 
.02* 
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TABLE 8 (Continued) 
Dexameth-
asone 
Suppres- Dif-
sion erence PROBST PROB HO: LS MEAN (I) = 
Treatment Test Scores HO;LS MEANS I/J LS MEAN (J) 
Cognitive Normal 20.5 .0001**** 1 .1092 .7348 .0503* 
Therapy(1) 
Cognitive Abnormal 14.9 .0001**** 2 .2080 .7176 
Therapy(2) 
Antidepres­ Normal 19.4 .0001**** 3 .1063 
sant Medi­
cation (3) 
Antidepres­ Abnormal 13.6 .0001**** 4 
sant Medi­
cation (4) 
* p Z. .05 
** p ̂  .01 
*** p .001 
**** p y .0001 
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TABLE 9 
Group Means for Pre-Intervention and Post-Intervention 
Scores on the Beck Depression Inventory 
Groupa Pre Post 
1 X 
= 
30.4 X = 9.9 X = 20.15 
2 X = 27.8 X = 8.4 X = 18.10 
3 X = 35.7 X = 20.8 X 
= 
28.75 
4 X 
= 
26.1 X = 12.5 X = 19.30 
X = 30.0 X = 12.9 X 
= 
21.45 
aGroup 1 = Normal Dexamethasone Suppression Test; Cognitive Therapy 
Group 2 = Normal Dexamethasone Suppression Test; Antidepressant Therapy 
Group 3 = Abnormal Dexamethasone Suppression Test; Cognitive Therapy 
Group 4 = Abnormal Dexamethasone Suppression Test; Antidepressant 
Therapy 
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TABLE 10 
2 (Dexamethasone Suppression Test Result) x 2 (Treatment) 
Univariate Analysis of Variance on Difference Scores 
from the Depression Adjective Checklist 
With Least Squared Means 
SOURCE df MS F 
Treatment 1 14.1 .38 
Dexamethasone 
Suppression Test 
Result 
1 317.8 8.46** 
Treatment x 
Dexametha sone 
Suppression Test 
Result 
1 6.5 .17 
Subject (Treatment 
x Dexamethasone 
Suppression Test) 
39 37.6 
Least Squared Means 
Treatment 
Difference 
Scores 
PROB A T 
HO:LS MEAN=0 
PROB 
LS MEAN 
A T 
1=LS 
HO: 
MEAN 2 
Cognitive Therapy 
Antidepressant 
Medication 
10.8 
12.1 
.0001**** 
.0001**** 
.48 
Dexametha sone 
Suppression 
Test Result 
Difference 
Scores 
PROB A T 
HO:LS MEAN=0 
PROB 
LS MEAN 
AT 
1=LS 
HO: 
MEAN 2 
Normal 
Abnormal 
14.2 
8.7 
.0001**** 
.0001**** 
.0061** 
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TABLE 10 (Continued) 
Dexameth-
asone 
Suppres- Dif-
sion erence PROB T PROB 
Treatment Test Scores HO:LS MEANS I/J 
HO: LS MEAN (I) = 
LS MEAN (J) 
Cognitive Normal 13.9 .0001**** 
Therapy(1) 
Cognitive Abnormal 7.7 .0003**** 
Therapy(2) 
Antidepres- Normal 19.4 
sant Medi­
cation (3) 
,0001**** 
.0229* .8346 .1248 
.0159**.4482 
.0901 
Antidepres- Abnormal 13.6 
sant Medi­
cation (4) 
.0001**** 
* p Z .05 
** p .01 
*** p .001 
**** p ^ .0001 
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TABLE 11 
Group Means for Pre-Intervention and Post-Intervention 
Scores on the Lubin Depression Adjective Checklist 
Group5 Pre Post 
1 X = 20.5 X 
= 6.6 X = 13.55 
2 X = 22.0 X = 7.5 X = 14.75 
3 X = 22.7 X = 15.0 X = 18.85 
4 X = 20.1 X = 10.3 X = 15.20 
X 
= 
21.33 X = 9.85 X — 15.59 
aGroup 1 = Normal Dexamethasone Suppression Test; Cognitive Therapy 
Group 2 = Normal Dexamethasone Suppression Test; Antidepressant Therapy 
Group 3 = Abnormal Dexamethasone Suppression Test; Cognitive Therapy 
Group 4 = Abnormal Dexamethasone Suppression Test; Antidepressant 
Therapy 
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TABLE 12 
2 (Dexamethasone Suppression Test Result) x 2 (Treatment) 
Univariate Analysis of Variance on Difference Scores 
from the Personal Beliefs Inventory 
With Least Squared Means 
SOURCE df MS F 
Treatment 1 1.35 6.92** 
Dexamethasone 
Suppression Test 
Result 
1 .42 2.17 
Treatment x 
Dexamethasone 
Suppression Test 
Result 
1 . .18 .94 
Subject (Treatment 
x Dexamethasone 
Suppression Test) 
39 .19 
Least Squared Means 
Treatment 
Difference 
Scores 
PROB T 
HO:LS MEAN=0 
P R O B T  
LS MEAN 1=LS 
HO: 
MEAN 2 
Cognitive Therapy 
Antidepressant 
Medication 
.65 
.31 
.0001**** 
.0024**** 
.01** 
Dexamethasone 
Suppression 
Test Result 
Difference 
Scores 
PROB T 
HO:LS MEAN=0 
PROB T 
LS MEAN 1=LS 
HO: 
MEAN 2 
Normal 
Abnormal 
.58 
.38 
.0001**** 
.0004**** 
.1542 
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TABLE 12 (Continued) 
Dexameth-
asone 
Suppres- Dif-
sion erence PROBST PROB HO: LS MEAN (I) = 
Treatment Test Scores HO;LS MEANS I/J LS MEAN (J) 
Cognitive 
Therapy(1) 
Normal .81 .0001**** 1 .0916 .0145** .0071** 
Cognitive 
Therapy(2) 
Abnormal .49 .0011*** 2 .4578 .2936 
Antidepres­
sant Medi­
cation (3) 
Normal .34 .0132** 3 .7360 
Antidepres­
sant Medi­
cation (4) 
Abnormal .28 .0517* 4 
* p ̂  .05 
** p .01 
*** p Z. .001 
**** p ̂  .0001 
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TABLE 13 
Group Means for Pre-Intervention and Post-Intervention 
Scores on the Personal Beliefs Inventory 
Group5 Pre Post 
1 X = 3.2 X = 2.4 X = to
 
• 00
 
2 X = 3.1 X = 2.8 X = 2.95 
3 X = 3.2 X = 2.7 X 
= 
2.95 
4 X = 3.1 X = 2.8 X = 2.95 
X = 3.15 X = 2.67 X = 2.95 
aGroup 1 = Normal Dexamethasone Suppression Test; Cognitive Therapy 
Group 2 = Normal Dexamethasone Suppression Test; Antidepressant Therapy 
Group 3 = Abnormal Dexamethasone Suppression Test; Cognitive Therapy 
Group 4 = Abnormal Dexamethasone Suppression Test; Antidepressant 
Therapy 
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TABLE 14 
One-Way (Treatment) Analysis of Variance With Least Squared Means 
on Difference Scores for Subjects With 
Normal Dexamethasone Suppression Test Results 
SOURCE df MS F 
Treatment 1 .279 .22 
Subjects (Treatment) 21 1.24 
Least Squared Means 
Difference PROBST PROB-^T HO: 
Treatment Scores HOsLS MEAN=0 LS MEAN 1=LS MEAN 2 
Cognitive Therapy .025 .9388 .6403 
Antidepressant .245 .4729 
Medication 
* p ̂  .05 
** p ̂  .01 
*** p Z .001 
**** p .0001 
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TABLE 15 
One-way (Treatment) Analysis of Variance With Least Squared Means 
on Difference Scores for Subjects With 
Abnormal Dexamethasone Suppression Test Results 
SOURCE df MS F 
Treatment 1 1.57 .58 
Subjects (Treatment) 18 2.70 
Least Squared Means 
Difference PROBĴ .T PROBST HO: 
Treatment Scores HO;LS MEAN=0 LS MEAN 1=LS MEAN 2 
Cognitive Therapy 1.28 .0242* .4565 
Antidepressant 1.84 .0024** 
Medication 
* p ̂  .05 
** p .01 
*** p /- .001 
**** p .0001 
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TABLE 16 
Group Means for Pre-Intervention and Post-Intervention 
Scores from the Dexamethasone Suppression Test 
Groupa Pre Post 
1 X 
= C
N
 in • X 
= O
 
in • X 
= .51 
2 X = 1.2 X = .94 X = 1.07 
3 X = 5.8 X 
= 
4.5 X = 5.15 
4 X = 5.5 X = 3.7 X = 4.60 
X = 3.25 X = 2.41 X = 2.83 
aGroup 1 = Normal Dexamethasone Suppression Test; Cognitive Therapy 
Group 2 = Normal Dexamethasone Suppression Test; Antidepressant Therapy 
Group 3 = Abnormal Dexamethasone Suppression Test; Cognitive Therapy 
Group 4 = Abnormal Dexamethasone Suppression Test; Antidepressant 
Therapy 
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TABLE 17 
2 (Presence or Absence of Melancholia) x 2 (Treatment) 
Multivariate Analysis of Variance 
Using Difference Scores for the Global Measures of Depression 
SOURCE WILKS' LAMBDA df F p 
Treatment .966 3,37 .43 .73 
Presence or .764 3,37 3.81 .01** 
Absence of 
Melancholia 
Treatment x .966 3,37 .43 .73 
Presence or 
Absence of 
Melancholia 
Subject (Treatment 
x Presence or 
Absence of Melancholia) 
* p Z .05 
* * p /  .0 1  
*** p Z .001 
**** p Z. .0001 
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TABLE 18 
2 (Presence or Absence of Melancholia) x 2 (Treatment) 
Univariate Analysis of Variance on Difference Scores from the 
Depression Scale of the Minnesota Multiphasic Personality Inventory 
With Least Squared Means 
SOURCE df MS 
Treatment 
Presence or 
Absence of 
Melancholia 
Treatment x 
Presence or 
Absence of 
Melancholia 
Subject (Treatment 
x Presence or 
Absence of Melancholia) 
1 
1 
39 
.75 .04 
75.3 4.49* 
16.9 
16.8 
.32 
Least Squared Means 
Difference PROB At PROB A.T HO: 
Treatment Scores HO:LS MEAN=0 LS MEAN 1=LS MEAN 2 
Cognitive Therapy 12.1 .0001**** .9210 
Antidepressant 11.9 .0001**** 
Medication 
Difference PROB A T PROB A. T HO: 
Melancholia Scores HO:LS MEAN=0 LS MEAN 1=LS MEAN 2 
Without 13.6 .0001**** .0473* 
With 10.7 .0001**** 
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TABLE 18 (Continued) 
Melan- erence PROBST PROB HO: LS MEAN (I) = 
Treatment cholia Scores HO:LS MEANS I/J LS MEAN (J) 
Cognitive 
Therapy(1) 
Without 14.1 .0001**** 1 .0314* .3690 .1541 
Cognitive 
Therapy(2) 
With 10.1 .0001**** 2 .1560 .5726 
Antidepres­
sant Medi­
cation (3) 
Without 11.3 .0001**** 3 .4784 
Antidepres­
sant Medi­
cation (4) 
With 11.3 .0001**** 4 
* p Z .05 
»* p Z. .01 
*** p .001 
**** p J- .0001 
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TABLE 19 
2 (Presence or Absence of Melancholia) x 2 (Treatment) 
Univariate Analysis of Variance on Difference Scores 
from the Beck Depression Inventory 
With Least Squared Means 
SOURCE df MS 
Treatment 
Presence or 
Absence of 
Melancholia 
Treatment x 
Presence or 
Absence of 
Melancholia 
Subject (Treatment 
x Presence or 
Absence of Melancholia) 
1 
1 
39 
19.2 
532.6 
.63 
58.8 
.33 
9.05** 
.01 
Least Squared Means 
Difference PROB Jh>T PROBST HO: 
Treatment Scores HOtLS MEAN=0 LS MEAN 1=LS MEAN 2 
Cognitive Therapy 17.3 .0001**** .4265 
Antidepressant 15.4 .0001**** 
Medication 
Difference PROB T PROB AT HO: 
Melancholia Scores HOtLS MEAN=0 LS MEAN 1=LS MEAN 2 
Without 19.9 .0001**** .0046** 
With 12.7 .0001**** 
TABLE 19 (Continued) 
Melan- erence PROB \T  PROB HO: LS MEAN (I) = 
Treatment cholia Scores HO;LS MEANS I/J LS MEAN (J) 
Cognitive 
Therapy(1) 
Without 20.8 .0001**** 1 .0314* .5676 .0138** 
Cognitive 
Therapy(2) 
With 13.7 .0001**** 2 .1097 .5714 
Antidepres­
sant Medi­
cation (3) 
Without 19.1 .0001**** 3 .0393* 
Antidepres­
sant Medi­
cation (4) 
With 11.6 .0003**** 4 
* p /L .05 
** p .01 
*** P .001 
**** p jL. .0001 
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TABLE 20 
2 (Presence or Absence of Melancholia) x 2 (Treatment) 
Univariate Analysis of Variance on Difference Scores 
from the Lubin Depression Adjective Checklist 
With Least Squared Means 
SOURCE df MS 
Treatment 
Presence or 
Absence of 
Melancholia 
1 
1 
14.1 
275.8 
.37 
7.12** 
Treatment x 
Presence or 
Absence of 
Melancholia 
Subject (Treatment 
x Presence or 
Absence of Melancholia) 
39 
3.29 
38.7 
.09 
Least Squared Means 
Difference PROB •It PROB -X T HO: 
Treatment Scores H0:LS MEAN=0 LS MEAN 1=LS MEAN 2 
Cognitive Therapy 10.6 .0001**** .6509 
Antidepressant 11.5 .0001**** 
Medication 
Difference PROB Jik T PROB -^T HO: 
Melancholia Scores HO:LS MEAN=0 LS MEAN 1=LS MEAN 2 
Without 13.6 .0001**** .0117** 
With 8.4 .0001**** 
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TABLE 20 (Continued) 
Treatment 
Dif-
Melan- erence PROB —X T PROB 
cholia Scores HO;LS MEANS I/J 
Cognitive Without 13.4 
Therapy (1) 
Cognitive With 7.6 
Therapy(2) 
Antidepres- Without 13.8 
sant Medi­
cation (3) 
HO: LS MEAN (I) = 
LS MEAN (J) 
Antidepres- With 
sant Medi­
cation (4) 
9.1 
.0001**** 
.0007**** 
.0001**** 
.0004**** 
.0380* .8931 .1468 
.0268*.6405 
.1151 
* p ̂  .05 
** p .01 
*** p ̂  .001 
**** p ̂  .0001 
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TABLE 21 
2 (Presence or Absence of Melancholia) x 2 (Treatment) 
Univariate Analysis of Variance on Difference Scores 
from the Personal Beliefs Inventory 
With Least Squared Means 
SOURCE df MS 
Treatment 
Presence or 
Absence of 
Melancholia 
Treatment x 
Presence or 
Absence of 
Melancholia 
Subject (Treatment 
x Presence or 
Absence of Melancholia) 
1 
1 
39 
1.34 6.60** 
.08 .41 
..16 
.20 
,78 
Least Squared Means 
Difference PROB JS T PROB A.T HO: 
Treatment Scores H0:LS MEAN=0 LS MEAN 1=LS MEAN 2 
Cognitive Therapy .65 .0001**** .0276* 
Antidepressant .32 .0038** 
Medication 
Difference PROB_\T PROBST HO: 
Melancholia Scores HO:LS MEAN=0 LS MEAN 1=LS MEAN 2 
Without .53 .0001**** .5643 
With .44 .0004*** 
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TABLE 21 (Continued) 
Treatment 
Melan­
cholia 
Dif-
erence 
Scores 
PROB T 
HOsLS MEANS 
PROB HO: 
I/J 
LS MEAN (I) = 
LS MEAN (J) 
Cognitive 
Therapy(1) 
Without .75 .0001**** 1 . 2914 .0128*.0594* 
Cognitive 
Therapy(2) 
With .54 .0008*** 2 .2126 .3811 
Antidepres­
sant Medi­
cation (3) 
Without .30 .0173** 3 .8386 
Antidepres­
sant Medi­
cation (4) 
With .34 .0515* 4 
* p .05 
** p ̂  .01 
*** p ̂  .001 
**** p .0001 
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TABLE 22 
One-way (Treatment) Analysis of Variance With Least Squared Means 
on Difference Scores from the Dexamethasone Suppression Test 
for Subjects Without Melancholia 
SOURCE df MS F 
Treatment 1 1.8 .65 
Subjects (Treatment) 25 2.7 
Least Squared Means 
Difference PROB ̂ T PROB HO: 
Treatment Scores HO;LS MEAN=0 LS MEAN 1=LS MEAN 2 
Cognitive Therapy .20 .6664 .4269 
Antidepressant .71 .1185 
Medication 
* p Z. .05 
** p ̂  .01 
*** P .001 
**** p .0001 
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TABLE 23 
One-Way (Treatment) Analysis of Variance With Least Squared,Means 
on Difference Scores from the Dexamethasone Suppression Test 
for Subjects With Melancholia 
SOURCE df MS F 
Treatment 1 .69 .49 
Subjects (Treatment) 14 1.42 
Least Squared Means 
Difference PROB A T  PROB X T  HO: 
Treatment Scores HOsLS MEAN=0 LS MEAN 1=LS MEAN 2 
Cognitive Therapy 1.2 .0108** .4966 
Antidepressant 1.6 .0034** 
Medication 
* p .05 
** p Z- .01 
*** p .001 
**** p zl .0001 
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APPENDIX N 
Consent for Use of Audio-Tapes 
Dennis L. McKnight, M.A., has my permission to use audio-tapes that will 
be made while I am participating in the research involving the 
assessment and treatment of depression for purposes of psychiatric/ 
psychological research, professional training, or professional 
consultation. I understand that undergraduate or graduate studens 
enrolled in psychology courses at UNC-G may view or listen to my tapes 
for these purposes. 
I further understand that other than for the purposes above, these 
recordings will be treated as strictly private and confidential 
material. In addition, I also understand that at no time will these 
audio-tapes be identified by my name. 
I hereby expressly waive any possible claim on my part to damages in any 
form in connection therewith. 
Signature: 
Witness: 
Date: 
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APPENDIX O 
COGNITIVE-BEHAVIORAL APPROACH TO TREATING DEPRESSION 
Session #1 
Steps 
1. Therapist introduces himself and reviews treatment contract 
that was agreed on during the last screening interview. 
2. The agenda for the first session is outlined, and includes the 
following: 
a. Description of the therapy used in this project. 
b. Allowing the client an opportunity to describe the 
problems which were involved in his/her decision to 
participate in this project (e.g., problems related to 
their depression). 
c. Emphasizing in this therapy the learning of a skill 
(detecting, monitoring and correcting dysfunctional 
thoughts) to cope with depression. 
d. Preparing the subject to do the assigned homework. 
3. The therapist gives a general rationale and description of 
cognitive-behavioral therapy, focusing on the following points: 
a. The treatment to be received in this project is called 
cognitive-behavioral therapy. 
b. Main idea is: What people think influences the way they 
feel and the way they behave. 
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c. This therapy assumes that as depressed people develop, 
they learn to take a negative view of themselves (e.g., 
"I'm no good"), of the world (e.g., "The world's 
unfair"), and of the future (e.g., "Things won't work 
out"). 
d. Within this negative view, a depressed person has certain 
assumptions they utilize when stressed, and these 
assumptions influence the way depressed people deal with 
the world and what they think of themselves (e.g., "I'm 
not good at anything", "I can't get along with anybody"). 
e. These assumptions are unique to each depressed 
individual. 
f. Although depression is a serious disorder, research has 
suggested that cognitive-behavioral therapy is an 
effective treatment approach. 
g. Finally, the therapist again covers issues of 
confidentiality, as was done in the screening sessions. 
4. The therapist provides a rationale for homework; 
a. Homework is a vital part of therapy, and there is some 
suggestion that homework is instrumental in maintaining 
client's improvement after termination. 
b. Homework allows clients to practice what they learn in 
the session in their every day world. 
c. Homework provides useful information for the sessions, 
such as the client's weekly activities and how the 
therapy is progressing. 
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d. Completing the homework is vital to the therapy and the 
research project. The contract concerning the deposit 
and payback for homework and attendance is stressed. 
5. Subject is asked to describe problems associated with their 
depression, and their decision to participate in the research project. 
6. The therapist introduces the concepts "cognition" and 
"automatic thoughts" by stating that treatment will begin by learning a 
new skill (e.g., to detect and to self-monitor automatic thoughts). The 
therapist notes that the first two sessions will be spent learning to 
detect and monitor automatic thoughts. The last six sessions will be 
spent learning skills to cope with negative automatic thoughts. 
a. A "cognition" is defined as either a thought or a visual 
image that you may not be very aware of unless you focus 
your attention on it. In depression, these cognitions 
are called "automatic thoughts" and have a negative 
theme. Some characteristics of automatic thoughts are as 
follows: 
1. They are automatic, in other words they just seem to 
occur. 
2. They are based on a low opinion of oneself. 
3. They are unreasonable, inaccurate, and dysfunctional 
although they seem plausible at the time—the more 
one believes them, the more discomfort they cause. 
4. They are involuntary, in other words one has 
difficulty turning them off. 
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The therapist further elaborates the relationship between 
thoughts, feelings, and behavior. 
1. Therapist illustrates relationship by contrasting 
differences between thoughts and feelings when one 
is at home alone in the evening and hears a noise 
and thinks, "It's a burglar" vs. "It's my spouse". 
2. The therapist asks client to shut eyes and imagine 
an unpleasant scene and note her emotional response. 
Therapist gives some instruction with pleasant scene 
and stresses contrast. 
3. Other examples of negative automatic thoughts may 
be: 
a. "Being depressed means I'm weak." 
b. "I should be able to solve this alone." 
c. "I'll never meet all the requirements of the 
project." 
d. "The therapist probably won't like me." 
The therapist gives the following to aid in identifying 
automatic thoughts: 
1. Increases in negative and positive emotions. 
2. Troublesome life situations or events. 
Therapist attempts to elicit automatic thoughts from 
client by asking, "Would you share the thoughts you had 
prior to the session today?" (Can be related to the 
session today or the client's depression.) 
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7. Therapist provides rationale for the following homework 
assignment (e.g., self-monitoring automatic thoughts) and passes out 
Daily Record of Dysfunctional Thoughts—Form I (one record for each day; 
one completed sample record). 
a. Automatic thoughts are the core of cognitive-behavior 
therapy, so it is important to identify them. The Daily 
Record of Dysfunctional Thoughts—Form I will aid in 
meeting this goal. 
b. This form should be completed every day each time your 
emotions change (e.g., feel happy or sad, calm or 
anxious) or each time you experience depression. Ideally 
the form should be completed when the automatic thoughts 
occur; however, if this is impossible, you need to have a 
standard time each day (e.g., 15 minutes after supper) to 
complete the form. You will need to make several entries 
each day since we will use this information during the 
next session. 
c. Therapist explains how to complete all parts of the Daily 
Record of Dysfunctional Thoughts—Form II by referring to 
sample form he passes out. 
1. A positive or negative change in emotion or a 
depressed mood is a cue to complete the form. 
Therefore, complete the "emotion" column first 
(e.g., describe emotion and rate its degree). 
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2. Fill in the date. 
3. Complete the "situation" column (e.g., describe 
event and thoughts preceding the emotion). 
4. Complete the "automatic thoughts" column (e.g., 
describe the negative thoughts that preceded the 
emotion and rate its believability). 
d. Therapist answers questions and has client practice 
several examples. 
8. The therapist raises the issue that negative automatic 
thoughts can occur during treatment. For example, negative thoughts may 
occur in relation to the treatment sessions, the therapist, or the 
homework. If such automatic thoughts occur, it is important that you 
record them and bring them and bring them up for us to discuss. 
a. The therapist attempts to elicit examples from the 
client. 
b. The therapist provides typical examples taken from Beck, 
Rush, Shaw, and Emery et al., 1979, Chapter 14. See 
Handout entitled "Examples of Negative Automatic Thoughts 
Regarding Therapy." 
c. The client discusses negative automatic thoughts 
concerning therapy from both sources a and b. 
9. The therapist asks each client to describe her thoughts 
regarding the homework assignment. 
•* 
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Session #2 
1. The therapist reviews the last session along with the homework 
and praises her completion of the task. (If a client did not complete 
the task, she is instructed to make at least three entries relevant to 
dysphoric mood or positive or negative change in affect.) The therapist 
administers the Depression Adjective Checklist. (Allow 5 minutes.) 
2. The therapist outlines the following agendas 
a. Introduction to new concepts—depressive assumptions. 
1. What they are. 
2. How to identify them. 
b. Review of homework. 
1. Individual identified themes. 
2. Client learns how to identify logical errors in an 
effort to identify depressive assumptions. 
3. Individual identifies assumptions. 
c. Assign homework. (Allow 5 minutes.) 
3. The therapist defines, describes, and stresses the importance 
of depressive assumptions: Faulty assumptions appear to be involved in 
the likelihood that a person will become depressed. It is important 
that we detect these faulty assumptions to decrease the chance that you 
will become depressed in the future. In order to identify these 
depressive assumptions, we will pay particular attention to the 
automatic thoughts which you have recorded. Often common "themes" can 
be identified from the automatic thoughts. Yet, every person has her 
own set of assumptions which they probably learned during childhood from 
their parents or peers. For example, a parent may say to the child, 
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"Be nice or Nancy won't like you." After repeating such phrases the 
child may develop a more general rule: "My worth depends on what others 
think of me." Examples of faulty assumptions that increase the chance 
that a person will become depressed include (from Beck et al., 1979): 
a. "In order to be happy, I have to be successful in 
whatever I undertake." 
b. "To be happy, I must be accepted by all people at all 
times." 
c. "If I make a mistake, it means that I am inept." 
d. "I can't live without you." 
e. "If somebody disagrees with me, it means he doesn't like 
me." 
f. "My value as a person depends on what others think of 
me." (Allow 10 minutes.) 
4. The therapist introduces aids for identifying depressive 
assumptions: "In identifying depressive assumptions it helps to use the 
following steps: 
a. Monitor automatic thoughts. 
b. Identify them. 
c. Infer the primary assumption or rule. 
Therapist provides illustration). For example, one client 
reported these automatic thoughts. "My work is of poor 
quality. I can't fix the bicycle. I can't cut the grass. I 
can't make a sale. The wallpaper wasn't lined up well." 
d. What are the themes? (Performance and perfectionistic 
standards.) 
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e. What is a possible primary assumption? (My worth depends 
on the quality of my work.) (Allow 5 minutes.) 
5. The therapist introduces the next exercise. "We will use 
these steps (4a-c) to help you identify your depressive assumptions." 
It is important to be looking for "signals" that depressive assumptions 
may be occurring. Helpful signals include: 
a. The frequent use of global, vague words (e.g., stupid, 
silly, dumb). 
b. "Absolute words" (e.g., never, always, should). 
c. "Logical errors" or "thinking errors." 
Therapist passes out hand-out entitled, "Logical Errors or 
Thinking Errors" and discusses it. (Allow 15 minutes.) 
6. The therapist suggests that the client share her Daily Record 
of Dysfunctional Thoughts using the following framework: 
a. Look back over your homework and identify any common 
themes and/or assumptions. (If necessary, 
self-monitoring from Session 1 and 2 can also be 
reviewed.) 
b. Try to identify signals of depressive assumptions. 
c. On a piece of paper, we'll fill in this diagram for each 
person: 
1. emotions 
2. automatic thoughts 
3. themes 
4. depressive assumptions 
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d. Subjects are instructed to copy their diagram on the back 
of a Daily Record of Dysfunctional Thoughts. 
If a client gets "stumped," the following questions may be 
helpful: 
1. What made you particularly happy or unhappy about this 
event? (e.g., "I did well because someone praised me.") 
2. How do you look at the behavior of others? (e.g., "Mary 
is happy because she has a husband.") 
3. How are you justifying your feelings? (e.g., "Anyone who 
always makes mistakes would feel this depressed.") 
(Allow 45 minutes.) 
7. The therapist collects Daily Record of Dysfunctional 
Thoughts—Form I and passes out blank records. The therapist instructs 
the client to continue to complete the forms as usual, but at the end of 
each day, on the back of the form, identify: 
a. Common themes. 
b. Depressive assumptions. (Allow 5 minutes.) 
Session #3 
1. The therapist collects the client's homework from the previous 
session. The therapist praises the completion of this task. The 
therapist reviews the client's homework (also praising completion). If 
a client did not complete the homework assignment, she is instructed to 
make at least three entries relevant to dysphoric mood or positive or 
negative change in affect. The therapist administers the Depression 
Adjective Checklist. (Allow 15 minutes.) 
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2. The therapist outlines the following agenda for this session: 
a. Description of next stop in therapy—evaluating and 
correcting dysfunctional thoughts. 
b. Group discussion of alternative explanations using 
negative expectations about therapy as an example. 
c. Review homework looking for alternative explanations or 
for negative thoughts. 
d. Assign homework. (Allow 5 minutes.) 
3. The therapist describes the next step in treatment: We have 
been practicing and will continue to practice detecting automatic 
thoughts and depressive assumptions because we think that there is a 
relationship between feeling depressed and looking at the self, the 
world, and the future in a negative manner. However, just as important 
as the skill of identifying depressive thoughts and assumptions is the 
skill of correcting them. The goal of this step in therapy is for you 
to examine the evidence for and against your thoughts, using standards 
which a nondepressed person would use. Some of the steps which are 
important in correcting negative automatic thoughts include: 
a. Recognizing that thoughts and beliefs are inferences 
about the would rather than facts. 
b. Examining the logical evidence for and against the 
thought or belief. 
c. Providing an alternative response to the negative 
cognition. (Allow 10 minutes.) 
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4. The therapist begins discussion of some of the negative 
thoughts which may occur in relation to therapy: In Session 1 we noted 
that negative automatic thoughts can occur in relation to therapy, the 
therapist, or homework. 
a. What were some of the examples we raised? (If needed, 
the therapist refers to the Handout entitled "Examples of 
Negative Automatic Thoughts Regarding Therapy.") 
b. What evidence is there to support and to refute the 
thought? 
c. What are some alternative explanations for each thought? 
(See Chapter 14 in Beck et al., 1979, for alternative 
explanations.) 
For example, regarding the following negative automatic 
thought: "You are more interested in doing research than in 
helping me": 
1. Evidence to support—the project does involve 
research. Evidence to refute—the research and the 
treatment are not incompatible. 
2. Alternative response—"My participation in this 
research- treatment project stands to help me and to 
help others as researchers learn more about 
depression, its assessment, and treatment." (Allow 
15 minutes.) 
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5. The therapist suggests that the client share her Daily Record 
of Dysfunctional'Thoughts using the following framework: 
a. Identify your negative automatic thoughts. 
b. Describe the evidence you have to support and to refute 
the thoughts. 
c. Suggest an alternative interpretation for your negative 
automatic thoughts. 
If you get "stumped" in suggesting an alternative response, 
the following questions may aid you: 
1. What part of this situation is a fact and what part 
is my belief? 
2. How would a nondepressed person evaluate this event? 
3. Even if it is true, is it as bad as it seems? 
Note: Again the therapist's major activity is asking 
questions rather than making statements. (Allow 30 minutes.) 
6. The therapist collects Daily Record of Dysfunctional 
Thoughts—Form I and passes out the Daily Record of Dysfunctional 
Thoughts—Form II. Therapist passes out a completed sample of Form II. 
Therapist instructs clients to: 
a. Complete this form every day each time you feel sad and 
depressed or each time your emotions change. Ideally the 
form should be completed when the automatic thoughts 
occur; however, if this is impossible you need to have a 
standard time each day (e.g., 15 minutes after supper) to 
complete the form. You need to make several entries each 
day since we will use these data in the next session. 
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(See Session #1 for directions on how to complete the 
first four columns of the Daily Record of Dysfunctional 
Thoughts.) 
b. Provide a "RATIONAL RESPONSE" to each automatic thought 
and to rate the believability of the response. 
(Therapist reminds group of questions to aid alternative, 
rational response.) 
c. Write the "OUTCOME" of the automatic thought (i.e., 
re-rate believability and emotion.) 
d. Therapist explains how to complete all parts of the form 
by reviewing the sample; answers questions; has the group 
practice one entry. (For a - c allow 15 minutes.) 
Session #4 
1. The therapist reviews the client's homework and praises her 
completion of the task. (If a client did not complete the task, she is 
instructed to make at least three entries relevant to dysphoric mood or 
positive or negative change in affect and to supply the rational 
responses to go with each negative automatic thought.) The therapist 
administers the Depression Adjective Checklist. (Allow 5 minutes.) 
2. The therapist outlines the following agenda: 
a. Review the steps of and rationale for providing 
alternatives to automatic thoughts. 
b. Review depressive assumptions acknowledging the fact that 
they are difficult to give up, but suggesting skills for 
coping with depressive assumptions. 
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c. Review homework; identify depressive assumptions from 
homework, their pros and cons and long-term and 
short-term consequences; supply alternatives. 
d. Assign homework. (Allow 5 minutes.) 
3. The therapist begins review of the skills covered in Session 
#3: During the last session we focused on correcting negative automatic 
thoughts. As a brief review, I wonder if you could tell me: 
a. Why is it important to evaluate and to correct negative 
automatic thoughts? 
b. What are some of the steps involved in correcting 
negative automatic thoughts? 
c. What types of questions might you ask yourself if you 
have difficulty providing an alternative response to a 
negative authomatic thoughts? (Allow 10 minutes.) 
4. The therapist begins a review of depressive assumptions and 
the importance of evaluating them and providing alternative responses to 
them: During this session, we will apply the skills that we have been 
practicing to depressive assumptions. You may remember that depressive 
assumptions are important because their presence and use increases the 
likelihood that a person will become depressed. Some examples of the 
depressive assumptions we talked about included: "To be happy, I must 
be accepted by all people at all times." "If I make a mistake, it means 
that I an inept." We mentioned that the following cues often signal the 
presence of depressive assumptions: 
a. The frequent use of global, vague words (e.g., stupid, 
silly, dumb). 
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b. The frequent use of "absolutes" ( e . g . ,  should, ought, 
never). 
c. "Logical errors" (e.g., overgeneralization, 
magnification). 
In identifying depressive assumptions, we examined the common 
themes of negative automatic thoughts and inferred the 
depressive assumptions. (Allow 5 minutes.) 
5. The therapist provides rationale to be used in this session: 
Since depressive assumptions are important in the reoccurrence of 
depression, we are going to practice evaluating the logical evidence for 
and against the assumptions, and reevaluate the depressive assumptions. 
However, it is first important to recognize that it is difficult to 
"give up" an assumption or rule you have used your entire life which you 
may have learned from someone very significant to you. In order to cope 
with this reluctance we will examine the pros and cons, and the 
long-term and short-term consequences of each of the depressive thoughts 
that you identify. 
The therapist applies the above to the following depressive 
assumptions: "I'm only as good as my work." 
a. Short-term consequences: work hard, promoted. 
b. Long-term consequences: looses job, thinks he is a 
loser. 
c. Pros: encourage effort. 
d. Cons: insecure when job is insecure; effort seems 
motivated by fear. (Allow 5 minutes.) 
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6. The therapist suggest that each client share her Daily Record 
of Dysfunctional Thoughts using the following framework: 
a. Look back over your homework and identify any common 
themes and/or assumptions. 
b. The therapist and client fill in this diagram: 
1. emotions 
2. automatic thoughts 
3. themes 
4. depressive assumptions 
5. advantages of keeping this assumption 
6. disadvantages of keeping this assumption 
7. short-term effects of operating under this 
assumption 
8. long-term effects of operating under this 
assumption 
9. alternative assumption that is more useful than the 
depressive assumption. 
c. Subjects are instructed to copy their diagram on the back 
of a Daily Record of Dysfunctional Thoughts Form. 
Note: Again, the therapists asks many questions during this 
section and makes few statements. (Allow 55 minutes.) 
7. The therapist collects Daily Record of Dysfunctional 
Thoughts—Formli and passes out blank forms. The therapist instructs 
the client to continue to complete the forms as usual, but at the end of 
each day, on the back of the form, identify: 
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a. Common themes. 
b. Depressive assumptions. 
c. Alternatives to the depressive assumption. (Allow 5 
minutes.) 
Session #5 
1. The therapist reviews each client's homework, and praises her 
completion of the task. (If a client did not complete the task, she is 
instructed to make at least three entries relevant to dysphoric mood or 
positive or negative change in affect, to note the common themes and to 
infer the depressive assumptions, and to provide alternative rational 
responses to each automatic thought and depressive assumption.) The 
therapist administers the Depression Adjective checklist. (Allow 10 
minutes.) 
2. The therapist outlines the following agenda: 
a. Review logical errors. 
b. Describe the skills one can use to cope with logical 
errors. 
c. Review homework; look for logical errors; apply skills to 
cope with logical errors in offering alternative to 
negative automatic thoughts and depressive assumptions. 
(Allow 5 minutes.) 
3. The therapist begins a review of "logical errors" or "thinking 
errors"; In our early sessions, we discussed "logical errors" or 
"thinking errors" as signals of depressive assumptions. During this 
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session we will review these logical errors and will practice skills 
designed to cope with them or decrease their likelihood. (Allow 5 
minutes.) 
4. The therapist destributes handout entitled, "Skills to Cope 
with Logical Errors." For each of the seven cognitive errors, the 
therapist: 
a. Describes the error. 
b. Gives an example of the error. 
c. Elicits examples from the client. 
d. ' Describes the skill used to cope with the cognitive 
error. (Allow 20 minutes.) 
5. The therapist suggest that the client share her Daily Record 
of Dysfunctional Thoughts—Form II using the following framework: 
a. Look back over your homework and identify any of the 
logical errors we have discussed. 
b. We will fill in this diagram as we go: 
1. emotions 
2. automatic thoughts 
3. themes 
4. depressive assumptions and logical errors 
5. skills to cope with logical errors 
6. an alternative assumption that is more useful than 
the depressive assumption 
c. Subjects are instructed to copy their diagram on the back 
of a Daily Record of Dysfunctional Thoughts—Form II. 
Note: Again the therapist asks many questions during this 
section and makes few statements. (Allow 45 minutes.) 
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6. The therapist collects Daily Record of Dysfunctional 
Thoughts—Form II and passes out blank forms. The therapist instructs 
the client to continue to complete the form as usual and at the end of 
each day, on the back of the form, identify: 
a. Common themes. 
b. Depressive assumptions. 
c. Alternatives to the depressive assumptions. (Allow 5 
minutes.) 
Session #6 
1. The therapist collects the client's homework forms. (If a 
client did not complete the homework assignment, she is instructed to 
make at least three entries relevant to dysphoric mood or positive or 
negative change in affect.) The therapist administers the Depression 
Adjective Checklist. (Allow 5 minutes. 
2. The therapist outlines the following agenda: 
a. Description of the next step in therapy—evaluating and 
correcting dysfunctional thoughts and assumptions by 
designing experiments. 
b. Steps involved in designing experiments. 
c. Examples of experiments. 
d. Discuss new homework assignment. 
e. Practice new homework assignment. (Allow 5 minutes.) 
3. The therapist describes the next step in treatment: We have 
been practicing and will continue to practice detecting automatic 
thoughts and depressive assumptions because we think that there is a 
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relationship between feeling depressed and looking at the self, the 
world, and the future in a negative manner. To review, you may remember 
that depressive assumptions are important because their presence and use 
increases the likelihood that a person will become depressed. Some 
examples of the depressive assumptions we talked about included: "To be 
happy, I must be accepted by all people at all times." "If I make a 
mistake, it means that I am inept." 
We mentioned that the following cues often signal the presence of 
depressive assumptions: 
a. The frequent use of global, vague words (e.g., stupid, 
silly, dumb). 
b. The use of "absolutes" (e.g., should, ought, never). 
c. "Logical errors" (e.g., overgeneralization, 
magnification). 
In identifying depressive assumptions, we examined the common 
themes of negative automatic thoughts and inferred the 
depressive assumptions. However, just as important as the 
skill of identifying depressive thoughts and assumptions is 
the skill of correcting them. Since we have stated earlier 
that there is a difference between a thought and a fact, we 
will try now to subject thoughts to an experimental test. We 
will look at thoughts as hypotheses to be treated empirically 
and will gather data to refute and/or to support the 
hypotheses. (Allow 5 minutes.) 
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4. The therapist illustrates: For example, one depressed personl 
used the assumption—"If I assert myself (express myself openly and 
honestly), I will be rejected." The negative automatic thoughts which 
went along with this assumption were—"If I tell my supervisor I want to 
take the day off she will think that I am lazy and that I'm trying to 
avoid work." The experiment consisted of actually talking with the 
supervisor, recording what happens, and comparing these results with the 
predictions. 
A depressed student predicted that she would be a failure in 
college because her English professor suggested many revisions on her 
essay. One of her automatic thoughts included—"The professor probably 
wishes I wasn't in his class since I am donig so poorly." The 
experiment consisted of going to talk with the professor, who said that 
the student's paper was very creative, and it needed revising. He 
pointed out that he had written a lot to guide her revisions and make 
them easier. (Allow 5 minutes. 
5. The therapist mentions that there are several types of 
experiments. Some automatic thoughts are examined best by taking data 
on oneself (like the two outlined above). Other automatic thoughts are 
tested best by "surveying" others. For example, one depressed woman 
assumed: "Only unattractive women go out alone." When this client 
actually counted the numbers of attractive women who went out alone vs. 
the number of unattractive women who went out together, she found the 
numbers were approximately equal. (Allow 5 minutes.) 
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6. The therapist outlines the steps involved in testing 
assumptions: 
a. Identify the depressive or faulty assumption to be 
tested. 
b. Deduce a specific prediction from this general rule 
(often it helps to look at the automatic thoughts in 
order to deduce a specific prediction). 
c. State this prediction in a form that can be tested. 
Define vague terms and list behaviors necessary to carry 
out the test. Look at the situation in which 
corresponding negative, automatic thoughts occur for 
ideas about how to specify the hypothesis. 
d. Record the results from the experiment in an objective 
manner. That is, record the outcomes of the experiment 
in terms of what happened, rather than in terms of what 
you think about what happened. 
e. Compare the results you got to the prediction that you 
made. 
f. Ask yourself if other experiments are necessary. (Allow 
10 minutes.) 
7. The therapist introduces the new homework assignment Daily 
Record of Dysfunctional Thoughts—Form II as an aid in learning to test 
assumptions and/or negative, automatic thoughts. 
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a. The therapist points out that the first four columns 
(e.g., date, situation, emotions, automatic thoughts) are 
identical to Forms I and II. The therapist remonds the 
client that the cues for completing the form are 
dysphoria or a change in emotion. If it is impossible to 
complete the form at that moment, go back to the form at 
a standard time each day. 
b. The therapist mentions that column five, "WAYS TO TEST," 
(the negative thought or depressive assumption) involves 
creating a method which would support or refute the 
thought. This column is used to specify how you will 
collect your data. 
c. The therapist mentions that column six "OUTCOME OF TEST" 
involves recording the results of the experiment. 
Clients are encouraged to record the results of your 
experiment like "you would like for a newspaper report to 
report the news." 
d. The therapist mentions that column seven "THOUGHTS AND 
BELIEFS" involves re-rating the belief in the initial 
automatic thought or assumption and specifying and rating 
the new emotion. (Allow 10 minutes.) 
8. The therapist suggests that the client uses the new Form III 
to review her homework from the last session. The following format is 
used: 
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a. What depressive assumption would you like to test? (If 
client can't identify a depressive assumption, the 
therapist reviews. Such review is accomplished by 
listing emotions, automatic thoughts, themes, and 
deducing the assumptions.) 
b. What specific prediction can you deduce from this general 
assumption? (Aids: Look at corresponding situations and 
automatic thoughts.) 
c. How can we state this prediction in a testable form? 
(Define vague terms. List behaviors necessary to carry 
out the test.) 
d. Why type of data would you record? Are there any 
precautions you might take to make sure these data are 
objective? 
e. If any applicable examples arise, the therapist has group 
members conduct the experiment in group setting. In so 
doing the client practices: 
1. Recording data objectively. 
2. Comparing the results with the prediction. 
3. Asking if other experiments are necessary. 
When this is done, the therapist makes sure that the client 
has another or similar experiment to conduct as homework. 
(Allow 40 minutes.) 
9. The therapist assigns homework: 
a. Carry out the experiments which you designed and record 
the results. 
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b. Complete the Daily Record of Dysfunctional Thoughts— 
Form III. Therapist gives each client a completed sample 
of Form III. Complete Columns 1-5 each time you feel 
dysphoric or your emotions change. Complete Columns 6 
and 7 (i.e., actually perform an experiment) once a day. 
(Allow 5 minutes.) 
Session #7 
1. The therapist reviews each client's homework and praises her 
completion of the task. (If a client did not complete the task, she is 
instructed to make at least three entries relevant to dysphoric mood or 
positive or negative change in affect, completing Columns 1-5, Form III. 
Then the therapist stresses the importance of actually carrying out the 
experiments and attempts to get the subjects to agree to carry out one 
of these experiments as her new homework.) The therapist administers 
the Depression Adjective Checklist. (Allow 5 minutes.) 
2. The therapist outlines the following agenda: 
a. Review the rationale for and steps for hypothesis 
testing. 
b. Review homework (Form III). 
c. Learn a new skill which is particularly useful in testing 
hypotheses regarding problems (e.g., graded task 
assignment). 
d. Apply graded task assignment to a problem/hypothesis 
relevant to you. 
e. Assign homework. (Allow 5 minutes.) 
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3. The therapist begins review of the skills covered in Session 
#6: During the last session we focused on correcting negative automatic 
thoughts or depressive assumptions by hypothesis-testing or by setting 
up experiments. As a brief review, I wonder if you would tell me: 
a. Why it is important to set up experiments to evaluate 
automatic thoughts and depressive assumptions? 
(Automatic thoughts and depressive assumptions are 
beliefs, not facts. Experiments help in establishing or 
refuting their validity.) 
b. What are the steps involved in testing assumptions? 
1. Identify the depressive or faulty assumption to be 
tested. 
2. Deduce a specific prediction from this general rule 
(often it helps to look at the automatic thoughts in 
order to deduce a specific prediction). 
3. State this prediction in a form that can be tested. 
Define vague terms and list behaviors necessary to 
carry ott the test. Look at the situation in which 
corresponding negative, automatic thoughts occur for 
ideas about how to specify the hypothesis. 
4. Record the results from the experiment in an 
objective manner. That is, record the outcomes of 
the experiment in terms of what happened, rather 
than in terms of what you think about what happened. 
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5. Compare the results you got to the prediction that 
you made. 
6. Ask yourself if other experiments are necessary. 
(Allow 10 minutes.) 
4. The therapist suggests that each client share her Daily Record 
of Dysfunctional Thoughts—Form III. Therapist asks each client to 
review one experiment, beginning with Column 1 through Column 7. If a 
client has not carried out an experiment, the therapist helps her design 
an experiment that she can carry out in the session, at this time. 
(Allow 30 minutes.) 
5. The therapist introduces the rationale for and the steps 
involved in graded task assignment: 
a. Rationale: 
Graded task assignment offers one way of testing 
hypotheses that have to do with problems or doubts. This 
strategy is designed to help test automatic thoughts or 
assumptions like: "I can't do anything" or "I'll never 
be able to solve this problem." Graded task assignment 
will offer you a method of solving problems through your 
own effort and skill. 
b. Steps: 
1. Identify the problem (i.e., belief) on which you 
would like to work (e.g., "I can't accomplish my 
goals."). 
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2. Formulate a project. That is, write down the 
behaviors which are involved in the task. Start 
with the simplest and move to the more complicated. 
3. Perform these behaviors. Check off the parts of the 
task as you do them. 
4. Compare the results with the prediction that you 
made. (Allow 5 minutes.) 
6. The therapist suggests that the client practice using graded 
task assignment to test hypotheses using this format: 
a. The therapist gives the client a chance to ventilate and 
to express any cynical doubts that they have regarding 
the utility of this task. (The therapist responds with, 
"This is an experiment. We can test your automatic 
thoughts.") 
b. The therapist suggests that clients refer to the Daily 
Record of Dysfunctional Thoughts—Form III during this 
exercise. The therapist suggests that the client write 
down the "plan" in the following places. 
c. Identify the assumption which can be tested through the 
use of graded task assignment. (Write in Column 4.) 
d. Write down the steps involved in the task, Column 5. 
Note: The therapist aids the client in setting modest goals. 
(Allow 30 minutes.) 
7. For homework the therapist instructs the client to: 
a. Perform the behaviors listed in 6d, checking off the 
tasks as they are accomplished. 
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b. Complete Column 6 and 7. 
c. Use graded task assignment to test at least one other 
belief before the next session. 
d. Continue to complete Daily Record of Dysfunctional 
Thoughts—Form III, Columns 1-5, at least. (Allow 5 
minutes.) 
Session #8 
1- The therapist reviews each client's homework and praises her 
completion of the task. (If a client did not complete the task, then 
she is instructed to make at least three entries relevant to dysphoric 
mood or positive or negative change in affect, completing Columns 1-5, 
Form III. Then the therapist stresses the importance of actually 
carrying out one of these experiments as her new homework.) The 
therapist administers the Depression Adjective Checklist. (Allow 5 
minutes.) 
2. The therapist outlines the following agenda: 
a. Review the rationale and steps involved in using graded-
task assignment to test hypotheses. 
b. Review homework, Form III. 
c. Learn a new skill which is particularly useful in testing 
hypotheses regarding fulfilling daily goals (e.g., 
activity scheduling). 
d. Apply activity scheduling to a hypothesis relevant to 
you. 
e. Assign homework. (Allow 5 minutes.) 
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3. The therapist begins a review of the skills covered in Session 
#7: During the last session we focused on correcting negative automatic 
thoughts related to problems or doubts by graded task assignment. As a 
brief review, I wonder if you would tell me: 
a. What are the steps involved in graded task assignment? 
1. Identify the problem (i.e., belief) on which you 
would like to work. 
b. Formulate a project. That is, write down the behaviors 
which are involved in the task. Start with the simplest 
and move to the more complicated. 
c. Perform the behaviors. Check off the parts of the task 
as you do them. 
d. Compare the results with the prediction that you made. 
(Allow 5 minutes.) 
4. The therapist suggests that each client share her Daily Record 
of Dysfunctional Thoughts—Form III. Therapist asks each client to 
review one experiment in which she used graded task assignment to test a 
hypothesis. The therapist instructs the members to review what they 
place in Columns 1 through 7 on the Daily Record of Dysfunctional 
Thoughts—Form III. If a client has not carried out an experiment using 
graded task assignment, the therapist helps her design an experiment 
that she can carry out in the session, at this time. (In some cases 
this may not be possible; therefore, the client is encouraged to 
implement the experiment as homework.) (Allow 20 minutes.) 
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5. The therapist introduces the rationale for and steps involved 
in activity scheduling: 
a. Rationale: 
Activity scheduling offers one way of testing hypotheses 
that have to do with not accomplishing enough, being 
unable to carry out, and not doing anything pleasurable. 
Activity scheduling offers a method for collecting data 
on these hypotheses. 
b. Steps: (The therapist hands out Activity Schedules and 
blank Form III, asking the client to complete the steps 
involved in planning activities as she describes them.) 
1. Identify a hypothesis you use or have used which is 
related to inability to accomplish daily activities 
and not doing anything pleasurable (e.g., "I can't 
get anything done" or "I don't do anything fun."). 
Write this hypothesis in Column 4 of the Daily 
Record of Dysfunctional Thoughts—Form III. 
2. In Column 5 write that activity scheduling will be 
your method of testing the hypothesis. 
3. On the Activity Schedule, go through and write down 
all the standing appointments you have made (e.g., 
go to work, come to group meeting). 
4. On the Activity Schedule, go through and write down 
something for each day that you want to do (e.g., 
watch the evening news, play with my pet, write a 
letter, etc.). 
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5. Leave some time each day unscheduled. Right now 
what's more important than actually accomplishing 
the activity is planning the activity. Nobody 
accomplishes everything that she plans. Even if you 
don't carry out every activity, trying to carry them 
out and carrying out some of the activities is very 
important. 
6. For homework on the Activity Schedule, check off the 
tasks as you complete them. 
7. For homework on the Daily Record of Dysfunctional 
Thoughts—Form III in Column 6, write down the 
outcome of the experiment which involved scheduling 
activities. 
8. For homework, complete Column 7 of the Daily Record 
of Dysfunctional Thoughts—Form III. (Allow 45 
minutes.) 
6. For homework the therapist instructs the client to: 
a. Carry out their experiments on Activity Scheduling 
(review steps 1-7 above). 
b. Continue to complete Form III, Columns 1-5, at least. 
(Allow 10 minutes.) 
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Examples of Negative Auecaatic Thoughts Regarding Therapy' 
1. "Cognitive therapy is a rehash of 'the power of positive 
thinking'." 
2. "I'm not depressed because I distort reality, but be­
cause thir.cs really are bad. Anyone would become 
depressed." 
3. "Z know I look at things in a negative way, but I can't 
chance ay personality." 
4. believe what you are saying intellectually, but not 
ep.otior.ally." 
5. "Since I dor.'t like these negative thoughts, the reason 
they come must be that I want to be depressed." 
6. "I'a afraid once I'a over being depressed, I'll become 
anxious like I was before." 
7. " z  var.t a guarantee this therapy will cure ay depression." 
3. "Cognitive therapy is concerned with -cr.da.ne things in 
life ar.d not with the serious problems that sake ae 
depressed." 
5. "If negative cognitive distortions make ae ur.happv, does 
that aear. that positive cognitive distortions make ae 
happy?" 
10. "Z have been coning to therapy for several weeks, and 
I'a not any better." 
11. "Vou can't treat ay depression without seeing ay spouse, 
too. He/she caused the depression." 
12. "I'm saartar than the therapist. How car. she help ae?" 
13. "Vcu are aore interested in dome research than in 
helping ae." 
1-4. "Cognitive therapy won't work because ay depression is 
biological." 
15. "I have to assert ay independence by not letting the 
t.-.erapist get the best of ae." 
*3eck, Shaw, Rush, and Saery, 1979. 
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S<cills to Cope with Logical Errors 
or Assumotion Skill 
If it's true in one Exposure of faulty 
ease, it applies logic. Establish 
to any case which criteria of which 
is ever, slightly cases are "similar" 
similar. and to what degree. 
rhe only events that Use "log" to identify 
matter are failures successes patient 
deprivation, etc. forgot. 
Should measure self 
by errors, weak­
nesses, etc. 
Cognitive Err 
1. Overgeneraliti.-.g 
2. Selective 
abstraction 
3. Excessive 
responsibility 
(Assuming Per­
sonal Causality) 
4. Assuming Tans-
oral Causality 
(Predicting 
without suf­
ficient 
evidence 
5. Self-
references 
6. "Catastro-
phitir.g 
Oichotcmous 
thinking 
I am resaonsible 
for all bad 
things, failures, 
etc. 
If it has been true 
ir. the past, ther. 
it's always going 
to be true 
I am the center of 
everyone's, atten­
tion- -especi ally 
my bad perform­
ances. X am the 
cuase' of mis­
fortunes . 
Always think of the 
worst. It's most 
likely to happen 
to you. 
Everything either 
is one extreme or 
another (black or 
white; good or bad) 
Disattribution 
technique. 
Expose faulty logic. 
Specify factors 
which could in­
fluence outcome 
. ether than past 
events. 
Establish criteria 
to determiae when 
patient is the 
focus of atten­
tion and also the 
probable facts 
that cause bad 
experiences. 
Calculate real 
probabilities. 
Focus on evidence 
that the worst did 
not happen. 
Demonstrate that 
events may be 
evaluated on a 
continuum. 
Taken from Beck, R u s h ,  S h a w ,  and Emery, 1979, p. 261. 
D a i l y  R e c o r d  o f  O y a f u n c t i o n a l  T h o u g h t s - - F o r m  IT 
SITUATION 
Describe 
1. Actual event lending 
to unpleasant emotion, 
or 
2. Stream of thoughts, 
daydream, or recol­
lection, leading to 
unpleasant coot Inn. 
KHOTIOH(S) 
1. Specify aad( 
Anxious, 
•ngry, etc. 
2. Rate degree 
of emotion, 
1:100 
AUTOMATIC TIIOIIOMT(S) 
1. Write automatic thought(a) 
that preceded emotlons(a). 
2. Rate belief In automatic 
thought(a). 0:l00t 
RATIONAL RESrOIISE 
1. Write rational re­
sponse to automatic 
t bought(s). 
2. Rate belief In 
ratlonal response. 
0:100X 
OUTCOME 
1. Re-rate belief 
In automatic 
thouglit(a), 
0:100X 
2. Specify and 
rate subsequent 
emotions. 
0:100 
EXPLANATION: When* you experience an unpleasant emotion, note the situation Hint seemed lo stimulate tlie emotion 
(If tlie emotion occurred while you Were thinking, dnydreiiMlug, etc., pleaso note title.) Then note tlie 
automatic thought ussoclnted ultli the emotion. He cord the degree to vlilcli you Imlleve I he thoughts 
0* - not ot nil; 1002 completely. In rating ilegree of emotion i 1 - a trace; 100 - the moat Intenae poaalble. 
Adapted from Beck, Rush, Slinu, nnd Finery, 1979, p. 'i01. 
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APPENDIX P 
Consent Form II 
I understand that I am going to be interviewed by the primary 
researcher (Dennis L. McKnight, M.A.) and by a psychiatrist (Dr. Jarrett 
Barnhill), will be administered questionnaires, and will be asked to 
have a blood test done at a local laboratory to. be used in selecting 
subjects for a psychological-psychiatric investigation involving the 
assessment and treatment of depression. I have also been informed that 
if I am selected for this study that my treatment may be with anti­
depressant medication or a psychological treatment, whichever I am 
assigned. I understand that I do not have a choice as to what treatment 
I would receive, but I may withdraw from the study at any time. Also, I 
will be required to have two more blood tests taken after my treatment 
beings. While there is no charge for the treatment sessions, I will be 
asked to pay a total of $60.00 for the laboratory work and will be 
required to pay for medication if I receive the treatment using anti­
depressant medication. Furthermore, I have been informed that I am 
participating in research and alternative treatment for my problem is 
available through my local mental health clinic or through 
psychologists/psychiatrist in private practice. 
I understand that if I am not eligible for participation in this 
program I will be given a list of referrals for assessment and treatment 
in Winston-Salem and that I may contact if I so desire. Finally, all 
personal information (e.g., name) that I give is completely 
confidential, and will only be available to the experimenters. I 
further understand that specific numerical scores provided by laboratory 
tests and by questionnaires will be used (without my identity) for 
research purposes and publication. If I am eligible to participate, I 
understand that experimental procedures will be explained to me more 
fully before I decide to continue to participate. 
Signed: 
Witness: 
Date: 
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APPENDIX Q 
Consent Form III: Treatment Contract 
I, , hereby agree to participate 
in research to be conducted under direction of Dr. Rosemery 0. Nelson, 
Professor of Psychology, and Dr. Jarrett Barnhill, Psychiatrist, 
involving assessment and treatment for depressive disorders. As 
explained to me, for the next 9 weeks, I will be required to attend 
weekly group assessment and treatment sessions involving receiving 
anti-depressant medication/psychologically-based therapy 
(circle one) 
treatment (groups will consist of three subjects in each). I understand 
that I do not have a choice in my treatment, but that I may withdraw at 
any time. 
Although I am not paying for the treatment I receive, I have agreed 
to pay for laboratory tests (e.g., three blood tests), to pay for 
medication if necessary, and make a $50.00 "data deposit." I have 
agreed to have my money refunded, gradually and fully, if I come to all 
the sessions and participate in the treatment fully. I have also agreed 
to forfeit the percentage of money that matches the commitments I fail 
to keep. Specifically, I understand that my data deposit will be 
returned according to the following plan: 
If I come to all scheduled appointments, and participate 
in the treatments fully, my data deposit will be returned 
as follows: 
Session #1 $ 3 .00 
Session #2 4 .00 
Session #3 4 .00 
Session #4 5 .00 
Session #5 6 .00 
Session #6 6 .00 
Session #7 7 .00 
Session #8 7 .00 
Session #9 8 .00 
Total $50 .00 
I understand that if I miss a session, I may call Dennis McKnight 
in advance to reschedule the appointment. The rescheduled appointments 
should be within four days of my previous appointment. If I attend the 
rescheduled appointment, I will not forfeit any percentage of my data 
deposit. 
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I understand that if I become dissatisfied with this program, 
withdrawal can be arranged and my data deposit can be returned in full. 
However, I must contact Dennis McKnight before I miss a treatment 
session in order for my $50.00 to be returned. 
I understand that the purpose of this investigation is to evaluate 
approaches to assessing and treating depressive disorders, approaches 
which have shown to be useful for certain cases in the past. However, I 
also realize that there can be no guarantee that I will not be depressed 
because I participate in this research. However, hopefully, my 
participation will contribute to the development of effective assessment 
and treatment for others, as well as for myself. In addition, if at the 
end of this investigation, I am not satisfied with my progress here, I 
will receive a referral for continued assessment and treatment. 
Signed: 
Witness: 
Date: 
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APPENDIX R 
Debriefing Statement 
The general question which stimulated the investigation in which 
you have participated is: Is it worthwhile to view depression as two 
general subtypes, one subtype that results from a chemical imbalance in 
the brain, and the other subtype that results from faulty ways of 
thinking about situations? Furthermore, can a chemically based 
depression significantly improve using a psychological treatment (e.g., 
changing the way one views different situations that arise) or must 
medication be used? Likewise, can a supposedly reactive depression 
(e.g., depression resulting from faulty ways of thinking about the 
world) improve using medications, or must it be treated with a 
psychological treatment? 
As you may remember, I asked you to take the Dexamethasone 
Suppression Test (DST test for short) at the beginning and end of this 
study. This test is believed to differentiate between the subtypes of 
depression mentioned above. Positive suppressors are believed to be 
indicative of a chemical depression, while negative suppressors are 
indicative of a reactive depression. Some subjects in this study 
received an anti-depressant medication as their main form of treatment, 
while other subjects received a psychological treatment. Therefore, 
this study examined whether positive suppressors responded better, 
equally well, or not as well to medications or to a psychological 
treatment. It also examined whether negative suppressors responded 
better, equally well, or not as well to medications or to a 
psychological treatment. 
Each of the treatment approaches used in this study have shown to 
be effective in the treatment of depression. Treatment effectiveness in 
this investigation was assessed through the questionnaires and 
laboratory tests that you took. 
Although you may have been told in this study that your data 
deposit would be refunded only under certain circumstances, the data 
deposit was refunded, in full, to all subjects. 
Following the termination of this study, you were given a referral 
list for possible further evaluation and treatment, if you so desired. 
Feel free to call any of these telephone numbers or Charter Mandala 
Center if further treatment is necessary. 
APPENDIX S 
FIGURES 
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FIGURE 2 
DEPRESSION INVENTORY: NORMAL DEXAMETHASONE SUPPRESSION TEST 
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30 — 
FIGURE 3 
LUBIN DEPRESSION ADJECTIVE CHECKLIST: 
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FIGURE 4 
PERSONAL BELIEFS INVENTORY: NORMAL DEXAMETHASONE SUPPRESSION TEST 
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FIGURE 5 
NORMAL DEXAMETHASONE SUPPRESSION SUBJECTS: 
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FIGURE 6 
BECK DEPRESSION INVENTORY 
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